Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
NEWS
                Web Page URLs for STN Seminar Schedule - N. America
NEWS
                "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
                2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 4 DEC 14
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the
                IPC reform
NEWS 8 DEC 23
                New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
NEWS 9 JAN 13
                IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                INPADOC
                Pre-1988 INPI data added to MARPAT
NEWS 11 JAN 17
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31
                Monthly current-awareness alert (SDI) frequency
```

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

```
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:13:26 ON 07 FEB 2006

added to TULSA

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:13:44 ON 07 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5 DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Program Files\Stnexp\Queries\107645291.str



chain nodes : 6 7 8 9 10 12

ring nodes : 1 2 3 4 5 chain bonds :

2-6 4-12 6-7 6-9 7-8 7-10

ring bonds :

1-2 1-5 2-3 3-4 4-5 exact/norm bonds : 1-2 1-5 2-6 6-7 7-8

exact bonds :

2-3 3-4 4-5 4-12 6-9 7-10

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS

10:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 12:13:59 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 5444 TO ITERATE

36.7% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

19 ANSWERS

TOTAL

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 104456 TO 113304 603 TO 1465 PROJECTED ANSWERS:

19 SEA SSS SAM L1 L2

=> s l1 ful

FULL SEARCH INITIATED 12:14:05 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 107916 TO ITERATE

100.0% PROCESSED 107916 ITERATIONS 1081 ANSWERS SEARCH TIME: 00.00.01

L31081 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE ENTRY SESSION

FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 12:14:13 ON 07 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7 FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

L4 622 L3

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 5.06 172.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:20:41 ON 07 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5 DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>

Uploading C:\Program Files\Stnexp\Queries\107645292.str



chain nodes :

6 7 8 9 10 12

ring nodes :

1 2 3 4 5 13 14 15 16 17 18

chain bonds :

2-6 5-12 6-7 6-9 7-8 7-10 12-14

ring bonds :

1-2 1-5 2-3 3-4 4-5 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

1-2 1-5 2-6 5-12 6-7 7-8 12-14

exact bonds :

2-3 3-4 4-5 6-9 7-10

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 12:20:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5444 TO ITERATE

36.7% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 104456 TO 113304 PROJECTED ANSWERS: 193 TO 785

L6 9 SEA SSS SAM L5

9 ANSWERS

=> s 15 ful

FULL SEARCH INITIATED 12:21:01 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 107916 TO ITERATE

100.0% PROCESSED 107916 ITERATIONS

573 ANSWERS

SEARCH TIME: 00.00.02

L7 573 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION 166.94 339.15 FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:21:09 ON 07 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7 FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 17

21 L7 L8

=> d 18 ibib hitstr abs 1-21

ANSWER 1 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1042064 CAPLUS

DOCUMENT NUMBER:

143:332555

TITLE:

Aqueous composition comprising thiazole derivative Ueno, Ryuji; Hirata, Ryu; Harada, Yasuhiro

INVENTOR(S):

R-Tech Ueno, Ltd., Japan

PATENT ASSIGNEE(S): SOURCE:

PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE -----

```
20050929
                                             WO 2005-JP5607
     WO 2005089755
                          A1
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                             US 2004-553956P
                                                                 P 20040318
                          MARPAT 143:332555
OTHER SOURCE(S):
     183365-33-5 737822-86-5 737822-89-8
IT
     737822-91-2 737822-94-5 737823-04-0
     737823-05-1 737823-09-5 737823-19-7
     737823-29-9 737823-34-6 737823-47-1
     737823-48-2 737823-50-6 737823-52-8
     737823-55-1 737823-67-5 737823-78-8
     737823-84-6 737823-88-0 737823-92-6
     737823-96-0 737824-00-9 737824-05-4
     737824-09-8 737824-13-4 737824-15-6
     737824-17-8 737824-19-0 737824-21-4
     737824-23-6 737824-25-8 737824-27-0
     737824-30-5 737824-32-7 737824-34-9
     737824-40-7 737824-46-3 737824-54-3
     737824-56-5 737824-57-6 737824-60-1
     737824-76-9 737824-82-7 737824-83-8
     737824-84-9 737824-85-0 737824-86-1
     737824-87-2 737824-92-9 737825-15-9
     737825-19-3 737825-30-8 737825-35-3
     737825-38-6 737825-42-2 737825-45-5
     737825-49-9 737825-52-4 737825-56-8
     737825-60-4 737825-64-8 737825-68-2
     737825-70-6 737825-72-8 737825-74-0
     737825-76-2 737825-78-4 737825-80-8
     737825-82-0 737825-84-2 737825-86-4
     737825-88-6 737825-90-0 737825-92-2
     737825-94-4 737825-96-6 737825-98-8
     737826-00-5 737826-02-7 737826-05-0
     737826-07-2 737826-09-4 737826-11-8
     737826-13-0 737826-15-2 737826-16-3
     737826-22-1 737826-27-6 737826-33-4
     737826-39-0 737826-42-5 737826-43-6
     737826-44-7 737826-45-8 737826-48-1
     737826-59-4 737826-71-0 737826-74-3
     737826-77-6 737826-80-1 737826-86-7
     737826-88-9 737826-90-3 737826-92-5
     737826-98-1 737827-00-8 737827-02-0
     737827-05-3 737827-07-5 737827-09-7
     737827-14-4 737827-16-6 737827-21-3
     737827-23-5 737827-26-8 737827-29-1
     737827-34-8 737827-42-8 865294-39-9
     865294-40-2
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (preparation and stability of aqueous composition comprising thiazole
derivative)
     183365-33-5 CAPLUS
```

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737822-86-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C-NH}_2 \\ & \text{S} & \text{CH}_2 - \text{CH}_2 \end{array}$$

RN 737822-89-8 CAPLUS

CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737822-91-2 CAPLUS

CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-,
methyl ester, monohydriodide (9CI) (CA INDEX NAME)

HI

RN 737822-94-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$CH_2-CH_2$$
 $NHAC$

RN 737823-04-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-05-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminoiminomethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{C-NH}_2 \\ \end{array}$$

● HCl

RN 737823-09-5 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \text{NH} \\ & & & \text{NH} \\ & & \text{CH}_2 - \text{CH}_2 - \text{CH}_2 \\ & & \text{S} \end{array}$$

● HCl

RN 737823-19-7 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-29-9 CAPLUS

CN Acetamide, N-[4-[2-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737823-34-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH_2 CH_2

HCl

RN 737823-47-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-48-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-chloro-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

● HCl

RN 737823-50-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim CH₂- NH- C- NH₂

HCl

RN 737823-52-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim CH₂ \sim CH₂ \sim OEt

● HCl

RN 737823-55-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(ethylamino)iminomethyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-67-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $CH_2 - CH_2 = CH_2$
 $O = S - Me$
 $O = S - Me$

HCl

RN 737823-78-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH- C- NH₂ \sim NH- C- NH₂ \sim NHMe \sim O

● HCl

RN 737823-84-6 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim CH₂ \sim NHPh

● HCl

RN 737823-88-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2 \\ & \text{C} - \text{NMe}_2 \\ & \text{O} \end{array}$$

HCl

RN 737823-92-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} \\ & \text{C} \\ & \text{NH} \\$$

HCl

RN 737823-96-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-nitrophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-00-9 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Acnh
$$\sim$$
 CH₂ \sim CH₂ \sim HCl

RN 737824-05-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(trifluoromethyl)phenyl]methyll-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-09-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-3-pyridinyl-, dihydrochloride
(9CI) (CA INDEX NAME)

ACNH
$$NH = CH_2 - CH_2$$
 $C = O$
 NH
 $NH = CH_2 - CH_2$
 $NH = CH_2 - CH_2$

•2 HCl

RN 737824-13-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-phenoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-15-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737824-17-8 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-19-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-21-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737824-23-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim O

● HCl

RN 737824-25-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = NH - C - NH_2$$
 $C = O$
 $C = O$
 $C = O$
 $C = O$
 $C = O$

● HCl

RN 737824-27-0 CAPLUS

CN

4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$C=0$$

$$C=NH_{2}$$

$$C=NH_{2}$$

● HCl

RN 737824-30-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim

● HCl

RN 737824-32-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $C = 0$
 $C = NH_2 - CH_2 - CH_2$
 $C = NH_2 - CH_2 - CH_2$

● HCl

RN 737824-34-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim Ph

● HCl

RN 737824-40-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(phenylmethyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-Ph

● HCl

RN 737824-46-3 CAPLUS
CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me

RN 737824-54-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$NH$$
 $CH_2 - CH_2$
 CH_2
 CH_2

RN 737824-56-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Acnh
$$NH = C-NH_2$$
 $CH_2 - CH_2 = CH_2$
 $CH_2 = CH_2$
 $CH_2 = CH_2$

● HCl

RN 737824-57-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me

RN 737824-60-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(ethylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $CH_2 - CH_2 = CH_2$
 $CH_2 = CH_2$
 $CH_2 = CH_2$

HCl

RN 737824-76-9 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂- CH₂
 \sim CH₂- NH₂
 \sim CH₂- CH₂
 \sim CH₂- CH₂
 \sim CH₂- C

RN 737824-82-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-83-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-84-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me \sim O \sim S \sim Me

RN 737824-85-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(iminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-86-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NH-NH}_2 \\ \text{S} \end{array}$$

RN 737824-87-2 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{CH}_2 - \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2 \end{array}$$

RN 737824-92-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim SMe

RN 737825-15-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim CH₂- NH- C- NH₂
 \sim CH₂- NH- C- NH₂
 \sim CH₂- CH₂
 \sim CH₂- CH₂- CH₂
 \sim CH₂- CH₂- CH₂
 \sim CH₂- CH₂-

HCl

RN 737825-19-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl] ethyl]-5-thiazolyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-30-8 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-35-3 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-38-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5[(dimethylamino)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-NMe_2

●2 HC1

RN 737825-42-2 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 737825-45-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

●2 HCl

RN 737825-49-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

RN 737825-52-4 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $NH-C-NH_2$ $C-NH-CH_2-C-NMe_2$ 0 0

HCl

RN 737825-56-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 - \text{CH}_2 \\ & \text{C} - \text{NH} - \text{CH}_2 - \text{CH}_2 - \text{C} - \text{NMe}_2 \\ & \text{O} & \text{O} \end{array}$$

HCl

RN 737825-60-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2 - CH_2 - NHAC$$
 $C - NH - CH_2 - CH_2 - NHAC$
 $CH_2 - CH_2 - NHAC$

HCl

RN 737825-64-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl], monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-68-2 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-Nmethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2 - CH$$

HCl

RN 737825-70-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-[methyl(phenylmethyl)amino]-3oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim Me \sim CH₂-CH₂-CH₂-CH₂-Ph \sim O

● HCl

RN 737825-72-8 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $NH-C-NH_2$
 $C-NH-(CH_2)_3-C-NMe_2$
 0

• HCl

RN 737825-74-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737825-76-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737825-78-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{CH}_2 - \text{CH}_2 \\ & \text{S} & \text{Me} \\ & \text{O} & \text{O} \\ \end{array}$$

● HCl

RN 737825-80-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

•2 HCl

RN 737825-82-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-(3-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

•2 HCl

RN 737825-84-2 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(phenylacetyl)amino]ethyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2 - CH_2 - CH_2 - CH_2 - Ph$$
 $C - NH - CH_2 - CH_2 - NH - C - CH_2 - Ph$
 $C - NH - CH_2 - CH_2 - NH - C - CH_2 - Ph$

● HCl

RN 737825-86-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂ \sim NH-C-NH₂

● HCl

RN 737825-88-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-oxo-3[(phenylmethyl)amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-90-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim NH \sim NH \sim NH \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim NH

● HCl

RN 737825-92-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH

NH

$$CH_2 - CH_2$$

NH

 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$

PAGE 2-A

●2 HCl

, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-96-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂

$$\sim$$
 CH₂-CH₂ \sim Me

● HCl

RN 737825-98-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-00-5 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-02-7 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim HCl

737826-05-0 CAPLUS RN5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-CN[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-

2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

737826-07-2 CAPLUS RN5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-CN[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 737826-09-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1(hydroxymethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-11-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S,2S)-1[(dimethylamino)carbonyl]-2-hydroxypropyl]-, monohydrochloride (9CI) (CAINDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-13-0 CAPLUS

CN Pentanediamide, 2-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phen yl]ethyl]-5-thiazolyl]carbonyl]amino]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-15-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-16-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737826-22-1 CAPLUS

CN Propanamide, 3-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl] ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $CH_2-CH_2-C-NMe_2$ Me O

●2 HCl

RN 737826-27-6 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]e thyl]-5-thiazolyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim HC1 \sim CH₂ \sim

RN 737826-33-4 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]e thyl]-5-thiazolyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-39-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{2}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{4}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

•2 HCl

RN 737826-42-5 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me

RN 737826-43-6 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me

RN 737826-44-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

● HCl

RN 737826-45-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Acnh} \\ \text{S} \end{array} \begin{array}{c} \text{CH}_2 - \text{CH}_2 - \text{NH}_2 \\ \end{array}$$

● HCl

RN 737826-48-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{CH}_2-\text{CH}_2-\text{NH}-\text{C-NH}_2 \\ \end{array}$$

HCl

RN 737826-59-4 CAPLUS

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim CH₂ \sim NH \sim NH

● HCl

RN 737826-71-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

●2 HCl

RN 737826-74-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-morpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim CH₂ \sim NH \sim N

●2 HC1

RN 737826-77-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim NH

●2 HCl

RN 737826-80-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH

$$NH$$
 NH
 NH
 NH
 $C-NH_2$
 CH_2
 CH_2
 N
 NH
 $C-NH_2$
 NH
 NH

PAGE 2-A

●2 HCl

RN 737826-86-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

RN 737826-88-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

•2 HCl

RN 737826-90-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-2-thiazolyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$\sim$$
 CH₂ \sim CH₂

PAGE 2-A

| Me

●3 HCl

RN 737826-92-5 CAPLUS

CN

5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim CH₂- CH₂- C- NMe₂ \sim O

● HCl

RN 737826-98-1 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737827-00-8 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CH₂-CH₂-CH₂ \sim CH₂-CH₂ \sim CH₂-CH₂-CH₂ \sim CH₂-CH₂-CH₂ \sim CH₂-CH₂-CH₂-CH₂ \sim CH₂-

● HCl

RN 737827-02-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

•2 HCl

RN 737827-05-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = NH - C - NH_2$$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$

●2 HC1

ACNH
$$\sim$$
 CH₂ \sim CH₂

•2 HCl

RN 737827-09-7 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737827-14-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•2 HCl

RN 737827-16-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•2 HCl

RN 737827-21-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737827-23-5 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2 - CH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $O = S - Me$
 $O = S - Me$

RN 737827-26-8 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2$$
 H NH_2

RN 737827-29-1 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

● HCl

RN 737827-34-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(2-aminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

RN 737827-42-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim HC1

RN 865294-39-9 CAPLUS

CN

Carbamic acid, [4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim HCl

RN 865294-40-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HCl

а

AB The present invention provides an aqueous composition comprising a thiazole derivative

or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alc., boric acid or its salt, and water. The aqueous composition is very stable and can be stored for

long time. For example, a 0.3% aqueous solution of N-[4-[2-[4-

[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3thiazol-2-yl]acetamide (I) (pH 6) was prepared using HCl acid and an additive selected from glycerin 2.5%, mannitol 4.7%, or boric acid 1.68%. The solution was stored at 40° in the low-d. polyethylene container.

The concentration of the thiazole compound I after 1 mo, 3 mo, and 6 mo was 105.4,

110.6 and 112.3% of the original 100% concentration of I for glycerin, 103.7, 108.4 and 109.6% for mannitol, and 104.9, 106.2, and 108.2% for boric acid, resp.

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN L8

ACCESSION NUMBER:

2004:991104 CAPLUS

DOCUMENT NUMBER:

142:126546

TITLE:

Non-Nucleoside Benzimidazole-Based Allosteric

Inhibitors of the Hepatitis C Virus NS5B Polymerase:

Inhibition of Subgenomic Hepatitis C Virus RNA

Replicons in Huh-7 Cells

AUTHOR(S):

Beaulieu, Pierre L.; Bousquet, Yves; Gauthier, Jean; Gillard, James; Marquis, Martin; McKercher, Ginette;

Pellerin, Charles; Valois, Serge; Kukolj, George

CORPORATE SOURCE:

Departments of Chemistry and Biological Sciences,

Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S2G5,

Can.

SOURCE:

Journal of Medicinal Chemistry (2004), 47(27),

6884-6892

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

English

LANGUAGE:

CASREACT 142:126546

OTHER SOURCE(S): IT 390813-39-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(non-nucleoside benzimidazole-based allosteric inhibitors of hepatitis C virus NS5B polymerase and inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells)

390813-39-5 CAPLUS RN

1H-Benzimidazole-5-carboxamide, N-[(1S)-1-[2-(acetylamino)-4-thiazoly1]-2-CN (4-hydroxyphenyl)ethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 852446-55-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(non-nucleoside benzimidazole-based allosteric inhibitors of hepatitis C virus NS5B polymerase and inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells)

RN 852446-55-0 CAPLUS

CN Carbonic acid, 4-[(2S)-2-[2-(acetylamino)-4-thiazolyl]-2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]phenyl 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

AB A previously disclosed series of nonnucleoside allosteric inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) was optimized to yield novel compds. With improved physicochem. properties and activity in cell-based assays. Replacement of ionizable carboxylic acids with neutral substituents in lead compds. produced inhibitors with cellular permeability and antiviral activity in a cell-based assay of subgenomic HCV RNA replication (replicon EC50 as low as 1.7 μM). The improvement in potency in this ex vivo model of HCV RNA replication validates, in part, the mechanism by which this class of allosteric benzimidazole derivs. inhibits the polymerase and represents a significant step forward in the discovery of novel HCV therapeutics.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857384 CAPLUS

DOCUMENT NUMBER: 141:350160

TITLE: treatment of vascular hyperpermeable disease using

acylaminothiazoles and related compounds as/vascular

adhesion protein-1 (VAP-1) inhibitors.

INVENTOR(S): Ueno, Ryuji; Nagashima, Akira; Inoue, Takayuki;

Ohkubo, Mitsuru; Yoshihara, Kousei

PATENT ASSIGNEE(S): Sucampo Ag, Switz.; Fujisawa Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2004087138	A1 2004101	WO 2004-JP4596	20040331
W: AE, AG,	AL, AM, AT, AU, AZ	, BA, BB, BG, BR, BW, BY,	BZ, CA, CH,
CN, CO,	CR, CU, CZ, DE, DK	, DM, DZ, EC, EE, EG, ES,	FI, GB, GD,
GE, GH,	GM, HR, HU, ID, IL	, IN, IS, JP, KE, KG, KP,	KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG 20041014 CA 2004-2520957 20040331 CA 2520957 AΑ EP 1608365 20051228 EP 2004-724735 20040331 Α1 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK US 2003-458370P PRIORITY APPLN. INFO.: P 20030331 WO 2004-JP4596 W 20040331 OTHER SOURCE(S): MARPAT 141:350160 737822-91-2P 737824-46-3P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

IT

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 737822-91-2 CAPLUS

Carbamimidothioic acid, [4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-, CN methyl ester, monohydriodide (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-SMe} \end{array}$$

HI

737824-46-3 CAPLUS RN

CN

Acetamide, N-[4-[2-(4-aminophenyl)] ethyl] -5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

```
IT
    183365-33-5P 737822-86-5P 737822-89-8P
     737822-94-5P 737823-04-0P 737823-05-1P
    737823-09-5P 737823-19-7P 737823-29-9P
    737823-34-6P 737823-37-9P 737823-41-5P
    737823-47-1P 737823-48-2P 737823-50-6P
     737823-52-8P 737823-55-1P 737823-67-5P
     737823-78-8P 737823-84-6P 737823-88-0P
     737823-92-6P 737823-96-0P 737824-00-9P
     737824-05-4P 737824-09-8P 737824-13-4P
     737824-15-6P 737824-17-8P 737824-19-0P
     737824-21-4P 737824-23-6P 737824-25-8P
     737824-27-0P 737824-30-5P 737824-32-7P
     737824-34-9P 737824-40-7P 737824-54-3P
     737824-56-5P 737824-57-6P 737824-60-1P
     737824-76-9P 737824-82-7P 737824-83-8P
     737824-84-9P 737824-85-0P 737824-86-1P
     737824-87-2P 737824-92-9P 737825-09-1P
     737825-15-9P 737825-19-3P 737825-30-8P
     737825-35-3P 737825-38-6P 737825-42-2P
     737825-45-5P 737825-49-9P 737825-52-4P
     737825-56-8P 737825-60-4P 737825-64-8P
     737825-68-2P 737825-70-6P 737825-72-8P
     737825-74-0P 737825-76-2P 737825-78-4P
     737825-80-8P 737825-82-0P 737825-84-2P
     737825-86-4P 737825-88-6P 737825-90-0P
     737825-92-2P 737825-94-4P 737825-96-6P
     737825-98-8P 737826-00-5P 737826-02-7P
     737826-05-0P 737826-07-2P 737826-09-4P
     737826-11-8P 737826-13-0P 737826-15-2P
     737826-16-3P 737826-22-1P 737826-27-6P
     737826-33-4P 737826-36-7P 737826-39-0P
     737826-42-5P 737826-43-6P 737826-44-7P
     737826-45-8P 737826-48-1P 737826-59-4P
     737826-71-0P 737826-74-3P 737826-77-6P
     737826-80-1P 737826-86-7P 737826-88-9P
     737826-90-3P 737826-92-5P 737826-98-1P
     737827-00-8P 737827-02-0P 737827-05-3P
     737827-07-5P 737827-09-7P 737827-14-4P
     737827-16-6P 737827-21-3P 737827-23-5P
     737827-26-8P 737827-29-1P 737827-34-8P
     737827-42-8P
```

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 183365-33-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737822-86-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C-NH}_2 \\ & \text{NH} & \text{C-NH}_2 \\ & \text{S-NH} & \text{CH}_2 - \text{CH}_2 \\ \end{array}$$

RN 737822-89-8 CAPLUS

CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737822-94-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-04-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} - \text{C-Me} \\ & \text{S} \end{array}$$

RN 737823-05-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminoiminomethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{C-NH}_2 \\ & \text{CH}_2 - \text{CH}_2 \\ & \text{CH}_2 \\ \end{array}$$

● HCl

RN 737823-09-5 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ & \text{NH-C-CH}_2 - \text{NH-C-NH}_2 \\ \\ & \text{AcNH} \\ & \text{S} \end{array}$$

● HCl

RN 737823-19-7 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-29-9 CAPLUS

CN Acetamide, N-[4-[2-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737823-34-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ \parallel & \text{NH} - \text{C-NH}_2 \\ \hline & \text{S} & \text{Br} \end{array}$$

● HC1

RN 737823-37-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-41-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(methyleneamino)oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-47-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NHMe} \\ \\ \text{AcNH} \\ \\ \text{S-} \end{array}$$

RN 737823-48-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-chloro-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NH}_2 \\ \text{S-C1} \end{array}$$

● HCl

RN 737823-50-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{CH}_2 - \text{NH} - \text{C} - \text{NH}_2 \\ & \text{S} \end{array}$$

● HCl

RN 737823-52-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737823-55-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(ethylamino)iminomethyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-67-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737823-78-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂ \sim NH-C-NH₂ \sim NH-C-NH₂ \sim NH-C-NH₂ \sim NHMe \sim O

● HCl

RN 737823-84-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $C-NHPh$
 CH_2-CH_2
 $C-NHPh$

HC1

RN 737823-88-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim CH₂ \sim NH \sim N

● HCl

RN 737823-92-6 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH- C- NH₂ \sim C- NH- CH₂- Ph \sim O

● HCl

RN 737823-96-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-nitrophenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-00-9 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl
]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-05-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(trifluoromethyl)phenyl]methy
l]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH \sim NH

●2 HCl

RN 737824-15-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester
(9CI) (CA INDEX NAME)

ACNH
$$NH = C + NH_2$$
 $C = 0$
 $NH = C + NH_2$
 $C = 0$
 $NH = C + NH_2$
 $C = 0$
 $NH = C + NH_2$
 $C = 0$

RN 737824-17-8 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $C = 0$
 $NH = C - NH_2$
 $NH = C - NH_2$
 $NH = C - NH_2$

RN 737824-19-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-21-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH - C - NH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH_2$

● HCl

RN 737824-23-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737824-25-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 737824-27-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$C=0$$

$$C=NH_{2}$$

$$C-NH_{2}$$

HCl

RN 737824-30-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737824-32-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = NH - C - NH_2$$
 $C = 0$
 $C = NH_2 - CH_2 - CH_2$
 $C = NH_2 - CH_2 - CH_2$

● HCl

RN 737824-34-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2 \end{array}$$

● HCl

RN 737824-40-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(phenylmethyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CH₂-Ph

HCl

RN 737824-54-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-56-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me \sim CH₂ \sim Me

● HCl

RN 737824-57-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim MH \sim CH₂ \sim NH \sim

RN 737824-60-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(ethylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

HC1

RN 737824-76-9 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-82-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-83-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

O
$$\longrightarrow$$
 S \longrightarrow Me \longrightarrow CH2 \longrightarrow NHAC

RN 737824-84-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me \sim O \sim S \sim Me

RN 737824-85-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(iminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

RN 737824-86-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

RN 737824-87-2 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl}- (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH_2 CH_2

RN 737824-92-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-09-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-15-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2$$
 $CH_2 - NH - C - NH_2$
 $O = S - Me$

● HCl

RN 737825-19-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl] ethyl]-5-thiazolyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

● HCl

RN 737825-30-8 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$N_{S}$$
 CH_{2} CH_{2}

● HCl

RN 737825-35-3 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-38-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CH₂-NMe₂

•2 HCl

RN 737825-42-2 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

•2 HCl

RN 737825-45-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$NH = C - NH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $NH = C - NH_2$
 $NH = C - NH_2$
 $NH = C - NH_2$
 $NH = C - NH_2$

PAGE 2-A

●2 HCl

RN 737825-49-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

●2 HCl

RN 737825-52-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 - \text{CH}_2 \\ & \text{C} - \text{NH} - \text{CH}_2 - \text{C} - \text{NMe}_2 \\ & \text{O} & \text{O} \end{array}$$

● HCl

RN 737825-56-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737825-60-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $NH-C-NH_2$
 $C-NH-CH_2-CH_2-NHAC$
 $C-NH-CH_2-CH_2-NHAC$

HCl

RN 737825-64-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-

[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-68-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-Nmethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2 - CH$$

HCl

RN 737825-70-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-[methyl(phenylmethyl)amino]-3oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim Me \sim CH₂- CH₂- CH₂- CH₂- Ph \sim O

● HCl

RN 737825-72-8 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2$$

HCl

RN 737825-74-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737825-76-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-CH₂-CH₂-S-Me \sim O O

● HCl

●2 HCl

RN 737825-82-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-(3-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

● HCl

ACNH
$$\sim$$
 CH₂ - CH₂ \sim NH \sim \sim NH

● HCl

RN 737825-88-6 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-oxo-3[(phenylmethyl)amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-90-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

HCl

RN 737825-92-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH

NH

NH

NH

$$CH_2 - CH_2$$

NH

 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$

PAGE 2-A

●2 HCl

RN 737825-94-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-

, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-96-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim Me \sim CH₂-CH₂ \sim Me \sim O

● HCl

RN 737825-98-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-00-5 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $C = O$
 $NH = C - NH_2$
 $C = O$
 $NH = C - NH_2$
 $O = S - Me$
 $O = S - Me$

RN 737826-05-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 737826-07-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-09-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1(hydroxymethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

Absolute stereochemistry.

● HCl

RN 737826-13-0 CAPLUS

CN Pentanediamide, 2-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phen yl]ethyl]-5-thiazolyl]carbonyl]amino]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-15-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-16-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737826-22-1 CAPLUS

CN Propanamide, 3-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl] ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-CH₂-C-NMe₂
 \sim CH₂-N-CH₂-CH₂-C-NMe₂
 \sim Me

●2 HC1

RN 737826-27-6 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]e thyl]-5-thiazolyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-33-4 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]e thyl]-5-thiazolyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-36-7 CAPLUS

CN Carbamic acid, [4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]pheny 1]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

● HCl

RN 737826-39-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH - C - NH_2$$
 $CH_2 - CH_2$
 CH_2
 CH_2

●2 HC1

RN 737826-42-5 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

RN 737826-43-6 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$C$$
 CH_2 CH_2

RN 737826-44-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

HCl

RN 737826-45-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737826-48-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{CH}_2-\text{CH}_2-\text{NH}-\text{C-NH}_2 \\ \end{array}$$

HCl

RN 737826-59-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

● HCl

RN 737826-71-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-[(aminoiminomethyl)aminomethyl]ethyl]-5-[(1,1-[(aminoiminomethyl)aminomethyl]ethyl]-5-[(1,1-[(aminoiminomethyl)aminomethyl]ethyl]-5-[(1,1-[(aminoiminomethyl)aminomethyl]ethyl]ethyllaminomethylaminome

dioxido-4-thiomorpholinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI)
(CA INDEX NAME)

•2 HCl

RN 737826-74-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-morpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

●2 HCl

RN 737826-77-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim N

●2 HCl

RN 737826-80-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$\begin{array}{c} NH \\ \parallel \\ NH - C - NH_2 \end{array}$$

$$\begin{array}{c} CH_2 - CH_2 \\ \downarrow \\ CH_2 \\ \downarrow \\ N \\ C - NMe_2 \\ \parallel \\ O \end{array}$$

PAGE 2-A

•2 HCl

RN 737826-86-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

RN 737826-88-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH

$$NH$$
 CH_2
 CH_2

PAGE 2-A

•2 HCl

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-2-thiazolyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$\sim$$
 CH₂ \sim CH₂

PAGE 2-A

●3 HCl

Me

RN 737826-92-5 CAPLUS

CN

5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 - \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2 - \text{C} - \text{NMe}_2 \\ & \text{O} \end{array}$$

HCl

RN 737826-98-1 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-C-NHMe \sim O

● HCl

RN 737827-00-8 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ \parallel & \text{NH} \\ \text{CH}_2 - \text{CH}_2 - \text{CH}_2 \\ \text{CH}_2 - \text{CH}_2 - \text{C} - \text{NH}_2 \\ \parallel & \text{O} \end{array}$$

● HCl

RN 737827-02-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim N

●2 HCl

RN 737827-05-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

RN 737827-07-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

•2 HCl

RN 737827-09-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737827-14-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737827-16-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•2 HCl

RN 737827-21-3 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-,
dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HC1

RN 737827-23-5 CAPLUS
CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH_2 CH_2 NH_2 NH_2 CH_2 CH_2 NH_2 NH

RN 737827-26-8 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Acnh} & \text{N} \\ \text{S} & \text{CH}_2\text{--} \text{CH}_2 \\ \end{array}$$

RN 737827-29-1 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CH₂-CH₂ \sim Me

● HCl

RN 737827-34-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(2-aminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Acnh} \\ \text{S} \end{array} \begin{array}{c} \text{CH}_2 - \text{CH}_2 \\ \text{CH}_2 \end{array}$$

●2 HCl

RN 737827-42-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

IT 737827-47-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 737827-47-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{CH}_2-\text{CH}_2-\text{NH}-\text{C-NH}_2 \\ \end{array}$$

IT 183365-28-8P 183365-29-9P 737822-88-7P

737822-90-1P 737822-92-3P 737822-93-4P 737823-07-3P 737823-10-8P 737823-11-9P 737823-20-0P 737823-21-1P 737823-22-2P 737823-30-2P 737823-31-3P 737823-32-4P 737823-33-5P 737823-35-7P 737823-36-8P 737823-39-1P 737823-40-4P 737823-49-3P 737823-51-7P 737823-53-9P 737823-54-0P 737823-74-4P 737823-75-5P 737823-76-6P 737823-77-7P 737823-79-9P 737823-80-2P 737823-81-3P 737823-82-4P 737823-83-5P 737823-85-7P 737823-86-8P 737823-87-9P 737823-89-1P 737823-90-4P 737823-91-5P 737823-93-7P 737823-94-8P 737823-95-9P 737823-97-1P 737823-98-2P 737823-99-3P 737824-01-0P 737824-02-1P 737824-03-2P 737824-04-3P 737824-06-5P 737824-07-6P 737824-08-7P 737824-10-1P 737824-14-5P 737824-18-9P 737824-20-3P 737824-22-5P 737824-24-7P 737824-29-2P 737824-31-6P 737824-33-8P 737824-37-2P 737824-38-3P 737824-39-4P 737824-43-0P 737824-44-1P 737824-45-2P 737824-52-1P 737824-53-2P 737824-55-4P 737824-58-7P 737824-59-8P 737824-67-8P 737824-68-9P 737824-69-0P 737824-71-4P 737824-77-0P 737824-78-1P 737824-79-2P 737824-80-5P 737824-81-6P 737824-88-3P 737824-89-4P 737824-90-7P 737824-91-8P 737824-94-1P 737824-95-2P 737825-10-4P 737825-11-5P 737825-12-6P 737825-13-7P 737825-14-8P 737825-16-0P 737825-18-2P 737825-25-1P 737825-27-3P 737825-28-4P 737825-31-9P 737825-32-0P 737825-33-1P 737825-34-2P 737825-36-4P 737825-37-5P 737825-40-0P 737825-41-1P 737825-44-4P 737825-48-8P 737825-50-2P 737825-51-3P 737825-53-5P 737825-54-6P 737825-55-7P 737825-57-9P 737825-58-0P 737825-59-1P 737825-61-5P 737825-62-6P 737825-63-7P 737825-65-9P 737825-66-0P 737825-67-1P 737825-69-3P 737825-71-7P 737825-73-9P 737825-75-1P 737825-77-3P 737825-79-5P 737825-85-3P 737825-87-5P 737825-89-7P 737825-91-1P 737825-93-3P 737825-95-5P 737825-97-7P 737825-99-9P 737826-01-6P 737826-03-8P 737826-04-9P 737826-08-3P 737826-10-7P 737826-12-9P 737826-14-1P 737826-17-4P 737826-18-5P 737826-19-6P 737826-20-9P 737826-21-0P 737826-23-2P 737826-24-3P 737826-25-4P 737826-26-5P 737826-28-7P 737826-29-8P 737826-30-1P 737826-31-2P 737826-32-3P 737826-34-5P 737826-35-6P 737826-37-8P 737826-38-9P 737826-40-3P 737826-47-0P 737826-49-2P 737826-68-5P 737826-69-6P 737826-70-9P 737826-73-2P 737826-76-5P 737826-79-8P 737826-81-2P 737826-82-3P 737826-84-5P 737826-85-6P 737826-87-8P 737826-89-0P 737826-91-4P 737826-93-6P 737826-94-7P 737826-97-0P 737826-99-2P

```
737827-01-9P 737827-04-2P 737827-06-4P
    737827-08-6P 737827-10-0P 737827-13-3P
    737827-15-5P 737827-17-7P 737827-20-2P
    737827-22-4P 737827-25-7P 737827-28-0P
    737827-31-5P 737827-32-6P 737827-33-7P
    737827-35-9P 737827-43-9P 737827-44-0P
    737827-45-1P 737827-46-2P 740816-44-8P
    776326-32-0P 776326-33-1P 776326-34-2P
    776326-42-2P 776326-43-3P 776326-45-5P
    776326-51-3P 776326-53-5P 776327-07-2P
    776327-23-2P 776327-31-2P 776327-34-5P
    776327-40-3P 776327-70-9P 776327-71-0P
    776327-87-8P 776327-92-5P 776327-94-7P
    776327-96-9P 776327-98-1P 776328-14-4P
    776328-17-7P 776328-27-9P 776328-41-7P
    776328-45-1P 776328-48-4P 776328-56-4P
    777071-34-8P 777071-37-1P 777071-46-2P
    777071-49-5P 777081-32-0P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (treatment of vascular hyperpermeable disease using acylaminothiazoles
        and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)
RN
    183365-28-8 CAPLUS
    Acetamide, N-[4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA
CN
     INDEX NAME)
```

Double bond geometry as shown.

RN 183365-29-9 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737822-88-7 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

0

RN 737822-90-1 CAPLUS

CN Acetamide, N-[4-[(1E)-2-(4-aminophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737822-92-3 CAPLUS

CN Benzamide, N-[[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]thiox omethyl]- (9CI) (CA INDEX NAME)

RN 737822-93-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} S \\ NH-C-NH_2 \\ \hline \\ S \end{array}$$

RN 737823-07-3 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-10-8 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & & & & & \\ & & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ &$$

RN 737823-11-9 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737823-20-0 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-OH

RN 737823-21-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-22-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(diformylamino)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{CHO} \\ \text{CH}_2 - \text{N-CHO} \\ \\ \text{CH}_2 - \text{CH}_2 \end{array}$$

RN 737823-30-2 CAPLUS

CN Acetamide, N-[4-[2-(3-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-31-3 CAPLUS

CN Acetamide, N-[4-[2-(3-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-32-4 CAPLUS

CN Carbamic acid, [[3-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-33-5 CAPLUS

AcNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-OBu-t \sim OBu-t \sim OBu-t

RN 737823-35-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-36-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
S

$$CH_2-CH_2$$
 $N=C-OBu-t$
 $C-NH-C-OBu-t$
 C

RN 737823-39-1 CAPLUS

RN 737823-40-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-49-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-chloro-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-CH₂ \sim NH-C-OBu-t \sim C1

RN 737823-51-7 CAPLUS

CN Carbamic acid, [[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]methyl]ca rbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 737823-53-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[(1E)-2-(4-nitrophenyl)ethenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-54-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737823-74-4 CAPLUS

CN Acetamide, N-[5-[4-(methylthio)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-75-5 CAPLUS

CN Acetamide, N-[5-[4-(methylsulfonyl)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-76-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-77-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-79-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737823-80-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

AcNH
$$CH_2-CH_2$$
 $NH-C-OBu-t$ CO_2H

RN 737823-81-3 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-82-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methyl-(9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH₂ \sim NH₂ \sim NH₂ \sim NH₂ \sim NHMe

RN 737823-83-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-85-7 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-86-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenyl-(9CI) (CA INDEX NAME)

RN 737823-87-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-89-1 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-90-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

RN 737823-91-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-93-7 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-94-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 737823-95-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-97-1 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-98-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

RN 737823-99-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl] bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-01-0 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[[4-(methylthio)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH

$$CH_2$$
 CH_2
 CH_2

PAGE 2-A

RN 737824-06-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737824-07-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 737824-08-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[[4-

(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

RN 737824-10-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Acnh} & \text{CH}_2 - \text{CH}_2 \\ \hline \\ \text{CO}_2\text{H} \end{array}$$

RN 737824-14-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoy l]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-18-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-20-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-22-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylcarbonyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-24-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-29-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

RN 737824-31-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-CH_2
 CH_2-CH_2

RN 737824-33-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-37-2 CAPLUS

CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-38-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-39-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-phenyl-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-43-0 CAPLUS

CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-(phenylmethyl)-2-thiazolyl]-(9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH \sim CH \sim CH \sim Ph

RN 737824-44-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-45-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(phenylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 737824-52-1 CAPLUS

CN Acetamide, N-[5-[[4-(methylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-53-2 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-55-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-58-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me

RN 737824-59-8 CAPLUS

CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)

HI

RN 737824-67-8 CAPLUS

CN Acetamide, N-[5-[[4-(ethylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-68-9 CAPLUS

CN Acetamide, N-[5-[[4-(ethylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-69-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(ethylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-71-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737824-77-0 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737824-78-1 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737824-79-2 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

RN 737824-80-5 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-81-6 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-88-3 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-89-4 CAPLUS

CN Acetamide, N-[4-[2-[4-(cyanomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA

INDEX NAME)

RN 737824-90-7 CAPLUS

CN Benzeneethanimidic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{NH} & \text{NH} \\ \text{CH}_2-\text{CH}_2 \end{array}$$

● HCl

RN 737824-91-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ & \text{CH}_2 - \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2 \\ \end{array}$$

HCl

RN 737824-94-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfinyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-95-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfinyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-10-4 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN

737825-11-5 CAPLUS
Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-CN thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN

737825-12-6 CAPLUS
Benzoic acid, 4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-CN thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim C-OMe \sim O \sim S-Me \sim O

RN 737825-13-7 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-14-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

RN 737825-16-0 CAPLUS

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-18-2 CAPLUS

CN Carbamic acid, [[[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]methyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl)ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2 - CH_2$$
 $CH_2 - NH - C - OBu - NH - C$

RN 737825-25-1 CAPLUS

CN Acetamide, N-[5-[(4-iodophenyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN

737825-27-3 CAPLUS
Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-nitrophenyl)ethenyl]-5-CN thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

737825-28-4 CAPLUS RN

Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME) CN

RN

737825-31-9 CAPLUS Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[(1,1-CN dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

737825-32-0 CAPLUS RN

Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[(1,1-CNdimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

RN737825-33-1 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]pheny l]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737825-34-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phen yl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-36-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-((methylamino)carbonyl]phenyl] methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737825-37-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH_2 CH_3 CH_4 CH_5 CH_5 CH_6 CH

RN 737825-40-0 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-41-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-44-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-48-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-50-2 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737825-51-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-53-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-OBu-t \sim NH-C-OBu-t

RN 737825-54-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{AcNH} & \text{N} \\ \text{S} & \text{CH}_2\text{--} \text{CH}_2 \\ \\ \text{C--} \text{NH--} \text{CH}_2\text{--} \text{C--} \text{NMe}_2 \\ \\ \text{O} & \text{O} \end{array}$$

● HCl

RN 737825-55-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-,

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-57-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737825-58-0 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{AcNH} & \text{N} \\ \text{S} & \text{CH}_2\text{--}\text{CH}_2\text{--}\text{CH}_2\text{--}\text{C} \\ \text{NM}\text{--}\text{CH}_2\text{--}\text{CH}_2\text{--}\text{C} \\ \text{NM}\text{--}\text{O} & \text{O} \\ \end{array}$$

● HCl

RN 737825-59-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-61-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carb onyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH- C- OBu-t \sim C- NH- CH₂- CH₂- NHAC \sim OBu-t

RN 737825-62-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂- CH₂- NHAC \sim O

HCl

RN 737825-63-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl] bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-65-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-[(methylsulfonyl)amino]ethyl] amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-CH₂-NH-C-OBu-t \sim C-NH-CH₂-CH₂-NH-S-Me \sim O

RN 737825-66-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-67-1 CAPLUS

RN 737825-69-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-71-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-[methyl(phenylmethyl)amino]-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}-CH_{2}-CH_{2}-DH$$

$$C-NH-CH_{2}-CH_{2}-DH$$

$$C-NH-CH_{2}-CH_{2}-DH$$

$$C-NH-CH_{2}-DH$$

RN 737825-73-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(dimethylamino)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-75-1 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(2R)-2[(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737825-77-3 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(2S)-2[(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

RN 737825-79-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(methylsulfonyl)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimido yl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-85-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-[(phenylacetyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbon imidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-87-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[5-(dimethylamino)-5-oxopentyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2 - CH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH_2$

RN 737825-89-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-oxo-3-[(phenylmethyl)amino]propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-91-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[6-(dimethylamino)-6-oxohexyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-93-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(4-morpholinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-95-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-97-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(hexylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-99-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-oxo-4-(1-piperidinyl)butyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]b is-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-01-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(4-morpholinyl)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-03-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylthio)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2-CH_2$$
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2

RN 737826-04-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-08-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]b is-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-10-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbon imidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-12-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S,2S)-1[(dimethylamino)carbonyl]-2-hydroxypropyl]amino]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-14-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-4-amino-1-[(dimethylamino)carbonyl]-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-17-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methoxymethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-OBu-t \sim CH₂-CH₂ \sim OBu-t \sim

RN 737826-18-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-formyl-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-19-6 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[(2S)-2-[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-20-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-21-0 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(2S)-2[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

RN 737826-23-2 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-24-3 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-25-4 CAPLUS

CN Propanamide, 3-[[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

RN 737826-26-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-28-7 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737826-29-8 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737826-30-1 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]- (9CI) (CA INDEX NAME)

RN 737826-31-2 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-32-3 CAPLUS CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-

[(methylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
N

$$CH_2$$
 CH_2
 CH_2

RN 737826-34-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-35-6 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-37-8 CAPLUS
CN Carbamic acid, [4-[[2-(acetylamino)-4-[2-[4-[[(1,1dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 737826-38-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methoxycarbonyl)amino]pheny l]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-40-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737826-47-0 CAPLUS

CN Carbamic acid, [2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 737826-49-2 CAPLUS

CN Carbamic acid, [[2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]c arbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-68-5 CAPLUS

CN Acetamide, N-[5-[[3-(methylsulfonyl)phenyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-69-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-70-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

RN 737826-73-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-76-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-morpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 737826-79-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(3-oxo-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-81-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737826-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 737826-84-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(1-piperazinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{2}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{2}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

RN 737826-85-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$N$$
 CH_2 CH_2 CH_2 N C CH_2 N C CH_2 CH_2 N C CH_2 N C CH_2 CH

RN 737826-87-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-89-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-91-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 737826-93-6 CAPLUS

CN 2-Propenoic acid, 3-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737826-94-7 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737826-97-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(dimethylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-99-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(methylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-01-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(3-amino-3-oxopropyl)-4-

thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2-CH_2-C-NH_2$$
 $CH_2-CH_2-C-NH_2$
 $CH_2-CH_2-C-NH_2$

RN 737827-04-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 737827-06-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737827-08-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-10-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

Absolute stereochemistry.

RN 737827-15-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3R)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. .

RN 737827-17-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 737827-20-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3S)-3[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737827-22-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3S)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737827-25-7 CAPLUS

CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737827-28-0 CAPLUS

CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737827-31-5 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737827-32-6 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

RN 737827-33-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(acetylmethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-35-9 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]e thyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{O} \\ \text{NH-CH}_2\text{-CH}_2\text{-NH-C-OBu-t} \\ \text{ACNH-} \\ \text{S-} \end{array}$$

RN 737827-43-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(1E)-2-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737827-44-0 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737827-45-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737827-46-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 740816-44-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[[[(1,1-dimethylethoxy)carbonyl]amino][[(1,1-dimethylethoxy)carbonyl]imino]methyl] amino]phenyl]ethyl]-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)

RN 776326-32-0 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776326-33-1 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 776326-34-2 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 776326-42-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX. NAME)

Double bond geometry as shown.

RN 776326-43-3 CAPLUS

CN Carbamic acid, [[C(Z)]-[4-[2-[2-(acetylamino)-5-[(3-pyridinylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776326-45-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 776326-51-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776326-53-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)

RN 776327-07-2 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776327-23-2 CAPLUS

CN Acetamide, N-[5-[(dimethylamino)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776327-31-2 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776327-34-5 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776327-40-3 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776327-70-9 CAPLUS

CN Carbamic acid, [[C(Z)]-[4-[2-(acetylamino)-5-[[(4-pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776327-71-0 CAPLUS

CN Carbamic acid, [[C(Z)]-[4-[2-[2-(acetylamino)-5-[[(3-pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 776327-87-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776327-92-5 CAPLUS

CN Acetamide, N-[5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776327-94-7 CAPLUS

CN Acetamide, N-[5-(4-morpholinylmethyl)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776327-96-9 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776327-98-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[(Z)-[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 776328-14-4 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 776328-17-7 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776328-27-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776328-41-7 CAPLUS

CN Acetamide, N-[4-[2-(3,4-dinitrophenyl)ethenyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776328-45-1 CAPLUS

CN Acetamide, N-[4-[2-(3,4-dinitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 776328-48-4 CAPLUS

CN Acetamide, N-[5-[(methylamino)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 776328-56-4 CAPLUS

CN Benzeneacetamide, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{CH}_2-\text{CH}_2\\ \text{CH}_2-\text{CH}_2 \end{array}$$

RN 777071-34-8 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 777071-37-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 777071-46-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 777071-49-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 777081-32-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

GΙ

AB A method for treating a vascular hyperpermeable disease (except macular edema), comprises administration of a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. Thus, N-[4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide (preparation given) was refluxed with HCl and cyanamide in EtOH for 26 h to give title compound (I). I inhibited human plasma VAP-1 (SSAO) with IC50 = 0.15 µM. REFERENCE COUNT:

11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648516 CAPLUS

DOCUMENT NUMBER: 141:190785

TITLE: Preparation of thiazole derivatives as VAP-1

inhibitors for treatment of macular edema and other

VAP-1 associated diseases

INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka;

Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
WO 2004067521
                            A1
                                   20040812
                                               WO 2004-JP708
                                                                         20040127
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
                                   20040812
                                               CA 2004-2514573
     CA 2514573
                            AA
                                                                         20040127
                            A1
     US 2004259923
                                   20041223
                                                US 2004-764529
                                                                         20040127
     EP 1587800
                            Α1
                                   20051026
                                                EP 2004-705519
                                                                         20040127
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.:
                                                US 2003-442509P
                                                                      Ρ
                                                                         20030127
                                                US 2003-458369P
                                                                      Ρ
                                                                         20030331
                                                US 2003-517377P
                                                                      Р
                                                                         20031106
                                                WO 2004-JP708
                                                                      W
                                                                         20040127
OTHER SOURCE(S):
                           MARPAT 141:190785
     737822-91-2P, Methyl N-[4-[2-[2-(acetylamino)thiazol-4-
     yl]ethyl]phenyl]imidothiocarbamate hydroiodide 737823-19-7P,
     N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]thiazol-2-yl]acetamide
     737823-37-9P, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]thiazol-2-
     yl]acetamide 737824-46-3P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-
     (methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-45-8P,
     N-[4-[2-[4-(2-Aminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (VAP-1 inhibitor; preparation of thiazole derivs. as VAP-1 inhibitors for
        treatment of macular edema and other VAP-1 associated diseases)
RN
     737822-91-2 CAPLUS
CN
     Carbamimidothioic acid, [4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-,
     methyl ester, monohydriodide (9CI) (CA INDEX NAME)
```

HI

RN 737823-19-7 CAPLUS
CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CFINDEX NAME)

RN 737823-37-9 CAPLUS CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-46-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-45-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

IT 183365-33-5P, N-[4-[2-[4-(4,5-Dihydrothiazol-2ylamino)phenyl]ethyl]thiazol-2-yl]acetamide 737822-86-5P,
N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide
737822-89-8P, N-[4-[(E)-2-[4-(4,5-Dihydrothiazol-2ylamino)phenyl]ethenyl]thiazol-2-yl]acetamide 737822-94-5P,
N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]thiazol-2yl]acetamide 737823-04-0P, N-[4-[2-[4(Ethanimidoylamino)phenyl]ethyl]thiazol-2-yl]acetamide
737823-05-1P, N-[4-[2-[4-[Amino(imino)methyl]phenyl]ethyl]thiazol2-yl]acetamide hydrochloride 737823-09-5P, N-[4-[2-[2(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-[[amino(imino)methyl]amino]aceta

```
mide hydrochloride 737823-29-9P, N-[4-[2-[3-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide
hydrochloride 737823-34-6P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide
hydrochloride 737823-41-5P, N-[4-[2-[4-
[[(Methyleneamino)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide
737823-47-1P, N-[4-[2-[4-[[(Imino)(methylamino)methyl]amino]phenyl
]ethyl]thiazol-2-yl]acetamide 737823-48-2P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-chlorothiazol-2-yl]acetamide
hydrochloride 737823-50-6P, N-[4-[2-[4-
[[[Amino(imino)methyl]amino]methyl]phenyl]ethyl]thiazol-2-yl]acetamide
hydrochloride 737823-52-8P, Ethyl 2-(acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxylate
hydrochloride 737823-55-1P, N-[4-[2-[4-
[[(Ethylamino)(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide
737823-67-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride
737823-78-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-methylthiazole-5-carboxamide
hydrochloride 737823-84-6P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-phenylthiazole-5-carboxamide
hydrochloride 737823-88-0P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N, N-dimethylthiazole-5-
carboxamide hydrochloride 737823-92-6P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-benzylthiazole-5-carboxamide
hydrochloride 737823-96-0P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-nitrobenzyl)thiazole-5-
carboxamide hydrochloride 737824-00-9P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-
(methylsulfonyl)benzyl]thiazole-5-carboxamide hydrochloride
737824-05-4P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-
(trifluoromethyl)benzyl]thiazole-5-carboxamide hydrochloride
737824-09-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-(3-pyridinyl)thiazole-5-
carboxamide dihydrochloride 737824-13-4P, 2-(Acetylamino)-4-[2-
[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-phenoxybenzyl)thiazole-5-
carboxamide hydrochloride 737824-15-6P, Ethyl
4-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
1-5-yl]carbonyl]-1-piperazinecarboxylate 737824-17-8P,
N-[5-[(4-Acetyl-1-piperazinyl)carbonyl]-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide
737824-19-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]thiazol-2-yl]acetamide
hydrochloride 737824-21-4P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-
thiomorpholinylcarbonyl)thiazol-2-yl]acetamide hydrochloride
737824-23-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]thiazol-2-yl]acetamide
hydrochloride 737824-25-8P, Ethyl 1-[[2-(acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-4-
piperidinecarboxylate hydrochloride 737824-27-0P,
1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
1-5-yl]carbonyl]-4-piperidinecarboxamide hydrochloride
737824-30-5P, 1-[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N-methyl-4-
piperidinecarboxamide hydrochloride 737824-32-7P,
1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
1-5-yl]carbonyl]-N,N-dimethyl-4-piperidinecarboxamide hydrochloride
```

```
737824-34-9P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-phenylthiazol-2-yllacetamide hydrochloride 737824-40-7P.
N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-benzylthiazol-2-
yl]acetamide hydrochloride 737824-54-3P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-56-5P,
N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride
737824-57-6P, N-[4-[2-[4-[[Hydrazino(imino)methyl]amino]phenyl]eth
yl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide
737824-60-1P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-[4-(ethylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride
737824-76-9P, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-82-7P,
N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-83-8P,
N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-84-9P,
N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-85-0P,
N-[4-[2-[4-((Iminomethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide
737824-86-1P, N-[4-[2-[4-[[Hydrazino(imino)methyl]amino]phenyl]eth
yl]thiazol-2-yl]acetamide 737824-87-2P, N-[4-[2-[4-(2-Amino-2-
iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-92-9P,
N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-
(methylthio)benzyl]thiazol-2-yl]acetamide 737825-09-1P,
N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]-5-[4-
(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-15-9P,
N-[4-[2-[4-[[(Amino(imino)methyl]amino]methyl]phenyl]ethyl]-5-[4-
(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride
737825-19-3P, Methyl 4-[[2-(acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate
hydrochloride 737825-30-8P, 4-[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-
dimethylbenzamide hydrochloride 737825-35-3P,
4-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
1-5-yl]methyl]-N-methylbenzamide hydrochloride 737825-38-6P,
N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-
[(dimethylamino)methyl]thiazol-2-yl]acetamide dihydrochloride
737825-42-2P, N-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide
dihydrochloride 737825-45-5P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-
piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride
737825-49-9P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-(4-thiomorpholinylmethyl)thiazol-2-yl]acetamide dihydrochloride
737825-52-4P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-
oxoethyl]thiazole-5-carboxamide hydrochloride 737825-56-8P,
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-
(dimethylamino) -3-oxopropyl]thiazole-5-carboxamide hydrochloride
737825-60-4P, 2-(Acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxamide
hydrochloride 737825-64-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-
[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride
737825-68-2P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-
N-methylthiazole-5-carboxamide hydrochloride 737825-70-6P,
```

```
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-
[benzyl(methyl)amino]-3-oxopropyl]thiazole-5-carboxamide hydrochloride
737825-72-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-
oxobutyl]thiazole-5-carboxamide hydrochloride 737825-74-0P,
(2R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]t
hiazol-5-yl]carbonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride
737825-76-2P, (2S)-1-[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N, N-
dimethyl-2-pyrrolidinecarboxamide hydrochloride 737825-78-4P,
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-
(methylsulfonyl)ethyl]thiazole-5-carboxamide hydrochloride
737825-80-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-pyridinylmethyl)thiazole-5-
carboxamide dihydrochloride 737825-82-0P, 2-(Acetylamino)-4-[2-
[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(3-pyridinylmethyl)thiazole-
5-carboxamide dihydrochloride 737825-84-2P, 2-(Acetylamino)-4-[2-
[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-[(2-
phenylacetyl)amino]ethyl]thiazole-5-carboxamide hydrochloride
737825-86-4P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-
oxopentyl]thiazole-5-carboxamide hydrochloride 737825-88-6P,
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-
(benzylamino) -3-oxopropyl]thiazole-5-carboxamide hydrochloride
737825-90-0P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-
oxohexyl}thiazole-5-carboxamide hydrochloride 737825-92-2P,
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(4-
morpholinyl)propyl]thiazole-5-carboxamide dihydrochloride
737825-94-4P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(2-oxo-1-
pyrrolidinyl)propyl]thiazole-5-carboxamide hydrochloride
737825-96-6P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-hexylthiazole-5-carboxamide
hydrochloride 737825-98-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-oxo-4-(1-
piperidinyl)butyl]thiazole-5-carboxamide hydrochloride
737826-00-5P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-
oxobutyl]thiazole-5-carboxamide hydrochloride 737826-02-7P,
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-
(methylsulfonyl)phenyl]thiazole-5-carboxamide hydrochloride
737826-05-0P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-
methyl-2-oxoethyl]thiazole-5-carboxamide hydrochloride
737826-07-2P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-1-benzyl-2-
(dimethylamino) -2-oxoethyl]thiazole-5-carboxamide hydrochloride
737826-09-4P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-
(hydroxymethyl) -2-oxoethyl]thiazole-5-carboxamide hydrochloride
737826-11-8P, 2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S,2S)-1-
[(dimethylamino)carbonyl]-2-hydroxypropyl]thiazole-5-carboxamide
hydrochloride 737826-13-0P, (2S)-2-[[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]amino]-N,N-
dimethylpentanediamide hydrochloride 737826-15-2P,
N-[4-[2-[4-[[(Imino)(methylamino)methyl]amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-16-3P,
```

```
(2S) -1 - [[2 - (Acetylamino) -4 - [2 - [4 - [[amino(imino)methyl]amino]phenyl]ethyl]t
hiazol-5-yl]methyl]-N,N-dimethyl-2-pyrrolidinecarboxamide dihydrochloride
737826-22-1P, 3-[[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl](methyl)amino]-
N, N-dimethylpropanamide dihydrochloride 737826-27-6P,
4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thia
zol-5-yl]ethyl]-N,N-dimethylbenzamide hydrochloride 737826-33-4P
, 4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]th
iazol-5-yl]ethyl]-N-methylbenzamide hydrochloride 737826-36-7P,
Methyl N-[4-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]et
hyl]thiazol-5-yl]methyl]phenyl]carbamate hydrochloride
737826-39-0P 737826-42-5P, 4-[2-[2-(Acetylamino)-5-[4-
(methylsulfonyl)benzyl]thiazol-4-yl]ethyl]-N-[amino(imino)methyl]benzamide
737826-43-6P, tert-Butyl [2-[[4-[2-[2-(acetylamino)-5-[[4-
(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]amino]-2-
oxoethyl]carbamate 737826-44-7P, N-[4-[2-[2-(Acetylamino)-5-[4-
(methylsulfonyl)benzyl]thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide
hydrochloride 737826-48-1P, N-[4-[2-[4-[2-
[[Amino(imino)methyl]amino]ethyl]phenyl]ethyl]thiazol-2-yl]acetamide
hydrochloride 737826-59-4P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[3-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride
737826-71-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-[(1,1-dioxido-4-thiomorpholinyl)methyl]thiazol-2-yl]acetamide
dihydrochloride 737826-74-3P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-morpholinylmethyl)thiazol-2-
yl]acetamide dihydrochloride 737826-77-6P, N-[4-[2-[4-
[(Amino(imino)methyl]amino]phenyl]ethyl]-5-[(3-oxo-1-
piperazinyl)methyl]thiazol-2-yl]acetamide dihydrochloride
737826-80-1P, 4-[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N, N-dimethyl-
1-piperazinecarboxamide dihydrochloride 737826-86-7P,
morpholinylcarbonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide
dihydrochloride 737826-88-9P, N-[4-[2-[4-
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-
piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride
737826-90-3P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]thiazol-2-
yl]acetamide trihydrochloride 737826-92-5P,
3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-
5-yl]-N, N-dimethylpropanamide hydrochloride 737826-98-1P,
3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-
5-yl]-N-methylpropanamide hydrochloride 737827-00-8P,
3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-
5-yl]propanamide hydrochloride 737827-02-0P,
1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
1-5-yl]methyl]-N,N-dimethyl-4-piperidinecarboxamide dihydrochloride
737827-05-3P, 1-[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-4-
piperidinecarboxamide dihydrochloride 737827-07-5P,
1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
1-5-yl]methyl]-4-piperidinecarboxamide dihydrochloride
737827-09-7P, (3R)-1-[[2-(Acetylamino)-4-[2-[4-
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-
3-piperidinecarboxamide dihydrochloride 737827-14-4P,
(3R) -1 - [[2 - (Acetylamino) -4 - [2 - [4 - [[amino(imino)methyl]amino]phenyl]ethyl]t
hiazol-5-yl]methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride
737827-16-6P, (3S)-1-[[2-(Acetylamino)-4-[2-[4-
```

[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride 737827-21-3P, (3S) -1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]t hiazol-5-yl]methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride 737827-23-5P, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737827-26-8P, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl]acetamide 737827-29-1P, N-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-Nmethylacetamide hydrochloride 737827-34-8P, N-[4-[2-[4-[(2-Aminoethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide dihydrochloride 737827-42-8P, N-[4-[2-[4-[[Amino(imino)methy1]amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737827-47-3P, N-[4-[2-[4-[2-[[Amino(imino)methyl]amino]ethyl]pheny l]ethyl]thiazol-2-yl]acetamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(VAP-1 inhibitor; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)

RN 183365-33-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737822-86-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{NH} & \text{NH} \\ \text{NH} & \text{CH}_2 \\ \text{NH} & \text{CH}_2 \\ \text{CH}_2 - \text{CH}_2 \end{array}$$

RN 737822-89-8 CAPLUS

CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737822-94-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-lH-imidazol-2-yl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-04-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

RN 737823-05-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminoiminomethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737823-09-5 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \text{NH} \\ & & & \text{NH} \\ & & \text{C} \\ & & \text{CH}_2 \\ & & \text{CH}_2 \\ & & \text{CH}_2 \\ \end{array}$$

HCl

RN 737823-29-9 CAPLUS

CN Acetamide, N-[4-[2-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737823-34-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Br

● HCl

RN 737823-41-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(methyleneamino)oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Acnh} \\ \text{S} \end{array} \begin{array}{c} \text{CH}_2 - \text{O} - \text{N} \\ \text{CH}_2 - \text{CH}_2 \end{array}$$

RN 737823-47-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NHMe} \\ \\ \text{AcNH} \\ \\ \text{S} \end{array}$$

RN 737823-48-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-chloro-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NH}_2 \\ \text{CH}_2 - \text{CH}_2 \\ \end{array}$$

● HCl

RN 737823-50-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ - CH₂ \sim CH₂ - NH- C- NH₂

● HCl

RN 737823-52-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-, ethyl ester, monohydrochloride
(9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $C-OEt$
 O

● HCl

RN 737823-55-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(ethylamino)iminomethyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-67-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737823-78-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂
 \sim C-NHMe

● HCl

RN 737823-84-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂ \sim NH-C-NH₂ \sim NH-C-NH₂ \sim NHPh \sim O

● HCl

RN 737823-88-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{C$$

● HCl

RN 737823-92-6 CAPLUS

CN

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-Ph \sim O

● HCl

RN 737823-96-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-nitrophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-00-9 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-05-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-09-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-3-pyridinyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂

•2 HCl

RN 737824-13-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-phenoxyphenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 737824-15-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester
(9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂ \sim NH-C-NH₂

RN 737824-17-8 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$NH = C + NH_2$$
 $CH_2 - CH_2 = 0$
 $NH = C + NH_2$
 $CH_2 - CH_2 = 0$

RN 737824-19-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim HCl

RN 737824-21-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737824-23-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim O

RN 737824-25-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737824-27-0 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

ACNH

NH

$$NH$$
 NH
 NH

RN 737824-30-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH- C- NH₂ \sim NH- C- NH₂ \sim NH- C- NHMe \sim NHMe \sim NH- C- NHMe \sim NHM \sim

● HCl

RN 737824-32-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $C = 0$
 $C = NMe_2$
 $C = NMe_2$

● HCl

RN 737824-34-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NH}_2 \\ \text{S-CH}_2 - \text{CH}_2 - \text{CH}_2 \\ \end{array}$$

● HCl

RN 737824-40-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(phenylmethyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CH₂-Ph

RN 737824-54-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-56-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = CH_2 - CH_2$$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$

HCl

RN 737824-57-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me

RN 737824-60-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(ethylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

● HCl

RN 737824-76-9 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CH₂-NH₂ \sim CH₂

RN 737824-82-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-83-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 737824-84-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-85-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(iminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-86-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-87-2 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH_2 CH_2

RN 737824-92-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim SMe

RN 737825-09-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Acnh
$$CH_2-CH_2$$
 CH_2-O-NH_2
 CH_2-O-NH_2
 CH_2-O-NH_2

RN 737825-15-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH

$$CH_2 - NH - C - NH_2$$
 $CH_2 - NH - C - NH_2$
 $O = S - Me$

RN 737825-19-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl] ethyl]-5-thiazolyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-30-8 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = CH_2 - CH_2$$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$

RN 737825-35-3 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = CH_2 - CH_2$$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$
 $CH_2 - CH_2 = CH_2$

● HCl

RN 737825-38-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NH}_2 \\ \text{NH-C-NH}_2 \\ \text{CH}_2 - \text{CH}_2 \\ \end{array}$$

•2 HCl

RN 737825-42-2 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

•2 HCl

RN 737825-45-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$NH = C + NH_2$$
 $CH_2 - CH_2 = CH_2$
 $NH = C + NH_2$
 $CH_2 - CH_2 = CH_2$
 $NH = C + NH_2$
 $NH = C$

PAGE 2-A

●2 HCl

RN 737825-49-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

●2 HCl

RN 737825-52-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim NH- C- NH₂ \sim C- NH- CH₂ - C- NMe₂ \sim O

RN 737825-56-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{C$$

● HCl

RN 737825-60-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-CH_2-NHAC CH_2-CH_2-NHAC CH_2-CH_2-NHAC

RN 737825-64-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{CH}_2 - \text{CH}_2 \\ & \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{NH} - \text{S} - \text{Me} \\ & \text{O} & \text{O} \\ & \text{O} & \text{O} \\ \end{array}$$

● HCl

RN 737825-68-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-Nmethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $CH_2-CH_2-CH_2-CH_2-CH_2$ $CH_2-CH_2-CH_2-CH_2-CH_2$

RN 737825-70-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-[methyl(phenylmethyl)amino]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-CH₂ \sim Me \sim C-NH-CH₂-CH₂-CH₂-CH₂-Ph \sim O

● HCl

RN 737825-72-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂

$$\sim$$
 C-NH-(CH₂)₃-C-NMe₂

$$\sim$$
 O

● HCl

RN 737825-74-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

Absolute stereochemistry.

● HCl

RN 737825-78-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{CH}_2 \\ & \text{$$

● HCl

RN 737825-80-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = C - NH_2$$
 $CH_2 - CH_2$
 $NH = C - NH_2$
 $CH_2 - CH_2$
 $NH = C - NH_2$

•2 HCl

RN 737825-82-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-(3-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

•2 HCl

RN 737825-84-2 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(phenylacetyl)amino]ethyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-86-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

● HCl

RN 737825-88-6 CAPLUS CN 5-Thiazolecarboxamide,

5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-oxo-3-[(phenylmethyl)amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-NH₂ \sim NH-C-NH₂ \sim NH-CH₂-CH₂-C-NH-CH₂-Ph \sim O

● HCl

RN 737825-90-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

HCl

RN 737825-92-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH

$$CH_2 - CH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$

PAGE 2-A

●2 HCl

RN 737825-94-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-

, monohydrochloride (9CI) (CA INDEX NAME)

N— (CH₂)₃-NH-C
N
CH₂
CH₂
CH₂

$$CH_2$$
 CH_2
 CH_2
 CH_2
 CH_2
 CH_2
 CH_2
 CH_2

● HCl

RN 737825-96-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-hexyl-, monohydrochloride (9CI)
(CA INDEX NAME)

ACNH
$$CH_2 - CH_2$$
 $CH_2 - CH_2$ $CH_2 - CH$

● HCl

RN 737825-98-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ - CH₂ \sim HC1 \sim CH₂ \sim O \sim NH \sim NH \sim CH₂ \sim NH \sim

RN 737826-00-5 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-02-7 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737826-05-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-07-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-09-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1(hydroxymethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-11-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]-N-[(1S,2S)-1[(dimethylamino)carbonyl]-2-hydroxypropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 737826-13-0 CAPLUS

CN Pentanediamide, 2-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phen yl]ethyl]-5-thiazolyl]carbonyl]amino]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 737826-15-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-16-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•2 HCl

RN 737826-22-1 CAPLUS

CN Propanamide, 3-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl] ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

RN

737826-27-6 CAPLUS Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-(aminoiminomethyl)amino]phenyl]eCNthyl]-5-thiazolyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

737826-33-4 CAPLUS RN

Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]e CNthyl]-5-thiazolyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH - C - NH_2$$

ACNH $CH_2 - CH_2$
 CH_2
 CH

RN 737826-36-7 CAPLUS

CN Carbamic acid, [4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]pheny 1]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim MeO \sim C \sim NH \sim CH₂ \sim CH₂

● HCl

RN 737826-39-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 737826-42-5 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737826-43-6 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-44-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

● HCl

RN 737826-48-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{CH}_2-\text{CH}_2-\text{NH}-\text{C-NH}_2 \\ \end{array}$$

HCl

RN 737826-59-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim CH₂ \sim NH \sim N

● HCl

RN 737826-71-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{9}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{9}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

●2 HCl

RN 737826-74-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-morpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim NH \sim CH₂ \sim NH \sim

●2 HC1

RN 737826-77-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = CH_2 - CH_2$$
 $CH_2 - CH_2 = CH_2$
 $NH = CH_2$
 $CH_2 - CH_2 = CH_2$

2 HCl

RN 737826-80-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

•2 HCl

RN 737826-86-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

RN 737826-88-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

●2 HCl

RN 737826-90-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-2-thiazolyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$\sim$$
 CH₂ \sim CH₂

| Me PAGE 2-A

●3 HCl

RN 737826-92-5 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-CH₂ \sim NH-C-NH₂ \sim CH₂-CH₂-C-NMe₂ \sim O

● HCl

RN 737826-98-1 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{NH} & \text{NH} \\ \text{NH} & \text{C} \\ \text{NH} & \text{C$$

● HCl

RN 737827-00-8 CAPLUS
CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{NH-C-NH}_2 \\ \text{NH-C-NH}_2 \\ \text{CH}_2 - \text{CH}_2 - \text{C-NH}_2 \\ \parallel \\ \text{O} \end{array}$$

● HCl

RN 737827-02-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

●2 HCl

RN 737827-05-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$NH = CH_2 - CH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$
 $CH_2 - CH_2$

●2 HCl

RN 737827-07-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-,
dihydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$C-NH_{2}$$

$$C-NH_{2}$$

•2 HCl

RN 737827-09-7 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-,
dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•2 HCl

RN 737827-14-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737827-16-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HCl

RN 737827-21-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•2 HCl

RN 737827-23-5 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2$$
 H NH_2 $CH_2 - CH_2$ O S Me O

RN 737827-26-8 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737827-29-1 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]eth yl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ & \text{NH} & \text{C} \\ & \text{NH} & \text{C$$

● HCl

RN 737827-34-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(2-aminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Acnh} \\ \text{S} \end{array} \begin{array}{c} \text{NH- CH}_2\text{-- CH}_2\text{-- NH}_2 \\ \text{CH}_2\text{-- CH}_2 \end{array}$$

●2 HCl

RN 737827-42-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 737827-47-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \text{CH}_2 - \text{CH}_2 - \text{NH} - \text{C} - \text{NH}_2 \\ \\ \text{S} \end{array}$$

IT 183365-28-8P, N-[4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2yl]acetamide 183365-29-9P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol2-yl]acetamide 737822-88-7P, N-[4-[(Z)-2-(4Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737822-90-1P,
N-[4-[(E)-2-(4-Aminophenyl)ethenyl]thiazol-2-yl]acetamide
737822-92-3P, N-[4-[2-[4-[(Benzoylamino)carbonothioyl]amino]pheny

```
l]ethyl]thiazol-2-yl]acetamide 737822-93-4P,
N-[4-[2-[4-[(Aminocarbonothioy1)amino]phenyl]ethyl]thiazol-2-yl]acetamide
737823-06-2P, N-[4-[(Z)-2-(4-Cyanophenyl)ethenyl]thiazol-2-
yl]acetamide 737823-07-3P, N-[4-[2-(4-Cyanophenyl)ethyl]thiazol-
2-yl]acetamide 737823-08-4P, 4-[2-[2-(Acetylamino)thiazol-4-
yl]ethyl]benzenecarboximidic acid ethyl ester hydrochloride
737823-10-8P, tert-Butyl [2-[[4-[2-[2-(acetylamino)thiazol-4-
yl]ethyl]phenyl]amino]-2-oxoethyl]carbamate 737823-11-9P,
N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide
hydrochloride 737823-20-0P, N-[4-[2-[4-
(Hydroxymethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-21-1P,
N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]thiazol-2-yl]acetamide
737823-22-2P, N-[4-[2-[4-[(Diformylamino)methyl]phenyl]ethyl]thiaz
ol-2-yl]acetamide 737823-30-2P, N-[4-[2-(3-
Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-31-3P,
N-[4-[2-(3-Aminophenyl)ethyl]thiazol-2-yl]acetamide 737823-32-4P
737823-33-5P 737823-35-7P 737823-36-8P
737823-38-0P, Methyl 4-[(Z)-2-[2-(acetylamino)thiazol-4-
yl]ethenyl]benzoate 737823-39-1P, Methyl 4-[2-[2-
(acetylamino) thiazol-4-yl] ethyl] benzoate 737823-40-4P,
N-[4-[2-[4-[[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-
yl)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-49-3p
737823-51-7P 737823-53-9P, Ethyl 2-(acetylamino)-4-[(E)-
2-(4-nitrophenyl)ethenyl]thiazole-5-carboxylate 737823-54-0P,
Ethyl 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylate
737823-74-4P, N-[5-[4-(Methylthio)phenyl]-4-[(E)-2-(4-
nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-75-5P,
N-[5-[4-(Methylsulfonyl)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-
yl]acetamide 737823-76-6P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-
(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737823-77-7p
737823-79-9P, Ethyl 2-(acetylamino)-4-[2-[4-[(tert-
butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylate
737823-80-2P, 2-(Acetylamino)-4-[2-[4-[(tert-
butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylic acid
737823-81-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-
[(methylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-82-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-
methylthiazole-5-carboxamide 737823-83-5P 737823-85-7P
, tert-Butyl [4-[2-[2-(acetylamino)-5-(anilinocarbonyl)thiazol-4-
yl]ethyl]phenyl]carbamate 737823-86-8P, 2-(Acetylamino)-4-[2-(4-
aminophenyl)ethyl]-N-phenylthiazole-5-carboxamide 737823-87-9p
737823-89-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-
[(dimethylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-90-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-
dimethylthiazole-5-carboxamide 737823-91-5P 737823-93-7P
, tert-Butyl [4-[2-[2-(acetylamino)-5-[(benzylamino)carbonyl]thiazol-4-
yl]ethyl]phenyl]carbamate 737823-94-8P, 2-(Acetylamino)-4-[2-(4-
aminophenyl)ethyl]-N-benzylthiazole-5-carboxamide 737823-95-9p
737823-97-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[(4-
nitrobenzyl)amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-98-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(4-
nitrobenzyl)thiazole-5-carboxamide 737823-99-3P
737824-01-0P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[[4-
(methylthio) phenyl] methyl] amino] carbonyl] thiazol-4-
yl]ethyl]phenyl]carbamate 737824-02-1P, tert-Butyl
[4-[2-[2-(acetylamino)-5-[[[[4-(methylsulfonyl)phenyl]methyl]amino]carbony
l]thiazol-4-yl]ethyl]phenyl]carbamate 737824-03-2P,
2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-
(methylsulfonyl)benzyl]thiazole-5-carboxamide 737824-04-3p
```

```
737824-06-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[[4-
(trifluoromethyl)phenyl]methyl]amino]carbonyl]thiazol-4-
yl]ethyl]phenyl]carbamate 737824-07-6P, 2-(Acetylamino)-4-[2-(4-
aminophenyl)ethyl]-N-[4-(trifluoromethyl)benzyl]thiazole-5-carboxamide
737824-08-7P 737824-10-1P, 2-(Acetylamino)-4-[2-(4-
aminophenyl)ethyl]thiazole-5-carboxylic acid 737824-11-2P
737824-12-3P 737824-14-5P 737824-16-7P
737824-18-9P 737824-20-3P 737824-22-5P
737824-24-7P 737824-26-9P 737824-28-1P
737824-29-2P 737824-31-6P 737824-33-8P
737824-37-2P 737824-38-3P, N-[4-[2-(4-Aminophenyl)ethyl]-
5-phenylthiazol-2-yl]acetamide 737824-39-4P 737824-43-0P
737824-44-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-benzylthiazol-2-
yl]acetamide 737824-45-2P 737824-52-1P
737824-53-2P 737824-55-4P 737824-58-7P,
N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-59-8P
737824-67-8P 737824-68-9P 737824-69-0P
737824-71-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-
(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate
737824-77-0P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-
(methylthio)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate
737824-78-1P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-
(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate
737824-79-2P, Methyl 4-[2-[2-(acetylamino)-5-[[4-
(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]benzoate
737824-80-5P, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-81-6P,
N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-
2-yl]acetamide 737824-88-3P, N-[4-[2-[4-
(Chloromethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-89-4P,
N-[4-[2-[4-(Cyanomethy1)phenyl]ethyl]thiazol-2-yl]acetamide
737824-90-7P, 2-[4-[2-[2-(Acetylamino)thiazol-4-
yl]ethyl]phenyl]ethanimidic acid methyl ester hydrochloride
737824-91-8P, N-[4-[2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl]thiazo
1-2-yl]acetamide hydrochloride 737824-93-0P 737824-94-1P
, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfinyl)benzyl]thiazol-2-
yl]acetamide 737824-95-2P 737825-10-4P, Methyl
4-[(E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]thiazol-4-
yl]ethenyl]benzoate 737825-11-5P, Methyl 4-[(E)-2-[2-
(acetylamino) -5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethenyl]benzoate
737825-12-6P, Methyl 4-[2-[2-(acetylamino)-5-[4-
(methylsulfonyl)phenyl]thiazol-4-yl]ethyl]benzoate 737825-13-7P,
N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazo
1-2-yl]acetamide 737825-14-8P, N-[4-[2-[4-[[(1,3-Dioxo-1,3-
dihydro-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]-5-[4-
(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-16-0P,
N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-
2-yl]acetamide 737825-17-1P, N-[4-[2-[4-
(Aminomethyl) phenyl] ethyl] -5-[4-(methylsulfonyl) phenyl] thiazol-2-
yl]acetamide 737825-18-2P 737825-25-1P,
N-[5-(4-Iodobenzyl)-4-[2-(4-nitrophenyl)vinyl]thiazol-2-yl]acetamide
737825-27-3P 737825-28-4P, Methyl 4-[[2-(acetylamino)-4-
[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]benzoate 737825-29-5P
737825-31-9P, Methyl 4-[[2-(acetylamino)-4-[2-[4-[(tert-
butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate
737825-32-0P, 4-[[2-(Acetylamino)-4-[2-[4-[(tert-
butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoic acid
737825-33-1p, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-
```

```
[(dimethylamino)carbonyl]phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate
737825-34-2P 737825-36-4P, tert-Butyl
[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]thiazol-
4-yl]ethyl]phenyl]carbamate 737825-37-5P 737825-39-7P
737825-40-0P, N-[4-[2-(4-Aminophenyl)ethyl]-5-
[(dimethylamino)methyl]thiazol-2-yl]acetamide 737825-41-1P
737825-43-3P 737825-44-4P 737825-46-6P
737825-48-8P 737825-50-2P 737825-51-3P
737825-53-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[2-
(dimethylamino) -2-oxoethyl]amino]carbonyl]thiazol-4-
yl]ethyl]phenyl]carbamate 737825-54-6P, 2-(Acetylamino)-4-[2-(4-
aminophenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide
hydrochloride 737825-55-7P 737825-57-9P, tert-Butyl
[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-
oxopropyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737825-58-0P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-
(dimethylamino) -3-oxopropyl]thiazole-5-carboxamide hydrochloride
737825-59-1P 737825-61-5P, tert-Butyl
[4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]thiazol-4-
yl]ethyl]phenyl]carbamate 737825-62-6P, 2-(Acetylamino)-N-[2-
(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxamide
hydrochloride 737825-63-7P 737825-65-9P, tert-Butyl
[4-[2-[2-(acetylamino)-5-[[[2-[(methylsulfonyl)amino]ethyl]amino]carbonyl]
thiazol-4-yl]ethyl]phenyl]carbamate 737825-66-0P,
2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-
[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride
737825-67-1P 737825-69-3P 737825-71-7P
737825-73-9P 737825-75-1P 737825-77-3P
737825-79-5P 737825-81-9P 737825-83-1P
737825-85-3P 737825-87-5P 737825-89-7P
737825-91-1P 737825-93-3P 737825-95-5P
737825-97-7P 737825-99-9P 737826-01-6P
737826-03-8P 737826-04-9P 737826-06-1P
737826-08-3P 737826-10-7P 737826-12-9P
737826-14-1P 737826-17-4P, tert-Butyl
[4-[2-[2-(acetylamino)-5-[[methoxy(methyl)amino]carbonyl]thiazol-4-
yl]ethyl]phenyl]carbamate 737826-18-5P, tert-Butyl
[4-[2-[2-(acetylamino)-5-formylthiazol-4-yl]ethyl]phenyl]carbamate
737826-19-6P 737826-20-9P, (2S)-1-[[2-(Acetylamino)-4-[2-
(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-2-
pyrrolidinecarboxamide 737826-21-0P 737826-23-2P,
tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(N,N-dimethylamino)-3-
oxopropyl]amino]methyl]thiazol-4-yl]ethyl]phenyl]carbamate
737826-24-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(N,N-
dimethylamino) -3-oxopropyl] (methyl)amino]methyl]thiazol-4-
yl]ethyl]phenyl]carbamate 737826-25-4P, 3-[[[2-(Acetylamino)-4-
[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl](methyl)amino]-N,N-
dimethylpropanamide 737826-26-5P 737826-28-7P, Methyl
4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thi
azol-5-yl]vinyl]benzoate 737826-29-8P, Methyl
4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thi
azol-5-yl]ethyl]benzoate 737826-30-1P, 4-[2-[2-(Acetylamino)-4-
[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]ethyl]benzoic
acid 737826-31-2P, tert-Butyl [4-[2-[2-(acetylamino)-5-[2-[4-
[(methylamino)carbonyl]phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate
737826-32-3P 737826-34-5P, tert-Butyl
[4-[2-[2-(Acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]thiaz
ol-4-yl]ethyl]phenyl]carbamate 737826-35-6P 737826-37-8P
, Methyl N-[4-[[2-(acetylamino)-4-[2-[4-[(tert-
```

```
butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]phenyl]carbamate
737826-38-9P 737826-40-3P, Ethyl 1-[[2-(acetylamino)-4-
[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-5-yl]methyl]-4-piperidinecarboxylate
737826-41-4P 737826-47-0P, tert-Butyl
[2-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]ethyl]carbamate
737826-49-2P 737826-68-5P 737826-69-6P,
N-[4-[2-(4-Aminophenyl)]-5-[3-(methylsulfonyl)]
yl]acetamide 737826-70-9P 737826-72-1P
737826-73-2P 737826-75-4P 737826-76-5P
737826-78-7P 737826-79-8P 737826-81-2P,
9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[(Z)-2-(4-
nitrophenyl)ethenyl]thiazol-5-yl]methyl]-1-piperazinecarboxylate
737826-82-3P, 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[2-(4-
aminophenyl)ethyl]thiazol-5-yl]methyl]-1-piperazinecarboxylate
737826-83-4P 737826-84-5P 737826-85-6P
737826-87-8P 737826-89-0P 737826-91-4P
737826-93-6P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-
butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]-2-propenoate
737826-94-7P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-
butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]propanoate
737826-95-8P 737826-96-9P 737826-97-0P
737826-99-2P 737827-01-9P 737827-03-1P
737827-04-2P 737827-06-4P 737827-08-6P
737827-10-0P 737827-11-1P 737827-12-2P
737827-13-3P 737827-15-5P 737827-17-7P
737827-18-8P 737827-19-9P 737827-20-2P
737827-22-4P 737827-24-6P 737827-25-7P,
N-[4-[2-(3,4-Diaminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-
yl]acetamide 737827-27-9P 737827-28-0P,
N-[4-[2-(3,4-Diaminophenyl)ethyl]thiazol-2-yl]acetamide
737827-30-4P 737827-31-5P 737827-32-6P,
N-[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-N-
methylacetamide 737827-33-7P 737827-35-9P, tert-Butyl
[2-[[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]amino]ethyl]carbamate
737827-43-9P, tert-Butyl N-[4-[2-[2-(acetylamino)-5-[(E)-2-[4-
(methylsulfonyl)phenyl]ethenyl]thiazol-4-yl]ethyl]phenyl]carbamate
737827-44-0P, tert-Butyl N-[4-[2-[2-(acetylamino)-5-[2-[4-
(methylsulfonyl)phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate
737827-45-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[2-[4-
(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide 737827-46-2P
740816-44-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
   (intermediate; preparation of thiazole derivs. as VAP-1 inhibitors for
   treatment of macular edema and other VAP-1 associated diseases)
183365-28-8 CAPLUS
Acetamide, N-[4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA
INDEX NAME)
```

Double bond geometry as shown.

RN

CN

RN 183365-29-9 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737822-88-7 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737822-90-1 CAPLUS

CN Acetamide, N-[4-[(1E)-2-(4-aminophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737822-92-3 CAPLUS

CN Benzamide, N-[[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]thiox omethyl]- (9CI) (CA INDEX NAME)

RN 737822-93-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} S \\ \parallel \\ NH-C-NH_2 \end{array}$$

RN 737823-06-2 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-cyanophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-07-3 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-08-4 CAPLUS

CN Benzenecarboximidic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 737823-10-8 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-11-9 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737823-20-0 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-21-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-22-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(diformylamino)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-30-2 CAPLUS

CN Acetamide, N-[4-[2-(3-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-31-3 CAPLUS

CN Acetamide, N-[4-[2-(3-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-32-4 CAPLUS

CN Carbamic acid, [[3-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-33-5 CAPLUS

CN Carbamic acid, [[3-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $N=C-OBu-t$
 $C-NH-C-OBu-t$
 $C-OBu-t$

RN 737823-35-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-36-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $NH-C-OBu-t$ $N=C-NH-C-OBu-t$ $N=C-NH-C-OBu-t$

RN 737823-38-0 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-39-1 CAPLUS

$$\begin{array}{c} \text{O} \\ \text{C-OMe} \\ \\ \text{S-} \end{array}$$

RN 737823-40-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-49-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-chloro-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

RN 737823-51-7 CAPLUS

CN Carbamic acid, [[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]methyl]ca rbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-53-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[(1E)-2-(4-nitrophenyl)ethenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-54-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737823-74-4 CAPLUS

CN Acetamide, N-[5-[4-(methylthio)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-75-5 CAPLUS

CN Acetamide, N-[5-[4-(methylsulfonyl)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737823-76-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737823-77-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2

RN 737823-79-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737823-80-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $NH-C-OBu-t$ CO_2H

RN 737823-81-3 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-82-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methyl-(9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH₂ \sim NH₂ \sim NH₂ \sim NHMe

RN 737823-83-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-85-7 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-86-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenyl-(9CI) (CA INDEX NAME)

RN 737823-87-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-89-1 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-90-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $C-NMe_2$
 0

RN 737823-91-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-((dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-93-7 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-94-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-CH_2-Ph CH_2-Ph

RN 737823-95-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737823-97-1 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-98-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

RN 737823-99-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_{2} - CH_{2}$$

$$CH_{3} - CH_{2}$$

$$CH_{4} - CH_{2}$$

$$CH_{5} - CH_{2}$$

$$CH_{2} - CH_{2}$$

$$CH_{2} - CH_{2}$$

RN 737824-02-1 CAPLUS
CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737824-03-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 737824-04-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

Acnh
$$CH_2$$
 CH_2 CH

PAGE 2-A

RN 737824-07-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 737824-08-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-10-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{AcNH} & \text{N} \\ \text{S} & \text{CH}_2\text{--} \text{CH}_2 \\ \\ \text{CO}_2\text{H} \end{array}$$

RN 737824-11-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

RN 737824-12-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(3-pyridinylamino)carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

$$CH_{3}-CH_{2}$$

$$CH_{4}-CH_{2}$$

$$CH_{5}-CH_{2}$$

$$CH_{5}-CH_{2}$$

$$CH_{6}-CH_{2}$$

$$CH_{7}-CH_{2}$$

RN 737824-14-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoy l]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-16-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737824-18-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2-CH_2$$
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2
 CH_2-CH_2

RN 737824-20-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-22-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylcarbonyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

$$t-BuO-C-NH$$
 O $N=C-NH-C-OBu-t$ ACNH $N=C-NH-C-OBu-t$

RN 737824-24-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-26-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737824-28-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_{2}-CH_{2}$$

$$CO_{2}H$$

$$C-NH$$

$$C-NH$$

$$C-NH$$

$$C-NH$$

$$C-OBu-t$$

$$C-NH$$

$$C-OBu-t$$

RN 737824-29-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-31-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2 - CH_2$$
 $CH_2 - CH_2$
 $CH_2 - CH$

RN 737824-33-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-37-2 CAPLUS

CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-38-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-39-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-phenyl-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737824-43-0 CAPLUS

CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-(phenylmethyl)-2-thiazolyl](9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH \sim CH \sim CH \sim CH \sim Ph

RN 737824-44-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-(phenylmethyl)-2-thiazolyl](9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-Ph

RN 737824-45-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(phenylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
— Ph

RN 737824-52-1 CAPLUS

CN Acetamide, N-[5-[[4-(methylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-53-2 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-55-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl)ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2
 CH_2

RN 737824-58-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim MH \sim C \sim NH \sim NH

RN 737824-59-8 CAPLUS

CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim CH₂ \sim Me \sim CH₂ \sim Me \sim CH₂ \sim Me

● HI

RN 737824-67-8 CAPLUS

CN Acetamide, N-[5-[[4-(ethylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN

737824-68-9 CAPLUS Acetamide, N-[5-[[4-(ethylsulfonyl)phenyl]methyl]-4-[2-(4-CNnitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

737824-69-0 CAPLUS RN

Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(ethylsulfonyl)phenyl]methyl]-CN4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 737824-71-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737824-77-0 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737824-78-1 CAPLUS

Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-5-[[4-CN(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN

737824-79-2 CAPLUS
Benzoic acid, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-CNthiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂

RN 737824-80-5 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-81-6 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-88-3 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-89-4 CAPLUS

CN Acetamide, N-[4-[2-[4-(cyanomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA

INDEX NAME)

RN 737824-90-7 CAPLUS

CN Benzeneethanimidic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} \\ & \text{CH}_2\text{--}\text{CH}_2 \\ & \text{CH}_2\text{--}\text{CH}_2 \\ \end{array}$$

● HCl

RN 737824-91-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \parallel \\ \text{CH}_2 - \text{CH}_2 \\ \end{array}$$

HCl

RN 737824-93-0 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfinyl)phenyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737824-94-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfinyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737824-95-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfinyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-10-4 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737825-11-5 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN

737825-12-6 CAPLUS
Benzoic acid, 4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-CNthiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$

O $C-OMe$
 $C-OMe$
 $C-OMe$

737825-13-7 CAPLUS RN

CNAcetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-OH
 CH_2-OH
 $O=S-Me$
 $O=S-Me$

RN 737825-14-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]methyl]phenyl]=5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

RN 737825-16-0 CAPLUS

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-17-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂- NH₂
 \sim CH₂- NH₂
 \sim CH₂- NH₂
 \sim CH₂- NH₂

RN 737825-18-2 CAPLUS

CN Carbamic acid, [[[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]methyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl)ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2 - CH_2$$
 $CH_2 - N$
 $CH_2 - NH - C - OBu - t$
 $CH_2 - NH - C - OBu - t$
 $CH_2 - NH - C - OBu - t$

RN 737825-25-1 CAPLUS

CN Acetamide, N-[5-[(4-iodophenyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-27-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737825-28-4 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737825-29-5 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

RN 737825-31-9 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737825-32-0 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

RN 737825-33-1 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737825-34-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phen yl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

AcNH
$$CH_2$$
 CH_2 CH

RN 737825-36-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl] methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737825-37-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737825-39-7 CAPLUS

CN Acetamide, N-[5-[(dimethylamino)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-40-0 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-NMe_2

RN 737825-41-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

$$t-BuO-C-NH$$
 O $N=C-NH-C-OBu-t$ $N=CH_2-CH_2$ CH_2-NMe_2

RN 737825-43-3 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-44-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737825-46-6 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737825-48-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737825-50-2 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737825-51-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-53-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim NH-C-OBu-t \sim C-NH-CH₂-C-NMe₂ \sim O

RN 737825-54-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{AcNH} & \text{N} \\ \text{S} & \text{CH}_2\text{--} \text{CH}_2 \\ \hline \\ \text{C--} \text{NH--} \text{CH}_2\text{--} \text{C--} \text{NMe}_2 \\ \\ \text{O} & \text{O} \end{array}$$

HCl

RN 737825-55-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-57-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂- CH₂- C- NMe₂ \sim O \sim O

RN 737825-58-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 737825-59-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-61-5 CAPLUS

CN Carbamic acid, [4-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carb onyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH- C- OBu-t \sim C- NH- CH₂- CH₂- NHAC \sim O

RN 737825-62-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-CH_2-NHAC CH_2-CH_2-NHAC CH_2-CH_2-NHAC

HC1

RN 737825-63-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

$$t-BuO-C-NH$$
 O $N=C-NH-C-OBu-t$ $N=C-NH$

RN 737825-65-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-((methylsulfonyl)amino]ethyl] amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂-CH₂-NH-C-OBu-t \sim C-NH-CH₂-CH₂-NH-S-Me \sim O

RN 737825-66-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

• HCl

RN 737825-67-1 CAPLUS

RN 737825-69-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-71-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-[methyl(phenylmethyl)amino]-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-,

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-73-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(dimethylamino)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-75-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(2R)-2[(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737825-77-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(2S)-2[(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737825-79-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(methylsulfonyl)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimido yl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-81-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(4-pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-83-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3-pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-85-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-[(phenylacetyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbon imidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-87-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[5-(dimethylamino)-5-oxopentyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-89-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-oxo-3-[(phenylmethyl)amino]propyl]amino]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-91-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[6-(dimethylamino)-6-oxohexyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-,

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2-CH_2$$
 CH_2-CH_2
 CH_2-CH_2

RN 737825-93-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(4-morpholinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl] bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-95-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-97-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(hexylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737825-99-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-oxo-4-(1-piperidinyl)butyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]b is-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-01-6 CAPLUS Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(4-morpholinyl)-4-CN

oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

737826-03-8 CAPLUS RN

CNCarbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylthio)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl] bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

AcNH
$$\sim$$
 CH₂-CH₂ \sim OBu-t \sim SMe

RN 737826-04-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
N

$$CH_2$$
 CH_2
 CH_2

RN 737826-06-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-1-methyl-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-08-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]b is-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-10-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbon imidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-12-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S,2S)-1-

[(dimethylamino)carbonyl]-2-hydroxypropyl]amino]carbonyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-14-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-4-amino-1-[(dimethylamino)carbonyl]-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-17-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methoxymethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂- CH₂ \sim NH- C- OBu-t \sim CH₂- CH₂ \sim OBu-t \sim OBu-t

RN 737826-18-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-formyl-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂-CH₂ \sim CHO

RN 737826-19-6 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[(2S)-2-[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-20-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-21-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(2S)-2[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737826-23-2 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 O $NH-C-OBu-t$ $CH_2-NH-CH_2-CH_2-C-NMe2$

RN 737826-24-3 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $CH_2-CH_2-C-NMe_2$ Me O

RN 737826-25-4 CAPLUS

CN Propanamide, 3-[[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

RN 737826-26-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-28-7 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[((1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737826-29-8 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737826-30-1 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]- (9CI) (CA INDEX NAME)

RN 737826-31-2 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-32-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]-4-thiazolyl]ethyl]phenyl]carbonimidoy l]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737826-34-5 CAPLUS
CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4[(dimethylamino)carbonyl]phenyl]-4-thiazolyl]ethyl]phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-35-6 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimid oyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$N$$
 $CH_2 - CH_2$ CH_2 CH_2

RN 737826-37-8 CAPLUS

CN Carbamic acid, [4-[[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 737826-38-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methoxycarbonyl)amino]pheny 1]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-40-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737826-41-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737826-47-0 CAPLUS

CN Carbamic acid, [2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737826-49-2 CAPLUS

CN Carbamic acid, [[2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]c arbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-68-5 CAPLUS

CN Acetamide, N-[5-[[3-(methylsulfonyl)phenyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737826-69-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-70-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-72-1 CAPLUS

CN Acetamide, N-[5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-73-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-75-4 CAPLUS

CN Acetamide, N-[5-(4-morpholinylmethyl)-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737826-76-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-morpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-78-7 CAPLUS

CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

RN 737826-79-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(3-oxo-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2$$
 CH_2 CH

RN 737826-81-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737826-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 737826-83-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carboni midoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 737826-84-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(1-piperazinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-85-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 737826-87-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-89-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-91-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

ACNH
$$CH_{2}-CH_{2}$$

$$CH_{2}-CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{5}$$

$$CH_{6}$$

$$CH_{7}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

$$CH_{1}$$

$$CH_{1}$$

$$CH_{2}$$

$$CH_{3}$$

$$CH_{4}$$

$$CH_{5}$$

$$CH_{7}$$

$$CH_{8}$$

PAGE 2-A

RN 737826-93-6 CAPLUS

CN 2-Propenoic acid, 3-[2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 CH_2-CH_2 CH_2-CH_2 CH_3 CH_4-CH_4 CH_5 CH_6 CH_7 CH_8 $CH_$

RN 737826-94-7 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

ACNH
$$CH_2-CH_2$$
 $CH_2-CH_2-C-OEt$ $CH_2-CH_2-C-OEt$

RN 737826-95-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 737826-96-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

RN 737826-97-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(dimethylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737826-99-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(methylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-01-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(3-amino-3-oxopropyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-03-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-

thiazolyl]methyl] - (9CI) (CA INDEX NAME)

ACNH
$$CH_{2} - CH_{2}$$

$$CH_{2} - CH_{2}$$

$$CH_{2} - CH_{2}$$

$$CH_{2} - CH_{2}$$

$$CO_{2}H$$

RN 737827-04-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-06-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737827-08-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

ACNH

$$CH_2$$
 CH_2
 CH_2

RN 737827-10-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 737827-11-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737827-12-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)

RN 737827-13-3 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3R)-3[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737827-15-5 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3R)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-17-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 737827-18-8 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

RN 737827-19-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737827-20-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3S)-3[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

RN 737827-22-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3S)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 737827-24-6 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(3,4-dinitrophenyl)ethenyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737827-25-7 CAPLUS

CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH₂ \sim CH₂ \sim NH₂ \sim NH₂

RN 737827-27-9 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(3,4-dinitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737827-28-0 CAPLUS

CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{NH}_2 \\ \text{NH}_2 \\ \text{NH}_2 \\ \text{CH}_2 - \text{CH}_2 \end{array}$$

RN 737827-30-4 CAPLUS

CN Acetamide, N-[5-[(methylamino)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737827-31-5 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737827-32-6 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{AcNH} & \text{N} \\ \text{S} & \text{CH}_2 - \text{CH}_2 \\ \\ \text{CH}_2 - \text{N} - \text{Ac} \\ \\ \text{Me} \end{array}$$

RN 737827-33-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(acetylmethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

RN 737827-35-9 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]e thyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{O} \\ \text{NH- CH}_2\text{-- CH}_2\text{--- NH- C-- OBu-t} \\ \text{ACNH} \\ \text{S} \end{array}$$

RN 737827-43-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(1E)-2-[4-(methylsulfonyl)phenyl]ethenyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 737827-44-0 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-

(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737827-45-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 737827-46-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Acnh
$$CH_2$$
 CH_2 CH

RN 740816-44-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino][[(1,1-dimethylethoxy)carbonyl]imino]methyl] amino]phenyl]ethyl]-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)

IT 737825-26-2

RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)

RN 737825-26-2 CAPLUS

CN Acetamide, N-[5-[(4-iodophenyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

GI

$$\bigcap_{\mathsf{Me}} \bigvee_{\mathsf{H}}^{\mathsf{N}} \bigvee_{\mathsf{S}}^{\mathsf{NH}_2}$$

Title compds. of formula R1NHXYZ [I; wherein R1 = acyl; X = a bivalent AB (un) substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, C6H4-R2; R2 = ABDE; A = a bond, alkylene, NH, SO2; B = a bond , alkylene, CO, O; D = a bond, alkylene, NH, CH2NH; E = (un)protected amino, N=CH2, dihydrothiazol-2-yl, dihydroimidazol-2-yl, C(=NH)R3; R3 = H, alkyl(thio), NHR4; R4 = H, NH2, alkyl; and pharmaceutically acceptable salts thereof] were prepared as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl) methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH2Cl2. Deprotection of [2-(acetylamino)thiazol-4-yl]methyl acetate using K2CO3 in MeOH, followed by reaction of the resulting alc. with MnO2 in MeOH/CHCl3 provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh3 and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC50 = 0.15 μM and 0.012 μM , resp.), but not the enzyme activities of other amine oxidases (IC50 >100 µM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). Treatment of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreous/plasma ratio of fluorescein concns. = 5.39 ± 0.73 \times 10-3 and 8.93 \pm 1.14 \times 10-3, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or treating VAP-1 associated diseases, especially macular edema (no data).

ΙI

L8 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2002:835624 CAPLUS DOCUMENT NUMBER: 139:6779

TITLE: Product class 17: thiazoles

AUTHOR(S): Kikelj, D.; Urleb, U.

CORPORATE SOURCE: Fac. Pharm., University Ljubljana, Slovenia SOURCE: Science of Synthesis (2002), 11, 627-833

CODEN: SSCYJ9

PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

IT 92061-29-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(review of preparation of thiazoles and reactions thereof)

RN 92061-29-5 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethenyl]-5-nitro-2-thiazolyl]- (9CI)

(CA INDEX NAME)

AB A review of synthetic methods to prepare thiazoles as well as reactive modifications of thiazole moieties.

REFERENCE COUNT: 1224 THERE ARE 1224 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L8 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:275966 CAPLUS

DOCUMENT NUMBER: 136:294739

TITLE: Preparation of pyridinyl-substituted benzamides as Apo

B secretion inhibitors

INVENTOR(S): Takasugi, Hisashi; Terasawa, Takeshi; Inoue,

Yoshikazu; Nakamura, Hideko; Nagayoshi, Akira; Ohtake, Hiroaki; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue,

Kazumasa; Ohtsubo, Makoto

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co.,

Ltd.

SOURCE: PCT Int. Appl., 266 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2002028835	A1 20020411	WO 2001-JP8581	20010928
W: AE, AG, AI	, AM, AT, AU, AZ,	BA, BB, BG, BR, BY, BZ	, CA, CH, CN,
CO, CR, CL	, CZ, DE, DK, DM,	DZ, EC, EE, ES, FI, GB	, GD, GE, GH,
GM, HR, HU	, ID, IL, IN, IS,	JP, KE, KG, KR, KZ, LC	, LK, LR, LS,
LT, LU, LV	, MA, MD, MG, MK,	MN, MW, MX, MZ, NO, NZ	, PH, PL, PT,
RO, RU, SI			
RW: GH, GM, KE	, LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZW, AT	, BE, CH, CY,
DE, DK, ES	, FI, FR, GB, GR,	IE, IT, LU, MC, NL, PT	, SE, TR, BF,
BJ, CF, CG	, CI, CM, GA, GN,	GQ, GW, ML, MR, NE, SN	, TD, TG
CA 2425097	AA 20020411	CA 2001-2425097	20010928

RN

CN

408367-83-9 CAPLUS

[1,1'-Biphenyl]-2-carboxamide, N-[4-[2-[2-(acetylamino)-4-

thiazolyl]ethyl]phenyl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

IT 183365-29-9, N-[4-[2-(4-Aminophenyl)ethyl]-1,3-thiazol-2yl]acetamide 408367-86-2, N-[4-[2-(4-Aminophenyl)vinyl]-1,3thiazol-2-yl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of pyridinyl-substituted benzamides as Apo B
 secretion inhibitors for treatment of obesity, NIDDM, and related
 conditions)

RN 183365-29-9 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 408367-86-2 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

GI

$$\begin{array}{c|c}
R^{2} & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\
 & = \\$$

Title compds. I [wherein R1 and R2 = independently alkyl, alkenyl, acyl, AB amino, (cyclo)alkoxy, aryl(oxy), sulfoxy, mercapto, sulfo, H, halo, NO2, CN, or OH; or R1R2 = a ring; Q1 = N or CH; L = (un)substituted unsatd. 3 to 10-membered heterocyclic group; X = (un)substituted monocyclic (hetero)arylene; Y = (A1)m(A2)n(A4)k; Z = direct bond, CH2, NH, or O; R =H or alkyl; A1 = (un) substituted alkylene or alkenylene; A2 = NR3, CONR3, NHCONH, CO2, O, O(CH2)2NR3, S, SO, or SO2; A4 = alkylene, alkenylene, or alkynylene; R3 = H or suitable substituent; k, m, and m = independently 0 or 1; or a salt thereof] were prepared as apolipoprotein B (Apo B) secretion inhibitors. For example, to a suspension of N-(4-aminophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide, 2-pyridinylacetic acid•HCl, and HOBT•H2O in CH2Cl2 was added to WSC•HCl, followed by TEA at 5°C. The mixture was stirred at room temperature for 24 h and worked up to give II. The latter inhibited Apo B secretion by 100% at 10-6 M in HepG2 cells and lowered cholesterol by 83% and triglyceride by 35% after 2 h at a dose of 32 mg/kg in ddY-mice. I are useful for the prophylaxis and treatment of diseases or conditions resulting from elevated circulating levels of Apo B, such as hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus, obesity, coronary heart diseases, myocardial infarction, stroke, restenosis, and Syndrome X. THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 5

ΙI

L8 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:51438 CAPLUS

DOCUMENT NUMBER: 136:118447

TITLE: Preparation of benzimidazolecarboxylates and related

compounds as viral polymerase inhibitors

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James; Kukolj, George; Austel, Volkhard INVENTOR(S):

Boehringer Ingelheim (Canada) Ltd., Can. PCT Int. Appl., 322 pp. PATENT ASSIGNEE(S):

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2002004425 W: AE, AG, CR, CU, HU, ID, LU, LV, SD, SE,	A2 20020117 AL, AM, AT, AU, AZ, CZ, DE, DK, DM, DZ, IL, IN, IS, JP, KE, MA, MD, MG, MK, MN, SG, SI, SK, SL, TJ,	WO 2001-CA989 BA, BB, BG, BR, BY, BEE, ES, FI, GB, GD, GKG, KP, KR, KZ, LC, MW, MX, MZ, NO, NZ, MM, TR, TT, TZ, UA, MA	GE, GH, GM, HR, LK, LR, LS, LT, PL, PT, RO, RU,
DE, DK,	KE, LS, MW, MZ, SD, ES, FI, FR, GB, GR,	SL, SZ, TZ, UG, ZW, I IE, IT, LU, MC, NL, I GW, ML, MR, NE, SN, I US 2001-898297	PT, SE, TR, BF,
		CA 2001-2412718 EP 2001-951274 GB, GR, IT, LI, LU, I	20010704 20010704 NL, SE, MC, PT,
IE, SI, JP 2004502761 US 6479508 CA 2439176 WO 2002070739 WO 2002070739	LT, LV, FI, RO, MK, T2 20040129 B1 20021112 AA 20020912 A2 20020912 A3 20030530	CY, AL, TR JP 2002-509292 US 2001-995099 CA 2002-2439176 WO 2002-CA323	20010704 20011127 20020306 20020306
W: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT, UA, UG, RW: GH, GM,	AL, AM, AT, AU, AZ, CU, CZ, DE, DK, DM, HU, ID, IL, IN, IS, LU, LV, MA, MD, MG, RO, RU, SD, SE, SG, US, UZ, VN, YU, ZA, KE, LS, MW, MZ, SD,	BA, BB, BG, BR, BY, I DZ, EC, EE, ES, FI, G JP, KE, KG, KP, KR, I MK, MN, MW, MX, MZ, I SI, SK, SL, TJ, TM, S ZM, ZW SL, SZ, TZ, UG, ZM, S BE, CH, CY, DE, DK, I	GB, GD, GE, GH, KZ, LC, LK, LR, NO, NZ, OM, PH, TN, TR, TT, TZ, ZW, AM, AZ, BY,
GR, IE, GN, GQ, EP 1370682 R: AT, BE,	IT, LU, MC, NL, PT, GW, ML, MR, NE, SN, A2 20031217	SE, TR, BF, BJ, CF, G TD, TG EP 2002-712681 GB, GR, IT, LI, LU, I	CG, CI, CM, GA, 20020306
JP 2004520839 NZ 528644 US 2003232816	T2 20040715 A 20050527 A1 20031218 B2 20040921 A1 20040610	JP 2002-570761 NZ 2002-528644 US 2002-238282	20020306 20020306 20020910
US 2004110126 US 2004224955 PRIORITY APPLN. INFO	A1 20040610 A1 20041111	US 2004-471164 US 2004-851710 US 2000-216084P US 2001-274374P US 2001-281343P US 2001-898297 WO 2001-CA989 US 2001-995099 WO 2002-CA323	20040205 20040521 P 20000706 P 20010308 P 20010405 A3 20010703 W 20010704 A3 20011127 W 20020306

US 2002-238282 A1 20020910

OTHER SOURCE(S): MARPAT 136:118447

IT 390812-57-4P 390813-39-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 390812-57-4 CAPLUS

CN Acetic acid, [4-[(2S)-3-[2-(acetylamino)-4-thiazolyl]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]propyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 390813-39-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-1-[2-(acetylamino)-4-thiazolyl]-2-(4-hydroxyphenyl)ethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

GI

$$R^{1}$$
 N
 R^{2}
 X
 R^{6}
 R^{6}

Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6AB membered (substituted) heterocyclyl; A = N, COR7, CR5; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H , alkyl; R1 = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CF3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1], were prepared Thus, Me 3-amino-4-cyclohexylaminobenzoate (preparation given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was saponified with aqueous NaOH in MeOH to give 91%

1-cyclohexyl-2-pyridin-2-yl-

1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC50 = 1-5 μ M.

ANSWER 8 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:229500 CAPLUS

DOCUMENT NUMBER: 129:4607

TITLE: Aromatic ring opening of fused thiophenes via

organolithium addition to sulfur

AUTHOR (S): Hill, B.; De Vleeschauwer, M.; Houde, K.; Belley, M.

CORPORATE SOURCE: Department Medicinal Chemistry, Merck Frosst Center

Therapeutic Research, Kirkland, QC, H9H 3L1, Can.

Synlett (1998), (4), 407-410

CODEN: SYNLES; ISSN: 0936-5214

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:4607

207229-66-1P 207229-72-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(ring opening of fused thiophenes via organolithium addition to sulfur)

RN 207229-66-1 CAPLUS

SOURCE:

CN Acetamide, N-[5-(butylthio)-4-[(1E)-2-chloro-3-hydroxy-3-phenyl-1-

propenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

207229-72-9 CAPLUS RN

Acetamide, N-[5-(butylthio)-4-(3-hydroxy-3-phenyl-1-propynyl)-2-thiazolyl]-CN (9CI) (CA INDEX NAME)

Fused thiophenes substituted by at least 1 Cl react with organolithium AΒ reagents at $-78\,^{\circ}$ by addition to the S atom. The anion generated after ring opening adds to electrophiles or gives elimination products if there is a leaving group in position 3 of the thiophene. The reaction is not general and is highly dependent on the substitution pattern of the thiophene and the nature of the organolithium. Side reactions such as proton abstraction and Li-Cl exchange compete with the ring cleavage. Thiophenes that are not fused to another aromatic ring do not give rise to this reaction, the only known exception being 3,4-dichloro-2,5dimethoxythiophene at room temperature

ANSWER 9 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:694359 CAPLUS

DOCUMENT NUMBER: 125:328705

TITLE: Preparation of 2-anilino-2-thiazolines and analogs as

nitric oxide synthase inhibitors

Katsura, Yousuke; Nishino, Shigetaka; Tomishi, Tetsuo INVENTOR(S):

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

PCT Int. Appl., 48 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION: DATENT NO

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9630350	A1 19961003	WO 1996-JP776	19960326
W: AU, CA, CN	HU, JP, KR, MX,	NO, NZ, US, AM, AZ,	BY, KG, KZ, MD,
RU, TJ, TM			
RW: AT, BE, CH	DE, DK, ES, FI,	FR, GB, GR, IE, IT,	LU, MC, NL, PT, SE
AU 9650155	A1 19961016	AU 1996-50155	19960326
JP 11503121	T2 19990323	JP 1996-529162	19960326
PRIORITY APPLN. INFO.:		GB 1995-6188	A 19950327
		WO 1996-JP776	W 19960326

OTHER SOURCE(S): MARPAT 125:328705

183365-33-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors)

RN 183365-33-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2thiazolyl] - (9CI) (CA INDEX NAME)

IT 183365-16-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors)

RN 183365-16-4 CAPLUS

CN Acetamide, N-[4-[3-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]propyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

$$(CH_2)_3$$
 $NHAC$
 $NHAC$

IT 183365-27-7P 183365-28-8P 183365-29-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors)

RN 183365-27-7 CAPLUS

CN Acetamide, N-[4-[3-(4-nitrophenyl)propyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 183365-28-8 CAPLUS

CN Acetamide, N-[4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 183365-29-9 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

GΙ

$$R^{2}$$
 R^{3} R^{3} R^{2} R^{3} R^{2} R^{3} R^{2} R^{3} R^{2} R^{3} R^{3

AB Title compds. [I; R = Z2(CH2)nZ1(CH2)mR1; R1 = heterocyclyl; R2,R3 = H; R2R3 = O; Z = CH2, O, S, (alkyl)imino; Z1 = bond, CH2, O, S; Z2 = phenylene; m,n = 0 or 1] were prepared Thus, title compound II gave 95% inhibition of nitric oxide synthase at 10-5g/mL in vitro.

L8 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1993:70022 CAPLUS

DOCUMENT NUMBER:

118:70022

TITLE:

photographic couplers and silver halide color

photographic materials

INVENTOR(S):

Takeuchi, Kihoshi; Sato, Kozo Fuji Photo Film Co., Ltd., Japan

PATENT ASSIGNEE(S): SOURCE:

Jpn. Kokai Tokkyo Koho, 24 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04204532	A2	19920724	JP 1990-330778	19901130
JP 2592354	B2	19970319		
PRIORITY APPLN. INFO.:			JP 1990-330778	19901130

IT 93044-41-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of photog. coupler)

RN 93044-41-8 CAPLUS

CN Acetamide, N-[5-nitro-4-(2-phenylethenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

GI

$$\mathbb{R}^1$$
 \mathbb{R}^1
 \mathbb{R}^2
 \mathbb{R}^2

AB Claimed are photog. couplers represented by general structure I. For I, R1, R2 = substituent; X = H, or group to be released upon coupling reaction with an oxidized aromatic primary amine developing agent. Also claimed are silver halide color photog. materials containing the couplers. The photog. materials give excellent color reproduction

L8 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1988:167461 CAPLUS

DOCUMENT NUMBER:

108:167461

TITLE:

Preparation of aminoazoles as antiarthritics

INVENTOR(S):

Ozato, Yukinori; Tamura, Nobuhiko; Masumori, Hiroaki;

Yamamoto, Michihiro; Kojima, Atsuyuki; Nishikaku,

Fumio; Kimura, Yoshihiko

PATENT ASSIGNEE(S):

Sumitomo Pharmaceuticals Co., Ltd., Japan

SOURCE:

Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 248399 R: AT, BE, CH,	A1	19871209	EP 1987-107959 IT, LI, NL, SE	19870602
US 4914112	Α	19900403	US 1987-55079	19870528
JP 63152368 JP 04080035	A2 B4	19880624 19921217	JP 1987-139305	19870602
US 5066666 US 5180731	A	19911119	US 1990-470731	19900126
JP 05247014	A A2	19930119 19930924	US 1991-732169 JP 1991-208501	19910718 19910724
PRIORITY APPLN. INFO.:				A 19860603 A 19860711
			US 1987-55079	A3 19870528 A3 19900126

IT 113757-88-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiarthritic)

RN 113757-88-3 CAPLUS

CN Acetamide, N-[4-[1-(2-fluoro[1,1'-biphenyl]-4-yl)ethyl]-2-thiazolyl]-

(9CI) (CA INDEX NAME)

GΙ

Q=
$$R^5$$
 Y
 Q^1 = R^6
 R^7
 R^8
 R^8

ACHR3BNR1R2 [I; A = R4ZZ1, benzo-fused heterocyclic moiety Q, Q1; B = AB divalent azole; R1, R3 = H, alkyl; R2 = H, alkyl, aralkyl, R9Z2; R4 = (halo)phenyl, (halo)thienyl; R5 = alkoxy, (halo)phenyl; R6 = alkoxy; R7 = alkyl; R8 = (halo)benzoyl; R9 = H, aryl, R10R11N, R12O, (un)substituted alkyl; R10 = H, alkyl; R11 = H, alkyl, alkenyl, cycloalkyl, aralkyl, aroyl; R1R2N, R10R11N = 5-, 6-, or 7-membered, saturated heterocyclyl; R12 = (polyhalo) alkyl; X = CH2, N; Y = CH:CH, O; Z = CO, HOCH, NH, R13ON:C, bond, 1,3-dioxolan-2-ylidene; R13 = H, alkyl; Z1 = phenylene, thienylene; Z2 = CO, COCO, CS, SO2] and their acid salts were prepared for treating autoimmune diseases. 3,4-FPhC6H3CHR13Me (II, R13 = CO2H) was converted to its acid chloride and treated with (Me3SiO)2C:CHOSiMe3 to give II (R13 = COCH2OH). The latter was stirred with Ph3P in CCl4 to give II (R13 = COCH2Cl) which was heated with MeNHCSNH2 in H2O to give (methylamino)thiazole III. In the adjuvant arthritis test in rats III had a min. ED of 25 mg/kg/day orally for 5 days.

ANSWER 12 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN L8

ACCESSION NUMBER: 1979:557394 CAPLUS

DOCUMENT NUMBER: 91:157394

TITLE: Derivatives of 1-bromo-3-(3-hydroxy-6-acetoxy-2,4,5-

trimethylphenyl) -2-propanone

AUTHOR(S): Makovetskii, V. P.; Dzvinchuk, I. B.; Svishchuk, A. A.

CORPORATE SOURCE: Inst. Org. Khim., Kiev, USSR

SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition)

(1979), 45(7), 637-41

CODEN: UKZHAU; ISSN: 0041-6045

DOCUMENT TYPE: Journal LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 91:157394

71558-41-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 71558-41-3 CAPLUS

CN Acetamide, N-[4-[[2,5-bis(acetyloxy)-3,4,6-trimethylphenyl]methyl]-2thiazolyl]- (9CI) (CA INDEX NAME)

GI

Brominating 5,2-RO(AcO)C6Me3CH2COMe (R = H, Me) gave 66.9-70.1% 5,2-RO(AcO)C6Me3CH2COCH2Br (I). I (R = H) was acetylated to 94.0% I (R = Ac) (II), and was treated with R1CO2H (R1 = H, Me, Ph, 2-HOC6H4, 2-furyl) in Me2CO containing Et3N to give 90.5-3.5% 2,5-(AcO)2C6Me3CH2COCH2O2CR1. II also reacted with R2OH (R2 = Ph, 2-O2NC6H4) to give 88.5-92.5% 2,5-(AcO)2C6Me3CH(OR2)COMe, or cyclized with thiourea to give 89.2% thiazole III.HBr (R = H), which gave 97.5% free base with NaOAc in DMF and then 98.2% III (R = Ac) with Ac2O.

L8 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1964:469168 CAPLUS

DOCUMENT NUMBER: 61:69168
ORIGINAL REFERENCE NO.: 61:12008b-d

TITLE: 5-Nitrothiazole derivatives

INVENTOR(S): Herrling, Siegfried; Mueckter, Heinrich

PATENT ASSIGNEE(S): Chemie Gruenenthal G.m.b.H.
SOURCE: 2 pp.; Addn. to Ger. 1159450

DOCUMENT TYPE: Patent LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

92061-29-5, Thiazole, 2-acetamido-4-(p-cyanostyryl)-5-nitro92164-96-0, Benzoic acid, p-[2-(2-acetamido-5-nitro-4thiazolyl)vinyl]- 98018-34-9, Benzenesulfonic acid,
m-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]-

(preparation of)

RN 92061-29-5 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethenyl]-5-nitro-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 92164-96-0 CAPLUS

CN Benzoic acid, p-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]- (7CI) (CA INDEX NAME)

RN 98018-34-9 CAPLUS

CN Benzenesulfonic acid, m-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]- (7CI) (CA INDEX NAME)

GI For diagram(s), see printed CA Issue.

AB 2-Acetamido-4-methyl-5-nitrothiazole (I) (4 g.) was refluxed with 25 ml. PrOH, 3 g. pNCC6H4CHO, and 0.5 ml. piperidine 1 hr. to yield 56% 2-acetamido-4-(p-cyanostyryl)-5- nitrothiazole, m. 299-300°. Terephthalaldehydic acid (II) (1.8 g.) was dissolved with warming in 60 ml. PrOH, 2 g. I and 1 ml. piperidine added, and the mixture refluxed 1 hr. to yield 39% 2- acetamido-4-(p-carboxystyryl)5 nitrothiazole (III), m. 300°. II (1.8 g.) was added to a solution of 1.5 g. diethanolamine in 20 ml. PrOH and then treated with 2 g. I to give 63% III. I (2 g.) was refluxed with 4.5 g. the piperidine salt of benzaldehyde 3 sulfonic acid, 20 ml. PrOH, and 0.5 ml. piperidine for 1 hr. to yield 27% 3[β(2 acetamido 5 nitrothiazol 4 ylvinyl]benzenesulfonic acid, m. >300°.

L8 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1964:52762 CAPLUS

DOCUMENT NUMBER: 60:52762

ORIGINAL REFERENCE NO.: 60:9281h,9282a-c TITLE: 5-Nitrothiazoles

INVENTOR(S): Herrling, Siegfried; Mueckter, Heinrich

PATENT ASSIGNEE(S): Chemie Gruenenthal G.m.b.H.

SOURCE: 3 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

Unavailable

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

DE 1159450 19631219 DE 19610527

92044-76-3, Thiazole, 2-acetamido-4-(o-chlorostyryl)-5-nitro-92044-77-4, Thiazole, 2-acetamido-4-(p-chlorostyryl)-5-nitro-92164-97-1, Thiazole, 2-acetamido-4-[3,4-(methylenedioxy)styryl]-5nitro- 92166-87-5, Thiazole, 2-acetamido-4-(o-methoxystyryl)-5nitro- 92166-88-6, Thiazole, 2-acetamido-4-(p-methoxystyryl)-5nitro- 92167-02-7, Phenol, 4-[2-(2-acetamido-5-nitro-4thiazolyl)vinyl]-2-methoxy- 92378-75-1, Thiazole, 2-acetamido-5-nitro-4-(p-nitrostyryl) - 92853-09-3, Thiazole, 2-acetamido-4-(3,4-dimethoxystyryl)-5-nitro- 93044-41-8, Thiazole, 2-acetamido-5-nitro-4-styryl- 93312-33-5, Thiazole, 2-acetamido-5-nitro-4-(3,4,5-trimethoxystyryl)- 93532-57-1, Thiazole, 2-acetamido-4-(m-chlorostyryl)-5-nitro- 93734-74-8, Acetanilide, 4'-[2-(2-acetamido-5-nitro-4-thiazolyl)-vinyl]-97027-80-0, Thiazole, 2-acetamido-4-(2,4-dichlorostyryl)-5-nitro-97027-81-1, Thiazole, 2-acetamido-4-(3,4-dichlorostyryl)-5-nitro-(preparation of)

RN 92044-76-3 CAPLUS

CN Thiazole, 2-acetamido-4-(o-chlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)

RN 92044-77-4 CAPLUS

CN Thiazole, 2-acetamido-4-(p-chlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)

RN 92164-97-1 CAPLUS

CN Thiazole, 2-acetamido-4-[3,4-(methylenedioxy)styryl]-5-nitro- (7CI) (CA INDEX NAME)

RN 92166-87-5 CAPLUS

CN Thiazole, 2-acetamido-4-(o-methoxystyryl)-5-nitro- (7CI) (CA INDEX NAME)

RN 92166-88-6 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methoxystyryl)-5-nitro- (7CI) (CA INDEX NAME)

RN 92167-02-7 CAPLUS

CN Phenol, 4-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]-2-methoxy- (7CI) (CA INDEX NAME)

RN 92378-75-1 CAPLUS

CN Thiazole, 2-acetamido-5-nitro-4-(p-nitrostyryl)- (7CI) (CA INDEX NAME)

RN 92853-09-3 CAPLUS

CN Thiazole, 2-acetamido-4-(3,4-dimethoxystyryl)-5-nitro- (7CI) (CA INDEX NAME)

ACNH
$$\sim$$
 CH \sim CH \sim OMe \sim OMe

RN 93044-41-8 CAPLUS

CN Acetamide, N-[5-nitro-4-(2-phenylethenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

RN 93312-33-5 CAPLUS

CN Thiazole, 2-acetamido-5-nitro-4-(3,4,5-trimethoxystyryl)- (7CI) (CA INDEX NAME)

RN 93532-57-1 CAPLUS

CN Thiazole, 2-acetamido-4-(m-chlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)

RN 93734-74-8 CAPLUS

CN Acetanilide, 4'-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]- (7CI) (CA INDEX NAME)

RN 97027-80-0 CAPLUS

CN Thiazole, 2-acetamido-4-(2,4-dichlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)

RN 97027-81-1 CAPLUS

CN Thiazole, 2-acetamido-4-(3,4-dichlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)

GI For diagram(s), see printed CA Issue.

Title compds. (I) were prepared by condensation of RCHO with the AB corresponding 4-methyl-5-nitrothiazole in HCONMe2, PrOH, or diethylene glycol di-Me ether, with piperidine or its acetate as catalyst. The following I (R1 = NHAc) were prepared (R, m.p., and % yield given): Ph, 256-7°, 70; o-ClC6H4, 249-50°, 58; p-ClC6H4, >265°, 49; 3,4-dichlorophenyl, >250°, 45; 2,4-dichlorophenyl, >250°, 52; p-MeOC6H4, >270°, 67; o-MeOC6H4, 213-14°, 67; 3,4-dimethoxyphenyl, 217-19°, 62; 3-methoxy-4 hydroxyphenyl, 228-30°, 54; 3,4-methylenedioxyphenyl, >260°, 51; p-02NC6H4, >250°, 48; p-AcNHC6H4, >260°, 59; 2-furyl, 262-3°, 63; 2-thienyl, >250°, 65; 2-quinolyl, 267°, 69; 2-pyridyl, 255°, 86.5°; 3-pyridyl, >260°, 78; m-ClC6H4, 245-7°, 56; 4-phenylthiazolyl, 245-7°, 43; 3,4,5-trimethoxyphenyl, $268-9^{\circ}$, 79.5. The following I (R1 = Me) were prepared: Ph, 106°, 77; 3,4-dimethoxyphenyl, 158-9°, 51.5; m-MeOC6H4, 125-7°, 37; 3-ethoxy-4-methoxyphenyl, 122-4°, 41.6; 3,4,5-trimethoxyphenyl, 119-21°, 45; o-ClC6H4, 127-9°, 39; 2-furyl, 124-7°, 35. Also were prepared the following I (R, R1, m.p., and % yield given): MeS, Ph, 102-3°, 61; MeS, 3-pyridyl, 161-3°, 58; H, Ph, 196-8°, 37. I (R = 4-pyridyl, R1 = NHAc) at 1 p.p.m. was active against Staphylococcus. = 3- or 4-pyridyl, R2 = NHAc) were active in 20-50% of mice infected with meningitis. I (R = 2-quinoly1, R1 = NHAc) at 1:200,000 and I (R = quinoly1, R1 = NHAc)3,4-dimethoxyphenyl, R1 = Me) at 1:1,000,000 were active against Trichomonas. The last compound at 1:250,000 and I (R = 3,4-dimethoxyphenyl, R2 = NHAc) at 1:100,000 were amebicides.

L8 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1963:85538 CAPLUS

DOCUMENT NUMBER: 58:85538
ORIGINAL REFERENCE NO.: 58:1448b-e

TITLE: 2-Aminothiazole derivatives. II

AUTHOR(S): Mahajanshetti, C. S.; Acharya, S. P.; Nargund, K. S.

CORPORATE SOURCE: Karnatak Univ., Dharwar, India

SOURCE: J. Indian Chem. Soc. (1962), 39, 427-31

```
DOCUMENT TYPE:
                         Journal
LANGUAGE:
                         Unavailable
     91267-83-3, Ketone, 2-acetamido-5-bromo-4-thiazolyl
     2,4-dichlorophenyl 91267-84-4, Ketone, 2-acetamido-5-bromo-4-
     thiazolyl 2,5-dichlorophenyl 91267-85-5, Ketone,
     2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl 91354-10-8,
     Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl 91392-18-6
     , Thiazole, 2-acetamido-4-benzyl- 91394-59-1, Thiazole,
     2-acetamido-5-bromo-4-(p-chlorobenzyl) - 91394-82-0, Thiazole,
     2-acetamido-5-bromo-4-(p-nitrobenzyl) - 91395-06-1, Ketone,
     2-acetamido-4-thiazolyl 2,4-dichlorophenyl 91395-07-2, Ketone,
     2-acetamido-4-thiazolyl 2,5-dichlorophenyl 91395-08-3, Ketone,
     2-acetamido-4-thiazolyl 3,4-dichlorophenyl 91397-47-6, Thiazole,
     2-acetamido-4-(p-nitrobenzyl) - 91397-80-7, Thiazole,
     2-acetamido-4-benzyl-5-(chloromercuri) - 91492-91-0, Thiazole,
     2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- 91498-42-9
     , Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl 91570-76-2,
     Thiazole, 2-acetamido-4-benzyl-5-bromo- 91762-15-1, Thiazole,
     2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- 91762-16-2,
     Thiazole, 2-acetamido-5-(chloromercuri)-4-p-methoxybenzyl)-
     91762-42-4, Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)-
     91806-50-7, Thiazole, 2-acetamido-4-(p-methylbenzyl)-
     91806-90-5, Thiazole, 2-acetamido-4-(p-methoxybenzyl)-
     91955-36-1, Ketone, 2-acetamido-4-thiazolyl p-tolyl
     91955-68-9, Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl
     91961-80-7, Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-
     (chloromercuri) - 91961-87-4, Thiazole, 2-acetamido-4-(2,4-
     dichlorobenzyl) - 91961-88-5, Thiazole, 2-acetamido-4-(2,5-
     dichlorobenzyl) - 91961-89-6, Thiazole, 2-acetamido-4-(3,4-
     dichlorobenzyl) - 92022-29-2, Ketone, 2-acetamido-5-bromo-4-
     thiazolyl p-tolyl 92025-09-7, Thiazole, 2-acetamido-5-bromo-4-
     (2,4-dichlorobenzyl) - 92025-10-0, Thiazole, 2-acetamido-5-bromo-
     4-(2,5-dichlorobenzyl) - 92025-11-1, Thiazole,
     2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- 92025-16-6, Ketone,
     2-acetamido-5-bromo-4-thiazolyl phenyl 92696-30-5, Thiazole,
     2-acetamido-5-(chloromercuri)-4-(2,4-dichlorobenzyl)- 92696-31-6
     , Thiazole, 2-acetamido-5-(chloromercuri)-4-(3,4-dichlorobenzyl)-
     92696-79-2, Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl
     phenyl 92849-20-2, Thiazole, 2-acetamido-5-bromo-4-(p-
     methylbenzyl) - 92849-29-1, Thiazole, 2-acetamido-5-bromo-4-(p-
     methoxybenzyl) - 93308-00-0, Ketone, 2-acetamido-5-bromo-4-
     thiazolyl p-methoxyphenyl 93308-06-6, Ketone,
     2-acetamido-5-(chloromercuri)-4-thiazolyl p-tolyl 93308-07-7,
     Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-methoxyphenyl
     93352-50-2, Ketone, 2-acetamido-4-thiazolyl phenyl
     97026-22-7, Thiazole, 2-acetamido-5-bromo-4-(2-chloro-4-
     methoxybenzyl) - 107084-04-8, Thiazole, 2-acetamido-5-
     (chloromercuri) -4 - (2-chloro-4-methoxybenzyl) -
        (preparation of)
RN
     91267-83-3 CAPLUS
CN
     Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,4-dichlorophenyl (7CI)
     INDEX NAME)
```

RN 91267-84-4 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91267-85-5 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91354-10-8 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)

RN 91392-18-6 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl- (7CI) (CA INDEX NAME)

RN 91394-59-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-chlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91394-82-0 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)

RN 91395-06-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 2,4-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91395-07-2 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91395-08-3 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91397-47-6 CAPLUS

CN Thiazole, 2-acetamido-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)

RN 91397-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-(chloromercuri)- (7CI) (CA INDEX NAME)

RN 91492-91-0 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91498-42-9 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)

RN 91570-76-2 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-bromo- (7CI) (CA INDEX NAME)

RN 91762-15-1 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)

RN 91762-16-2 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 91762-42-4 CAPLUS

CN Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 91806-50-7 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)

RN 91806-90-5 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 91955-36-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)

RN 91955-68-9 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)

RN 91961-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-(chloromercuri)- (7CI) (CA INDEX NAME)

RN 91961-87-4 CAPLUS

CN Thiazole, 2-acetamido-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91961-88-5 CAPLUS

CN Thiazole, 2-acetamido-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91961-89-6 CAPLUS

CN Thiazole, 2-acetamido-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92022-29-2 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)

RN 92025-09-7 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92025-10-0 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92025-11-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92025-16-6 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl phenyl (7CI) (CA INDEX NAME)

RN 92696-30-5 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92696-31-6 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92696-79-2 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl phenyl (7CI) (CA INDEX NAME)

RN 92849-20-2 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)

RN 92849-29-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 93308-00-0 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)

RN 93308-06-6 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-tolyl (7CI) (CA INDEX

NAME)

RN 93308-07-7 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)

RN 93352-50-2 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl phenyl (7CI) (CA INDEX NAME)

RN 97026-22-7 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 107084-04-8 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2-chloro-4-methoxybenzyl)-(7CI) (CA INDEX NAME)

AB Ph 2-amino-5-thiazolyl sulfides (I) and sulfones (II), having various substituents in the Ph ring, were prepared for evaluation of their antibacterial properties. Various required thiophenols were prepared by the Leuckart reaction from the corresponding anilines, whereas 3,4- and 3,6-Br(MeO)C6H3SH were prepared by reduction of the corresponding sulfonyl chlorides. 2-Acetamido-5-bromothiazole (III) was prepared by the method of Backer and Buisman (CA 40, 24463). III (0.02 mol), 0.02 mol K salt of a thiophenol, and 15-20 mL. MeCH(OH)CH2OH heated 4 h. at 130-40°, the mixture cooled, poured into H2O, the precipitate macerated with 10% aqueous NaOH (some

deacetylation occurred), filtered off, washed with H2O, dried, heated 15 min. with 10 mL. Ac2O, and worked up in the usual way gave the Ac derivative (IV) of I. To 0.5 g. I in AcOH was added 2 mL. 30% H2O2, kept 60 h. with intermittent addition of 0.5 mL. 30% H2O at intervals of 20 h., the precipitate filtered off (if no solid separated the solution was diluted with H2O), and crystallized

from AcOH gave the Ac derivative (V) of corresponding II. The following IV and V were prepared [substituent(s) in Ph ring, % yield IV, m.p., m.p. corresponding V given]: none 80, 226-7° 273-4°; 2,4-Br, Me, 78, 202-3°, 261-2°; 2,4-Me, Br, 80, 204-5°, 290-1°; 3,4-Cl, Br, 75, 195-6°, 262-3°; 3,4-Br(MeO), 78, 248-9°, 266-7°; 3,6-Br(MeO), 70, 210-11°, 237-8°; 2,5,4-Cl2(ETO), 66, 212-13°, 280° (decomposition); 3,4-Cl(PrO), 72, 145-6°, 216-17°; 2,4-Cl(BuO), 70, 164-5, 214-15°; 2,3-Cl2, 80, 229-30°, 265-6°; 2,4-Cl2, 70, 209-10°, 292-3°; 2,5-Cl2, 76, 222-4°, 245-6°.

The IV or V (0.5 g.) in 20-5 mL. EtOH-containing 2 mL. concentrated HCl refluxed 2

found to bacteriostatic in vitro against ${\tt E.}$ coli and ${\tt S.}$ aureus.

h., concentrated in vacuo, and the residue treated with dilute aqueous NH3 gave corresponding I and II, resp. The following I and II were prepared (substituents in Ph ring, m.p. I, m.p. I.HCl, m.p. corresponding II given): none, 135-6°, 183-4°, 227-8°; 2,4-Br, Me, 169-70°, 191-2°, 210-11°; 2,4-Me, Br, 254-5°, 205-6°, 182-3°; 3,4-Cl, Br, 125-6°, 186-7°, 220-1°; 3,4-Br(MeO), 164-5°, 195-6°, 203-4°; 3,5-Br(MeO), 142-3°, 108-9°, 218-19°; 2,5,4-Cl2(EtO), 152-3°, 197-8°, 249-50°; 3,4-Cl(PrO), 110-11°, 89-90°, 191-2°; 2,4-Cl(BuO), 86-7°, 82-3°, 151-2°; 2,3-Cl2, 175-6°, 211-12°, 219-20°; 2,4-Cl2, 166-7°, 198-9°, 186-7°; 2,5-Cl2, 82-3°, 181-2°, 227-8°. Some of the compds. were

L8 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1963:8817 CAPLUS

DOCUMENT NUMBER: 58:8817

ORIGINAL REFERENCE NO.: 58:1447b-h,1448a-b

TITLE: 2-Aminothiazole derivatives I
AUTHOR(S): Mahajanshetti, C. S.; Nargund, K. S.
CORPORATE SOURCE: Karnatak Univ., Dharwar, India

```
J. Indian Chem. Soc. (1962), 39, 420-6
SOURCE:
DOCUMENT TYPE:
                         Journal
LANGUAGE:
                         Unavailable
     91267-83-3, Ketone, 2-acetamido-5-bromo-4-thiazolyl
     2,4-dichlorophenyl 91267-84-4, Ketone, 2-acetamido-5-bromo-4-
     thiazolyl 2,5-dichlorophenyl 91267-85-5, Ketone,
     2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl 91354-10-8,
     Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl 91392-18-6
     , Thiazole, 2-acetamido-4-benzyl- 91394-59-1, Thiazole,
     2-acetamido-5-bromo-4-(p-chlorobenzyl) - 91394-82-0, Thiazole,
     2-acetamido-5-bromo-4-(p-nitrobenzyl) - 91395-06-1, Ketone,
     2-acetamido-4-thiazolyl 2,4-dichlorophenyl 91395-07-2, Ketone,
     2-acetamido-4-thiazolyl 2,5-dichlorophenyl 91395-08-3, Ketone,
     2-acetamido-4-thiazolyl 3,4-dichlorophenyl 91397-47-6, Thiazole,
     2-acetamido-4-(p-nitrobenzyl) - 91397-80-7, Thiazole,
     2-acetamido-4-benzyl-5-(chloromercuri) - 91492-91-0, Thiazole,
     2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- 91498-42-9
     , Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl 91570-76-2,
     Thiazole, 2-acetamido-4-benzyl-5-bromo- 91762-15-1, Thiazole,
     2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- 91762-16-2,
     Thiazole, 2-acetamido-5-(chloromercuri)-4-p-methoxybenzyl)-
     91762-42-4, Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)-
     91806-50-7, Thiazole, 2-acetamido-4-(p-methylbenzyl)-
     91806-90-5, Thiazole, 2-acetamido-4-(p-methoxybenzyl)-
     91955-36-1, Ketone, 2-acetamido-4-thiazolyl p-tolyl
     91955-68-9, Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl
     91961-80-7, Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-
     (chloromercuri) - 91961-87-4, Thiazole, 2-acetamido-4-(2,4-
     dichlorobenzyl) - 91961-88-5, Thiazole, 2-acetamido-4-(2,5-
     dichlorobenzyl) - 91961-89-6, Thiazole, 2-acetamido-4-(3,4-
     dichlorobenzyl) - 92022-29-2, Ketone, 2-acetamido-5-bromo-4-
     thiazolyl p-tolyl 92025-09-7, Thiazole, 2-acetamido-5-bromo-4-
     (2,4-dichlorobenzyl) - 92025-10-0, Thiazole, 2-acetamido-5-bromo-
     4-(2,5-dichlorobenzyl) - 92025-11-1, Thiazole,
     2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- 92025-16-6, Ketone,
     2-acetamido-5-bromo-4-thiazolyl phenyl 92696-30-5, Mercury,
     [2-acetamido-4-(2,4-dichlorobenzyl)-5-thiazolyl]chloro- 92696-31-6
     , Mercury, [2-acetamido-4-(3,4-dichlorobenzyl)-5-thiazolyl]chloro-
     92696-79-2, Mercury, (2-acetamido-4-benzoyl-5-thiazolyl)chloro-
     92849-20-2, Thiazole, 2-acetamido-5-bromo-4-(p-methylbenzyl)-92849-29-1, Thiazole, 2-acetamido-5-bromo-4-(p-methoxybenzyl)-
     93308-00-0, Ketone, 2-acetamido-5-bromo-4-thiazolyl
     p-methoxyphenyl 93308-06-6, Mercury, (2-acetamido-4-p-toluoyl-5-
     thiazolyl)chloro- 93308-07-7, Ketone, 2-acetamido-5-
     (chloromercuri)-4-thiazolyl p-methoxyphenyl 93352-50-2, Ketone,
     2-acetamido-4-thiazolyl phenyl 97026-22-7, Thiazole,
     2-acetamido-5-bromo-4-(2-chloro-4-methoxybenzyl) - 107084-04-8,
     Thiazole, 2-acetamido-5-(chloromercuri)-4-(2-chloro-4-methoxybenzyl)-
        (preparation of)
RN
     91267-83-3 CAPLUS
CN
     Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,4-dichlorophenyl (7CI)
     INDEX NAME)
```

RN 91267-84-4 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91267-85-5 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91354-10-8 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)

RN 91392-18-6 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl- (7CI) (CA INDEX NAME)

RN 91394-59-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-chlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91394-82-0 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)

RN 91395-06-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 2,4-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91395-07-2 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91395-08-3 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)

RN 91397-47-6 CAPLUS

CN Thiazole, 2-acetamido-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)

RN 91397-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-(chloromercuri)- (7CI) (CA INDEX NAME)

RN 91492-91-0 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91498-42-9 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)

RN 91570-76-2 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-bromo- (7CI) (CA INDEX NAME)

RN 91762-15-1 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)

RN 91762-16-2 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 91762-42-4 CAPLUS

CN Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 91806-50-7 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)

RN 91806-90-5 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 91955-36-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)

RN 91955-68-9 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)

RN 91961-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-(chloromercuri)- (7CI) (CA INDEX NAME)

RN 91961-87-4 CAPLUS

CN Thiazole, 2-acetamido-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91961-88-5 CAPLUS

CN Thiazole, 2-acetamido-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 91961-89-6 CAPLUS

CN Thiazole, 2-acetamido-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92022-29-2 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)

RN 92025-09-7 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92025-10-0 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92025-11-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92025-16-6 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl phenyl (7CI) (CA INDEX NAME)

RN 92696-30-5 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92696-31-6 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

RN 92696-79-2 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl phenyl (7CI) (CA INDEX NAME)

RN 92849-20-2 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)

RN 92849-29-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 93308-00-0 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)

RN 93308-06-6 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-tolyl (7CI) (CA INDEX

NAME)

RN 93308-07-7 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)

RN 93352-50-2 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl phenyl (7CI) (CA INDEX NAME)

RN 97026-22-7 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA INDEX NAME)

RN 107084-04-8 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2-chloro-4-methoxybenzyl)(7CI) (CA INDEX NAME)

GI For diagram(s), see printed CA Issue.

AB A series of 2-amino-4-benzyl- and 4-benzoylthiazoles along with their 2-acetamido-5-chloromercuri and 2-acetamido-5-bromo analogs were prepared for evaluation of their chemotherapeutic properties. Various propiophenones and acetophenones were prepared by the Friedel-Crafts reaction on substituted benzenes. α -Isonitrosopropiophenones were prepared according to Hartung and Crossley [Organic Syntheses, Collective Volume

II, 363(1950)]. α -Isonitroso-2',4'-dichloropropiophenone and its 3',4'-dichloro and 2',5'-dichloro isomers were new compds. and m. 115-16° 158-69°, and 147-8°, resp. The appropriate α -isonitrosopropiophenone and 10-15% aqueous H2SO4 (1:10 proportion by weight) steam distilled until no more oil appeared in the distillate, the heavy oil or solid in the distillate separated, the aqueous layer saturated with salt, extracted

with Et20, the combined oil or solid and extract washed with 2% aqueous NaHCO3, dried, evaporated, and the residue distd, in vacuo or crystallized from a suitable

solvent gave the following RCOAc (I) (R, % yield, m.p., b.p./ mm. given): 4-MeC6H4, 60, --, $117\text{-}20^\circ/5$; 4-MeOC6H4, 60, $46\text{-}7^\circ$, --; 4-ClC6H4, 50, --, $140\text{-}4^\circ/20$; 4-O2NC6H4, 59, $91\text{-}2^\circ$ --; 2,4-Cl2C6H3, 40, --, $142\text{-}7^\circ/10$; 3,4-Cl2C6H3, 40, $47\text{-}8^\circ$, --; 2,5-Cl2C6H3, 38, --, $154\text{-}7^\circ/12$. I (R = Ph) (0.02 mole) in 50 ml. boiling CS2 treated dropwise with the calculated amount Br in CS2 in sunlight, the solution refluxed 0.5 hr., evaporated, the residue dissolved in Et2O, the solution washed with 2° aqueous Na2S2O3, dried, treated with 0.02 mole powdered thiourea (exothermic reaction started soon), the mixture refluxed gently 30 min., the precipitate filtered off, washed with Et2O, suspended in H2O, and the mixture basified with dilute aqueous NH3 gave 66° II (R = Ph, R' = R'' = H), m. $160\text{-}1^\circ$; HCl salt m. $98\text{-}9^\circ$; Ac derivative (III) m. $195\text{-}6^\circ$; semicarbazone m. $220\text{-}1^\circ$ (decomposition). To 0.5 g. III in hot EtOH was added 0.7 g. HgCl2 and 1.2 g. NaOAc in H2O with shaking, the mixture refluxed 1 hr., cooled, the precipitate filtered off, washed with hot H2O,

EtOH,

and Et2O, air dried, dissolved in AcOH, and the solution diluted with H2O to give II (R = Ph, R' = Ac, R'' = HgCl) (IV), m. 273-4°. To a saturated solution of NaBr in 15 ml. MeOH was added 0.5 g. IV followed by a few drops Br until the red color persisted, the mixture shaken, treated with Na2SO3 to remove excess Br, refluxed 30 min., filtered while hot, the filtrate concentrated, and diluted with a min. amount H2O to give II (R = Ph, R' = Ac, R'' =

Br), m. 199-200°. The following II were prepared similarly (R, R', R'', % yield, m.p., m.p. HCl salt, m.p. Ac derivative, m.p. semicarbazone, m.p. 2-acetamido-5-chloromercuri analog, m.p. 2-acetamido-5-bromo analog given): 4-MeC6H4, H, H, 70, 153-4°, 215-16°, 200-1°, 208° (decomposition), 285-6°, 168-9°; 4-MeOC6H4, H, H, 67, 155-6°, 222° (decomposition), 197-8°, 231° (decomposition), 284° (blackens), 177-8°; 4-ClC6H4, H, H, 67, 157-8°, 234-5°, 217-18°, 207° (decomposition), 288-9°, 177-8% 2,4-Cl2C6H3, H, H, 47, 203-4°, 209-10°

```
179-80°, 198° (decomposition), 255° (blackens),
     206-7°; 3,4-Cl2C6H, H, H, 50. 198-9°, 215-16°,
     217-18°, 174-5°, 282-3°, 208-9°; 2,5-Cl2C6H3,
     H, H, 47, 168-9°, 202-3°, 190-1°, 204° (decomposition), 255° (decomposition), 200-1°. To ice cold Et2O-CH2N2
     (prepared from 25 g. H2NCONMeNO and 75 ml. 50% aqueous KOH) was added 0.05 mole
     PhCH2COCl in ice cold Et2O at below 5° with stirring, the whole
     stirred 5 hrs., treated with a stream of dry HCl until evolution of N
     ceased, kept 2 hrs., poured over crushed ice, the Et20 layer separated, washed
     with H2O and 5% aqueous NaHCO3, dried, evaporated, and the residue distilled
in vacuo
     (or crystallized in other cases) gave RCH2COCH2Cl (V) (R = Ph). The following
     V were prepared (R, % yield, m.p., b.p./mm. given): 4-MeC6H4, 80, --,
     135-40°/7; 4-MOC6H4, 78, --, 161-3°/15; 4-ClC6H4, 75, --,
     155-60°/6; 2,4-Cl2C6H3, 80, 72-3°, --; 2,5-Cl2C6H3, 78,
     73-4°, --; 3,4-Cl2C6H3, 75, --, 170-5°/10; 2,4-Cl (MeO) C6H3,
     75, --, 172-6^{\circ}/8. V (R = Ph) (0.02 mole), 0.02 mole powdered
     thiourea, and 20-5 m.l. EtOH refluxed 4 hrs., concentrated in vacuo, and the residue basified with aqueous NH3 gave 70% VI (R = Ph), m. 92-3°; Ac
     derivative m. 190-1°; 2-acetamido-5-chloromercuri analog (prepared as
     above) m. 291° (decomposition); 2-acetamido-5-bromo analog (prepared as
     above) m. 164-5°. The following VI were prepared similarly (R, %
     yield, m.p., m.p. Ac derivative, m.p. 2-acetamido-5-chloromercuri analog, m.p.
     2-acetamido-5-bromo analog given): 4-MeC6H4, 73, 109-10°,
     1147-8°, 264-5°, 177-8°; 4-MeOC6H4, 75,
     186-7°, 190-1°, 258-9°, 163-4°; 4-ClC6H4, 68,
     141-2°, 166-7°, 271-2°, 182-3°; 2,4-Cl2C6H3,
     70, 97-8°, 184-5°, 286-7°, 200-1°;
     2,5-Cl6C6H3, 67, 104-5°, 189-90°, 285-6°,
     181-2°; 3,4-Cl2C6H3, 72, 119-20°, 155-6°,
     280-1°, 235-6°; 2,4-Cl (MeO) C6H3. 70, 140-1°,
     169-70°, 289-90°, 189-90°; 4-O2NC6H4, 65,
     172-3°, 188-9°, 269-70°, 185-6°. Some of the
     compds. were found to bacteriostatic in vitro against Escherichia coli and
     Staphylococcus aureus.
     ANSWER 17 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:
                          1962:7698 CAPLUS
DOCUMENT NUMBER:
                          56:7698
                          56:1447f-i,1448a-i,1449a-i,1450a-i,1451a-i
ORIGINAL REFERENCE NO.:
                          A new cinnoline synthesis. I. Cyclization of mesoxalyl
TITLE:
                          chloride phenylhydrazones to give substituted
                          4-hydroxycinnoline-3-carboxylic acids
AUTHOR(S):
                          Barber, H. J.; Washbourn, K.; Wragg, W. R.; Lunt, E.
CORPORATE SOURCE:
                          May & Baker Ltd., Dagenham, UK
                          Journal of the Chemical Society, Abstracts (1961)
SOURCE:
                          2828-843
                          CODEN: JCSAAZ; ISSN: 0590-9791
DOCUMENT TYPE:
                          Journal
LANGUAGE:
                          Unavailable
OTHER SOURCE(S):
                          CASREACT 56:7698
TT
     91397-95-4, Thiazole, 2-acetamido-4-(p-chlorobenzyl)-
        (preparation of)
RN
     91397-95-4 CAPLUS
     Thiazole, 2-acetamido-4-(p-chlorobenzyl)- (7CI) (CA INDEX NAME)
CN
```

A series of 4-hydroxycinnoline-3-carboxylic acids (I) was prepared from AB suitably substituted phenylhydrazones of CO(CO2Et)2 (II). The I were converted by decarboxylation to the corresponding 4-hydroxycinnolines (III). Except for a single case, attempts to extend the scope of the synthesis to a wide variety of glyoxylic ester phenylhydrazones were unsuccessful. o-PhCH2OC6H4NO2 (199 g.) in 2 l. EtOH hydrogenated in the presence of 6 g. PtO2 at 40°/6 atmospheric during 4.5 hrs. gave 162 g. o-PhCH2OC6H4NH2, b0.1 150-6°, m. 37-9°. o-O2NC6H4O3SC6H4Me-p (IV) (384 g.) in 4 l. EtOH hydrogenated 7.5 hrs. at 6 atmospheric and 70° over 8 g. PtO2 gave 316 g. o-NH2 analog of IV, buff plates, m. 97-8°. p-O2NC6H4OCO2Et (444 g.) in 2.5 l. EtOH hydrogenated 40 min. at room temperature/20 atmospheric over 4.4 g. PtO2 yielded 350 g. p-H2NC6H4OCO2Et, buff solid, m. 73-4° (C6H6). Molten o-ClC6H4NH2 (1.275 kg.) added to 2.5 l. concentrated HCl, the mixture cooled to 0°, mixed with 5 kg. ice, diazotized at 0-5° with 705 g. NaNO2 in 1.67 1. H2O, filtered, added dropwise during 0.5 hr. with stirring to 1.6 l. CH2(CO2Et)2, 20 1. EtOH, 1.88 g. NaOAc, and 3 1. H2O at 0°, stirred 5 hrs., and filtered gave 2.836 kg. (crude) o-ClC6H4NHN:C(CO2Et)2, m. 76-7° (EtOH). Similarly were prepared the following XC6H4NHN:C(CO2Et)2 (X, crystal form, m.p., and % yield given): H (V), plates, 33-4° (petr. ether) [b0.2 145-50°), 95; o-Me, needles, 89-90° (petr. ether), 76; p-Me (VI), needles, 32-3°(petr. ether) (b0.05 135-6°), 62; m-Cl (VII), prisms, 57-8° (EtOH), 77; p-Cl (VIII), needles, 76 (EtOH), 76; p-Br (IX), needles, 73° (EtOH), 62; o-MeO, needles, 56-7°, 88; p-MeO, needles, 38° (petr. ether) (b0.1 160-75° with decomposition), 47 (in H2O); o-PhCH2O, brown needles, 76-8° (ligroine), 74; p-PhCH2O (X), needles, 73-4° (EtOH), 69; p-MeC6H4SO3, prisms, 106° (EtOH), 72; o-NO2, needles, 77-8° (EtOH), 91 (in H2O); p-NO2 (XI), orange plates, 79-82° (EtOAc-ligroine), 82 (in H2O); p-AcNH (XII), plates, 156-7° (C6H6), 56; p-EtO2CNH (XIII), prisms, 186-7° (EtOH),

75. All the compds. were yellow except where noted otherwise. Similarly were prepared the following ArNHN:CH(CO2Et)2 (Ar, crystal form, m.p., and % yield given): 2,3-Cl2C6H3, orange plates, 96-7°, 96; 2,4-Cl2C6H3, orange plates, 92° (EtOH), 93; 2,5-Cl2C6H3, needles, 90-2° (ligroine, b. 60-70°), 77; 3,4-Cl2C6H3, needles, 80-1°

(EtOH), 74; 3,4-BrMeC6H3, prisms, 73° (EtOH), 68°. All the

compds. were yellow except where noted otherwise. X (52 g.) in 600 cc. EtOH hydrogenated 7.5 hrs. at 27°/5 atmospheric over 10 g. 10% Pd-C yielded 28.4 g. p-HOC6H4NHN:C(CO2Et)2, yellow prisms m. 130-1°

[(CH2Cl)2]. VI (150 g.) in 280 cc. refluxing EtOH treated dropwise during 0.5 hr. with 280 cc. 2N NaOH, the mixture kept just alkaline to

phenolphthalein,
the red solution refluxed 10 min., and acidified with 0.5N HCl at room temperature

gave 88 g. p-MeC6H4NHN:C(CO2H)CO2Et (XIV), yellow needles m. 141° (decomposition) (EtOH). Similarly were obtained the following p-XC6H4NHN:C(CO2H)CO2Et (X, crystal form, m.p. with decomposition, and % yield given): H (XV), needles, 112-14° (EtOH), 62; Cl (XVI), needles, 167° (EtOH), 47; Br, needles, 177-9° (ACOH), 13 (isolated as

```
needles, 122-3° (EtOH) (it formed a very insol. Na salt, m.
     168-70°, and K salt, m. 239-40°), 97; p-NO2 (XVII), orange
     prisms, 201-2° (EtOCH2CH2OH), 66; AcNH (XVIII), needles,
     187° (EtOH), 87; EtO2CNH (XIX), plates, 166-7° (EtOH), 77.
     All the compds. were yellow except where noted otherwise. VII (2.3 kg.)
     in 4.8 l. boiling EtOH treated during 15 min. with stirring with 4.8 l. 2N
     NaOH, the mixture treated with 19.2 l. N NaOH, refluxed gently 20 min. with
     stirring, filtered into 2.9 l. concentrated HCl and 8.7 l. H2O, stirred and
kept
     at 35-40° by the addition of 15-20 kg. ice, and filtered gave 1.594 g.
     m-ClC6H4NHN:C(CO2H)2, m. 162-4° (decomposition) (EtOAc). Similarly were
     prepared the following XC6H4NHN:C(CO2H)2 (X, temperature and time in min. for
the
     2nd stage of the hydrolysis, m.p., and % yield given): H (XX), 18°,
     150, 162-3° (EtOH), 97; o-Me, 70-80°, 15, 181-2° (aqueous
     EtOH), 97; p-Me (XXI), 50°, 15, 169-70° (EtOH), 67; o-Cl
     (XXII), 70-80°, 15, 178-9° (AcOH) (prisms), 90; m-Cl
     (XXIII), 70-80°, 15, 170° (AcOH), 85; p-Cl, 70-80°,
     15, 186-7° (AcOH), 68; p-Br, 70-80°, 10, 91-3° (AcOH), 74; o-MeO (XXIV), 60-5°, 15, 159° (AcOH), 92; p-MeO,
     18°, 180, 140-2° (decomposition) (EtOH), 43 (red); o-PhCH2O,
     60-5°, 15, 154-5° (AcOH), 45 [more forcing conditions gave
     p-PhCH2OC6H4NHN:CHCO2H, m. 115-16° (decomposition) (EtOH)]; o-MeC6H4SO3,
     70-80°, 10, 175° (EtOH), 66; o-NO2, 70-80°, 10,
     195-7° (EtOAc), 72 (orange prisms); p-NO2 (XXV), 70-80°,
     10-15, 199-200° (EtOCH2CH2OH), 92 (buff); p-AcNH (XXVI),
     35°, 25, 180-1° (H2O), 90; p-EtO2CNH, 18°, 210,
     175-6° (EtOH), 55 (also 29% diester recovered) (orange rhombs).
     Similarly were prepared the following ArNHN: C(CO2H)2 (Ar, temperature and time
in
     min. for 2nd stage of the hydrolysis, m.p., and % yield given):
     2,3-Cl2C6H3, 70-80°, 15, 200-2° (AcOH), 83; 2,4-Cl2C6H3,
     70-80°, 15, 177-8° (EtOH), 83 (precipitation with N HCl, even at
     80°, gave the insol. di-Na salt, converted into the diacid only by
     stirring with 2N HCl at 85° during 2 hrs.); 2,5-Cl2C6H3, 70-80°, 15, 210-11° (AcOH), 86 (precipitated by the addition of hot
     concentrated HCl to the hot mixture); 3,4-Cl2C6H3, 70-80°, 10-15,
     185-6° (AcOH), 60; 3,4-BrMeC6H3 (XXVII), 70-80°, 10,
     187-8° (AcOH), 48. PCl5 (10.025 kg.) added with stirring to 4.98 g.
     XXII in 16.25 l. dry CHCl3 at room temperature and the mixture refluxed 1.5
hrs.
     gave 4.78 kg. o-ClC6H4NHN:C(COCl)2 (XXVIII), yellow prisms, m.
     129-30°. Similarly were prepared the following XC6H4NHN:C(COC1)2 (X,
     reaction medium, reagent, crystal form, m.p. with decomposition, and % yield
     given): H (XXIX), CHCl3, SOCl2, prisms, 132-5°, 96 [anilide m.
     174° (EtOH)]; o-Me, (CH2Cl)2, PCl5, prisms, 145-7°, 86;
     p-Me, CHCl3, PCl5, needles, 143-4°, 71; m-Cl (XXX), CCl4, PCl5,
     needles, 123-4°, 89°; p-Cl, (CH2Cl)2, PCl5, needles,
     156-7°, 89 (83% in PhNO2) [anilide m. 215° (C6H6)]; p-Br,
     CHCl3, PCl5, needles, 158-60°, 62; o-MeO (XXXI), C6H6, SOCl2,
     needles, 172-3°, 83; o-PhCH2O, CHCl3, SOCl2, prisms and plates,
     142-3°, 98; p-PhCH2O, CHCl3, PCl5, needles, 1213°, 32;
     o-MeC6H4SO3, C6H6, PCl5, needles, 121-3°, 90; o-NO2 (XXXII), CHCl3,
     PCl5, needles, 135-7°, 83; p-NO2, C6H6, PCl5, prisms,
     155-6°, 86. The following ArNHN:C(COC1)2 (Ar, reaction medium,
     reagent, crystal form, m.p. with decomtn., and % yield given): 2,3-Cl2C6H3, CCl4, PCl5, needles, 103-4°, 83; 2,4-Cl2C6H3, CHCl3,
     PCl5, plates, 145-6°, 58; 2,5-Cl2C6H3, CCl4, PCl5, prisms,
```

a by-product in the preparation of IX); MeO, needles, 122-3 (EtOH), 42; PhCH2O,

110-11°, 50; 3,4-Cl2C6H3, CHCl3, SOCl2, needles, 149-50°, 63. All the compds. were yellow. 5,2-Cl(O2N)C6H3CHBrCHBrCO2H (10 g.) added with stirring to 40 cc. 10% aqueous NaOH, warmed at 40-5 to solution, kept

3 hrs. at room temperature, and poured into 50 cc. 2N H2SO4 yielded 5.0 g. 5,2-Cl(O2N)C6H3C.tplbond.CCO2H, needles, m. 135° (decomposition). TiCl4 (1.975 l.) added with stirring to 4.78 kg. XXVIII in 27.5 l. dry C6H6 while being cooled to 95°, the mixture heated 6 hrs. at 95°, treated with 5.5 kg. NaOH in 69 l. H2O, steam distilled, filtered, the residue washed with hot H2O, the combined filtrate and washing acidified, and the crude precipitate dissolved in 45 l. 2N NH4OH, filtered, and repptd.

gave

3.464 kg. 8-chloro-4-hydroxycinnoline-3-carboxylic acid, m. 247-8° (decomposition). Similarly were prepared the following substituted I (substituent, color, m.p. with decomposition, and % yield given): H, fawn, 267-8° (AcOH), 77; 8-Me, colorless, 263-4° (AcOH), 92; 6-Me, fawn, 269 (HCONMe2), 87; 5-Cl (from XXX), silvery plates, $263-4^{\circ}$ (HCONMe2), 63; 6-Cl, colorless, 267° (HCONMe2), 96; 6-Br, yellow, 256-8° (HCONMe2), 83; 6-MeO, fawn, 258-9° (AcOH), 76; 8-(p-MeC6H4SO3), colorless, 255° (AcOH), 5; 6-NO2, yellow, 275° (AcOH), 20. The following disubstituted I (substituents, color, m.p. with decomposition, and % yield given): 7,8-di-Cl, colorless prisms, 249-50°, 68 (80% of the product separated during the reaction as a PhNO2-insol. TiCl4 complex which was filtered off and decomposed with boiling N NaOH, which was acidified to deposit the product); 6,8-di-Cl, fawn, 250-1° (AcOH), 27 (reaction time 21 hrs.); 5,8-di-Cl, fawn, 248-9° (AcOH), 11; 5,6-di-Cl, fawn, 268° (AcOH), 46; 5(or 7)-Br and 6-Me, fawn, 262-3° (HCONMe2), 40 (from crude acid chloride prepared in situ by treating XXVII with SOCl2 in C6H6 and evaporating

in

vacuo) (all compds. crystallized as needles except where noted otherwise). XXXII (67 g.) and 32.5 cc. TiCl4 in 350 cc. dry PhNO2 heated 8 hrs. at 95°, poured into 4.5 l. boiling H2O, steam distilled to remove the PhNO2, filtered, cooled, the yellow solid (32 g.) dried and extracted with 400 cc. boiling EtOAc left 5 g. 4-hydroxy-8-nitrocinnoline-3-carboxylic acid, pale green needles, m. 253-4° (decomposition). TiCl4 (420 cc.) added during 20 min. to 858 g. XXIX in 3.5 l. dry (CH2Cl)2, the mixture heated 7 hrs. on the steam bath, evaporated in vacuo, the residue powdered, extracted

with

hot 4N NaOH, the combined exts. acidified, a 400-g. portion of the crude product (757 g.) stirred 18 hrs. at 15° with 800 cc. concentrated HNO3, and poured on ice yielded 809 g. 4-hydroxycinnoline-3-carboxylic acid, m. 267-8° (AcOH). 5-Chloro-4-hydroxycinnoline (64 g.), 84 g. PCl5, and 250 cc. POCl3 stirred 1 hr. at 95°, cooled, filtered, the residual 4,5-dichlorocinnoline-HCl (71.3 g.) added during 5 min. to dry PhOK (from 44 g. KOH and 300 g. PhOH) in 2 l. dry C6H6 at 70-80°, the mixture evaporated in vacuo, the residue heated 1 hr. on the steam bath, cooled, extracted with CHCl3, and the extract worked up yielded 53.5 g. 5-chloro-4-phenoxycinnoline (XXXIII), brown needles, m. 118-19° (ligroine, b. 100-20). 4-Amino-5-chlorocinnoline, fawn needles, m. 178-9°, was prepared by the method of Keneford, et al. (CA 42, 5031b). 5,6-Dichloro-4-hydroxycinnoline (1.1 g.) and 5.5 cc. Ac20 refluxed 1 hr., poured onto ice, and filtered gave 1 g. acetate (XXXV), prisms, m. 178-9° (ligroine, b. 80-100). XXXIV (1.5 g.), 1.5 g. PCl5, and 4 cc. POCl3 heated 1.5 hrs. on the steam bath, the resulting 4,5,6-trichlorocinnoline-HCl (1.4 g.) filtered off, heated 1 hr. with 3 g. PhOH and 0.5 g. powdered KOH at 95, cooled, mixed with excess 2N NaOH, and extracted with CHCl3 yielded 1.45 g. 4-PhO analog of XXXV, needles, m. 189° (ligroine). The appropriate substituted I in Ph2CO 4 parts

heated 0.5-1 hr. at 180-210° until the CO2 evolution ceased, extracted with Et20 or ligroine (b. 80-100°), evaporated, the residue dissolved in boiling N Na2SO3, and the solution acidified gave the corresponding 4-hydroxycinnoline (XXXVI); method A. The crude reaction mixture extracted directly with boiling N Na2CO3 and the extract acidified gave the corresponding XXXVI; method B. On a larger scale the decarboxylation was performed in boiling Dowtherm. In this manner were prepared the following substituted XXXVI (substituents, method, color, m.p., and % yield given): none, -(in Dowtherm), colorless, 236-7° (EtOH), 82; 8-Me, A, fawn, 219-21° (repptd.), 56; 6-Me, A, fawn, 271° (AcOH), 64; 8-Cl, B, colorless, 198-9° (AcOH), 74; 5-Cl, A, fawn, 330-2° (HCONMe2), 70; 6-Cl, B, fawn, 296° (EtOH), 85; 7,8-di-Cl, A, colorless, 261-2° (AcOH), 95; 6,8-di-Cl, A, gray, 221-3° (AcOH), 90; 5,8-di-Cl, A, colorless, 222-4° (AcOH), 70; 5,6-di-Cl, A, fawn, 336-7° (AcOH), 65; 6-Br, A, fawn, 277-8° (EtOH), 45; 5(or 7)-Br and 6-Me, A, colorless, 288-9° (EtOCH2CH2OH), 45; 8-MeO, A, colorless, 162-3° (H2O), 96; 6-MeO, -(in Dowtherm), gray plates, 254-5° (MeOH), 31 (precipitated from BzPh with Et2O and extracted with H2O); 6-NO2, A, yellow prisms, m. 336° (AcOH), 70. All the compds. were needles unless otherwise stated. II (4.35 g.) and 4.95 g. 2,4-(O2N)2C6H3NHNH2 in 100 cc. AcOH heated 2 hrs. at 95°, cooled, poured with stirring into 800 cc. iced H2O, the solid filtered off, washed with H2O, a 2-g. portion of the residue (7.4 g.) extracted with 600 cc. boiling ligroine, b. 60-80°, filtered, and cooled gave 1.3 g. 2,4-(O2N)2C6H3NHN:C(CO2Et)2, bright yellow prisms, m. 116-17°. o-MeOC6H4NH2 (62.5 g.) diazotized in the usual manner, added with stirring at 20° to 66 g. CH2(CO2Me)2, 150 g. NaOAc, 1 l. MeOH, and 400 cc. H2O, and worked up gave 101 g. o-MeOC6H4NHN:C(CO2Me)2 (XXXVII), yellow plates, m. 111-12° (MeOH). Similarly were prepared the following XC6H4NHN:C(CO2Et)CN (X, m.p., % yield, and starting material used given): H (XXXVIII), 124-5° (C6H6), 93, NCCH2CO2Et (XXXIX); p-Cl, 157-8° (α -form, precipitated from an alkaline solution by 2N HCl) [124-5° (β -form, precipitated from an alkaline solution by CO2)], 96, XXXIX; p-MeO (XL), 120° (α -form, precipitated with 2N HCl) [81-2° (aqueous EtOH) (β -form)], 98, XXXIX; p-AcNH (XLI), 210° (50% aqueous C5H5N), 75, XXXIX. The following XC6H4NHN:CAB (X, A, B, m.p., % yield, and starting material used given): p-Me, CO2Me, CO2Me (XLII), 84-5° (MeOH), 78, CH2(CO2Me)2; p-Cl, CN, CN (XLIII), 187° (EtOH), 66, CH2(CN)2; H, CO2Et, NO2, 60-1° (petr. ether), 56, O2NCH2CO2Et (as the NH4 salt); p-Cl, CO2Et, NO2, 118-19° (EtOH), 40, O2NCH2CO2Et; p-Cl, Ac, Ac (XLIV), 132-3° (EtOH), 96, Ac2CH2; p- MeO, Ac, Ac (XLV), 100-1° (EtOH), 96, Ac2CH2. XLII (50 g.) in 100 cc. refluxing MeOH treated with 81 cc. 2.46N NaOH-MeOH, refluxed briefly, cooled, diluted with Et20, filtered, the residue ground with excess 2N HCl, and filtered gave 24 g. p-MeC6H4NH N: C(CO2)CO2Me (XLVI), m. 153-4° (MeOH). XLVI (20 g.) heated at 165° until the CO2 evolution ceased, the cold residue triturated with excess petr. ether, and filtered gave 5.1 g. α-form of p- MeC6H4NHN: CHCO2Me (XLVIII), m. 174-5° (MeOH); the filtrate evaporated and the residual sirup triturated with MeOH at -40° gave 9.5 g. β -form of XLVIII, m. 21-2° (light petroleum). XVI (20 g.) heated at 178° until the CO2 evolution ceased, cooled, and diluted with petr. ether gave 14.7 g. (crude) p-ClC6H4NHN:CHCO2Et (XLIX), which crystallized from EtOAc-ligroine (b. 60-80°) gave the pure α -form, m. 151-2°; crystallization from EtOH yielded the β -form, m. 68-9°, identical with the product obtained in 16% yield after dry distillation of the crude product from diazotized p-ClC6H4NH2 and CH2(CO2K)CO2Et. XL (26.8 g.) in 108 cc. 2N HCl heated 80 min. at 65-70° with 324 cc. 2N NaOH, cooled, kept at room temperature overnight, acidified with 2N HCl, and the precipitate (24.7 g.) extracted with

500 cc. boiling ligroine, b. 60-80°, yielded 22.7 g. p-MeOC6H4NHN:C(CN)CO2H(L), m. 154-5° (AcOH), which on recrystn. from aqueous EtOH was decarboxylated to p-MeOC6H4NHN:CHCN, m. 127-8°. Similarly was prepared the p-Cl analog of L, m. 160-1° (EtOH). p-ClC6H4NHN:CHCO2Et (109.3 g.) in 242 cc. refluxing absolute EtOH treated with 242 cc. 2.4N alc. NaOH, the mixture refluxed 20 min., cooled to 0°, and filtered gave 40 g. Na salt, pale yellow needles, m. 259-63° (decomposition) (EtOH), which acidified with iced 2N HCl gave 9% p-ClC6H4NHN: CHCO2H, m. 134-5°. The appropriate acid of the type p-RC6H4NHN:C(CO2H)B heated with SOCl2 in C6H6 or CHCl3 gave the corresponding p-RC6H4NHN:C(COCl)B (R, B, m.p., % yield, and solvent used given): Me, CO2Et, 76°, 45, C6H6; Cl, CN(LI), 151-4°, 65, C6H6 [anilide m. 218-19° (EtOH)]; MeO, CN (LIa), 138-40°, 68, CHCl8 [anilide m. 167-9° (EtOH)]; Cl, H (LII), 127-8°, 49, CHCl3; PhCH2O, CO2Et (LIII), 105-7°, 85, none (Na salt of acid treated with SOCl2). XIV (25 g.) treated with 13 g. SOCl2 in 700 cc. dry C6H6, the mixture evaporated in vacuo at 50°, dissolved in 200 cc. dry PhNO2, heated 2 hrs. at 95° with 27.4 g. SnCl4, divided into 4 equal portions, 1 portion treated with 190 cc. 1.95N NaOH, steam distilled to remove the PhNO2, filtered, and acidified hot with 45 cc. concentrated HCl yielded 2.7 g. crude 4-hydroxy-6-methylcinnoline-3-carboxylic acid, m. 265-6° (AcOH). LIII gave similarly at 95° during 3.75 hrs. only 5% low-melting acid, LII gave similarly 18% low-melting acid during 6 hrs., LI yielded 17% in 5 hrs., and LIa 2.5% in 6 hrs. LI, XLII, V, VIII, VI, XI, XII, XLVIII, LXIX, and XIV subjected to cyclization in Dowtherm at 250-60° or BzPh at 297° resulted in a complete breakdown with the evolution of MeOH or EtOH and HCN. XIII gave similarly 46% p-EtO2CNHC6H4NCO, m. 64-5° (petr. ether), which yielded with EtOH p-C6H4(NHOCOEt)2, m. 193-4° (EtOH). XIV, XIX, XXIV, XLIV, and XLV treated with concentrated H2SO4 gave at room temperature unchanged starting material

or sulfonation product and at 60-95° resulted in sulfonation and (or) decomposition XXXVIII and XLI treated with concentrated H2SO4 at room temperature

gave starting material or sulfonation product. XLIII yielded similarly the monoamide, m. 266° (AcOH). VIII, XV, XVI, XIV, XVIII, XX, XXI, XXIV, XXV, XLIII, and XLIV treated with polyphosphoric acid at 45-100° gave only unchanged starting material and at 100-65° decomposition products. XIII treated at 60-95° with concentrated H2SO4 and Ac20 gave the monosulfo derivative of XIII, isolated in low yield as the Na salt.

VIII treated at 110-20° with Et20.BF3 gave the BF3 complex, m. 193-4°, which with AcOH yielded XVI, m. 171°. XVII, XIV, XX, and XXI refluxed with POCl3 gave some unchanged starting material and intractable by-products. XXI and XXVI treated at 0-15° with anhydrous HF and XXIII treated at 40 with FSO3H gave only unchanged starting materials.

ANSWER 18 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1959:56393 CAPLUS

DOCUMENT NUMBER: 53:56393

ORIGINAL REFERENCE NO.: 53:10186g-i,10187a-c

TITLE: Thiazole derivatives as antispasmodics and

antihistaminics. III

Tripathy, Pranabandhu; Pujari, H. K.; Rout, M. K. AUTHOR (S):

CORPORATE SOURCE:

Ravenshaw Coll., Cuttack J. Indian Chem. Soc. (1958), 35, 407-10 SOURCE:

Journal DOCUMENT TYPE: LANGUAGE: Unavailable

ACNH
$$\sim$$
 CH₂- CH₂- Ph

CH₂- NEt₂

Thiazoles were condensed with HCHO and different ketones, quinolines, or AB pyrazolones. Thus, 1.76 g. 4-phenyl-2-aminothiazole (I), 1.2 g. PhCOMe, and 0.9 g. paraformaldehyde (II) in 3 ml. concentrated HCl and 2.5 ml. EtOH was refluxed 2 hrs., 0.6 g. addnl. II added, the mixture refluxed 3 hrs., the alc. distilled, the pasty mass treated with NH4OH until solidification (2-3 hrs.), the solid washed with H2O, and recrystd. from EtOH to yield 82% 2-(3-oxo-3-phenylpropylamino)-4-phenylthiazole, m. 115°. Similarly, the following thiazoles (R in 4-position, R' of NHCH2R' in 2-position, and m.p. given) were prepared in 70-88% yield: Ph, CH2CH2COC6H4OH-p, 78°; Ph, CH2COC6H4OH-p, 89°; Ph, CH2COCH: CHPh, 103°; Ph, CH2COC6H3 (OMe) OH-p, 81°; Ph, CH2COC6H4OMe-p, 86°; PhCH2CH2, CH2Bz, 145°; p-HOC6H4, CH2Bz, 180° (decomposition); p-HO(MeO)C6H3, CH2Bz, 160° (decomposition); β -C10H7, CH2Bz, 132°. I (1.76 g.), 1.2 g. II, and 1.73 g. 1-phenyl-3-methyl-5-pyrazolone (III) in 3 ml. concentrated HCl and 25 ml. EtOH was refluxed over asbestos-wire gauze 8 hrs., the alc. distilled, the mass poured into H2O, the gummy product hardened in contact with concentrated NH4OH, dissolved in NaOH, and repptd. with HOAc to yield 85% 2-(1-phenyl-3-methyl-5-oxo-4-pyrazolinylmethylamino)-4-phenylthiazole, m. 121°. Similarly, the 2-(1-phenyl-3-methyl-5-oxo-4-pyrazolinylmethylamino)-4arylthiazoles (aryl and m.p. given) were prepared in 65-85% yield: 4,3-HO(MeO)C6H3, 180° (decomposition); PhCH2CH2, 145-6°; p-HOC6H4, 160° (decomposition); β-ClOH7, 158°. Similarly, the condensation of III with 2-amino-4,5,6,7-tetrahydrobenzothiazole gave 2-(1-phenyl-3-methyl-5-oxo-4-pyrazolinylmethylamino)-4,5,6,7-tetrahydrobenzothiazole, m. 102° (decomposition). III and 8-hydroxyquinoline gave 2-(8-hydroxy-7-quinolinylmethylamino)-4-phenylthiazole, m. 101°. To 2.1 g. 2-acetamido-4-phenylthiazole 0.6 g. Et2NH in 5 ml. HOAc and 1 ml. formalin was added, the mixture refluxed 8 hrs., diluted with 10 ml. H2O, treated with saturated K2CO3, the precipitate filtered off, washed with H2O,

recrystd. from EtOH to yield 75% 2-acetamido 4-phenyl-5- (diethylaminomethyl)thiazole, m. 80°. Similarly, the following 2-acetamido-4-aryl-5-(diethylaminomethyl)thiazoles (aryl, m.p. given) were prepared in 80-85% yield: PhCH2CH2, 188° (decomposition); β -Cl0H7, 245° (decomposition).

L8 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1956:4689 CAPLUS

DOCUMENT NUMBER: 50:4689

and

ORIGINAL REFERENCE NO.: 50:963e-i,964a-b

TITLE: 4-Styrylthiazoles. Syntheses and relationships among

ultraviolet absorption spectra

AUTHOR(S): Southwick, Philip L.; Sapper, David I.

CORPORATE SOURCE: Carnegie Inst. of Technol., Pittsburgh, PA

SOURCE: Journal of Organic Chemistry (1954), 19, 1926-37

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal Unavailable OTHER SOURCE(S): CASREACT 50:4689

IT 93044-41-8, Thiazole, 2-acetamido-5-nitro-4-styryl-

859969-74-7, Thiazole, 2-acetamido-4-styryl-

(preparation of) RN 93044-41-8 CAPLUS

CN Acetamide, N-[5-nitro-4-(2-phenylethenyl)-2-thiazolyl]- (9CI) (CA INDEX

NAME)

RN 859969-74-7 CAPLUS

CN Thiazole, 2-acetamido-4-styryl- (5CI) (CA INDEX NAME)

GI For diagram(s), see printed CA Issue.

AB A number of 4-styrylthiazoles, PhCH:CHC:CR.S.CR':N (I), have been prepared and their ultraviolet absorption spectra studied. Adding 12.5 g. PhCH2COMe to 10.2 g. BzH and 0.75 g. NaOH in 400 cc. H2O at 58-60° with stirring and stirring the mixture 18-20 hrs. at 60° give 50-60% benzyl styryl ketone (II), m. 69-73°. Adding 21.6 g. Br to 15 g. II in 30 cc. hot CCl4 and adding another 30 cc. CCl4 give 54.5% 1,3,4-tribromo-1,4-diphenyl-2-butanone (III), m. 126-8°. Treating 10 g. III in 40 cc. Me2CO with 9.9 g. NaI in 60 cc. Me2CO and warming the mixture to 50° give 55% 1-iodo-1,4-diphenyl-3-buten-2-one (IV), m. 91.5-3°. Heating 0.75 g. iodomethyl styryl ketone (V) in 4 cc. EtOH with 0.25 g. HCSNH2.H2O in 4 cc. EtOH 1 hr. on a steam bath, making the mixture alkaline

with

NaOH, extracting with Et2O, and treating the residue of the ether extract with picric acid give 8% 4-styrylthiazole picrate, yellow prisms, m. 163-6°. Similarly 2 g. V and 0.55 g. MeCSNH2 refluxed 1 hr. in 10 cc. EtOH and kept 2 days at 20° give 19% 2-methyl-4-styrylthiazole (VI) picrate, yellow plates, m. 177-80° [HCl salt, m. 146-52°). Refluxing 3 g. 1-bromo-1,4-diphenyl-3-buten-2-one and 0.75 g. MeCSNH2 in 10 cc. absolute EtOH 2 hrs. gives 24% 2-methyl-4-styryl-5phenylthiazole-HCl, m. 145-55° (decomposition). Warming 2 g. V with 0.56 g. CS(NH2)2 in 10 cc. EtOH and keeping the mixture overnight at -10° give 57.5% 2-amino-4-styrylthiazole (VII).HI, cubes, crystallizing with 1 EtOH, m. 181-1.5° (free base, pale yellow needles, m. 160-2°). Heating 3 g. IV and 0.66 g. CS(NH2)2 1.5 hrs. in 15 cc. EtOH gives 48.2% 2-amino-4-styryl-5-phenylthiazole, yellow plates, m. 160-1.5°, which is also prepared in 38% yield by refluxing 5 g. II, 5.7 g. iodine, and 6 g. CS(NH2)2 in 20 cc. EtOH 12 hrs. (HI salt, needles, m. 217-28°). Treating 2 g. IV with 0.66 g. CS(NH2)SNH4 (VIII)

gives 28% 2-mercapto-4-styryl-5-phenylthiazole, light yellow needles, m. 224-5°. Similarly, 2 g. V and 0.88 g. VIII in 20 cc. EtOH give 49% 2-mercapto-4-styrylthiazole, yellow prisms, m. 210-11.5°. Treating 2 g. V with 32 g. Ba(CNS)2.SH2O (IX) in 15 cc. EtOH gives 67% thiocyanomethyl styryl ketone, plates, m. 118.5-19.5° which (0.6 g.), heated 5 hrs. with 12 cc. 3N HCl, gives 2-hydroxy-4-styrylthiazole, prisms, m. 211-14°. Refluxing 2.5 g. IV and 1.2 g. IX 5 hrs. in EtOH, extracting the mixture with Et2O, and heating the residue of the ether

1.5 hrs. with 10 cc. AcOH and 1 cc. concentrated HCl give 20% 2-hydroxy-4-styryl-5-phenylthiazole, pale yellow needles, m. 227-9°. Heating 2.1 g. VII 0.5 hr. in 20 cc. Ac20 gives 85% 2-acetamido-4-styrylthiazole, plates, m. 205.5-6.5°, which (0.9 g.), treated with 10 cc. concentrated HNO3, gives 38% 2-acetamido-4-styryl-5nitrothiazole, deep yellow needles, m. 261-2°; when this is oxidized with CrO3 in AcOH a small amount of BzOH is formed. The ultraviolet spectrum of VI shows a close resemblance to that of trans-stilbene or of 2- and 4-stilbazole. The effects on the ultraviolet spectrum of I with a NH2, SH, or OH in the 2-position and of the Ph group in the 5-position of the thiazole ring have been found to parallel in many respects the effects produced by the corresponding groups in derivs. of aromatic hydrocarbons.

ANSWER 20 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN L8

ACCESSION NUMBER: 1951:16499 CAPLUS

DOCUMENT NUMBER: 45:16499 ORIGINAL REFERENCE NO.: 45:2934d-h

TITLE: Reaction of ketones with iodine and thiourea

King, L. Carroll; Hlavacek, Robert J. AUTHOR(S): CORPORATE SOURCE: Northwestern Univ., Evanston, IL

SOURCE: Journal of the American Chemical Society (1950), 72,

3722-5

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal Unavailable LANGUAGE:

OTHER SOURCE(S): CASREACT 45:16499

859463-48-2, Thiazole, 2-acetamido-4-benzyl-5-phenyl-

(preparation of) 859463-48-2 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-phenyl- (5CI) (CA INDEX NAME)

RN

cf. C.A. 42, 6360f. The ketone (0.1 mol.), 0.2 mol. CS(NH2)2, and 0.1 AB mol. iodine, heated overnight on the steam bath, give the substituted 2-aminothiazole; the cooled reaction product is extracted with ether, the residue in boiling H2O filtered, the filtrate made alkaline with concentrated NH4OH,

and the precipitate crystallized from aqueous EtOH; if the product is an oil,

crystallized from Skellysolve C. The m.ps. of the Ac derivs. are given in parentheses. 4-Substituted 2-aminothiazoles: p-chlorophenyl, m. 163-4°, 89% [254-5°]; p-bromophenyl, m. 180-1°, 93%

```
[277-8°]; p-iodophenyl, m. 176-7°, 97% [302-3°];
     p-methoxyphenyl, m. 204-5°, 72% [287-8°];
     p-(methylmercapto)phenyl, m. 180-2°, 67% [232-3°];
     p-aminophenyl, m. 174-5°, 63% [di-Ac derivative, m. 284-6°]; p-biphenylyl, m. 207-8°, 99% [252-3°]; p-tolyl, m.
     124-5°, 84% [204-5°]; m-isomer, m. 79-92°, 64%
     [211-12°]; o-isomer, m. 81-2°, 70% [143-4°];
     p-nitrophenyl, m. 285-6°, 99% [306-7°]; m-isomer, m.
     188-90°, 84% [312-14°]; 2-naphthyl, m. 153-4°, 99%
     [239-40°]; 2-phenanthryl, m. 243-4°, 87% [304-5°];
     2-thienyl, m. 127-30°, 91% [199-207°]; tert-Bu, m.
     98-9°, 71% [173-4°]; o-hydroxyphenyl, m.
     139-40°, 37% [di-Ac derivative, m. 200-3°; HI salt, m.
     220-3° (each HI salt has 1 mol. H2O)]; m-isomer, m. 136-8°,
     59% [di-Ac derivative, 186-7°; HI salt, 95-7°]; p-isomer, m.
     198-200°, 62% [di-Ac derivative, m. 235-7°; HI salt m.
     240-2°]; 4-phenyl-5-Et, m. 68-9°, 65% [175-6°];
     4-phenyl-5-Bu, m. 103-4°, 54% [135-6°]; 4-phenyl-5-Bu, m.
     60-1°, 43% [187-8°]; 4-benzyl-5-Ph, m. 139-40°, 83%
     [164-5°]; 4,5-di-Ph, m. 184-5°, 99% [208-9°]; 4-phenyl-5-benzoyl, m. 215-16°, 18% [237-8°].
     aminothiazole from 4-methylcyclohexanone, C8H12N2S, m. 98-9°, 66%
     [162-3°]; the 3-isomer gives 24% 2-amino-5(or -7)-methyl-4,5,6,7
     -tetrahydrobenzothiazole, m. 110-11° [150-1°]. Compound from
     cycloheptanone, C8H12N2S, m. 75-6° 60% [124-5°]; from
     hydrindone, C10H8N2S, m. 213-14°, 53% [284-5°]; from
     3,4-dihydro-1(2H)-naphthalenone, m. 133-4°, 52% [233-4°];
     acenaphthenone gives 99% 8-aminoacenaphtho-1,2-thiazole, bright red, m.
     205-7° [309-11°]. Bromoacetomesitylene (4.6 g.) yields 3.8
     g. 2,4,6-trimethylphenacylisothiuronium bromide, m. 280-2°; it
     could not be cyclized to a thiazole.
     ANSWER 21 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
                          1951:13861 CAPLUS
ACCESSION NUMBER:
                          45:13861
DOCUMENT NUMBER:
ORIGINAL REFERENCE NO.:
                          45:2474d-g
TITLE:
                          Bacteriostatic sulfones. I. Bis(2-amino-4-substituted-
                          5-thiazolyl) sulfones
AUTHOR (S):
                          Libermann, D.; Moyeux, M.
                          Bulletin de la Societe Chimique de France (1950) 301-4
SOURCE:
                          CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE:
                          Journal
                          Unavailable
LANGUAGE:
OTHER SOURCE(S):
                          CASREACT 45:13861
ΙT
     859481-76-8, Thiazole, 5,5'-thiobis[2-acetamido-4-benzyl-
        (preparation of)
     859481-76-8 CAPLUS
RN
     Thiazole, 5,5'-thiobis[2-acetamido-4-benzyl- (5CI) (CA INDEX NAME)
CN
```

Bis(2-acetamido-4-methyl-5-thiazolyl) sulfide (15 g.) in 120 cc. glacial AB AcOH at 60-70° treated gradually with stirring with 15 cc. 30% H2O2 gave 11 g. of the di-Ac derivative (I), m. above 350°, of bis(2-amino-4-methyl-5-thiazolyl) sulfone (II). I (11 g.) boiled with 60 cc. AcOH and 40 cc. 6 N HCl gave 6 g. II, m. 248° (decomposition; from 50% MeOH). Similar oxidation of 17 g. bis(2-acetamido-4-propyl-5thiazolyl) sulfide gave first 15 g. of the sulfoxide, m. 193° (from MeOH), which was oxidized by a further H2O2 treatment to 8 g. of the di-Ac derivative (III), m. 260°, of bis(2-amino-4-propyl-5-thiazolyl) sulfone (IV). III heated 15 min. with 800 cc. 18% HCl gave 4 g. IV, m. 219° (from 50% EtOH). PhCH2CN (50 g.) in 250 cc. absolute EtOH saturated with HCl gas at 0°, let stand overnight, evaporated to dryness in vacuo, and the residue boiled 30 min. with 100 cc. EtOH, 17 cc. H2O, and 3 cc. concentrated HCl, gave 46 g. (71%) Et α -phenylacetoacetate, b5 127-30°. This in 130 cc. CS2 treated with cooling with 36 g. Br yielded 45 g. BrCH2COCHPhCO2Et which, shaken 12 hrs. with 18 g. SC(NH2)2 and 200 cc. H2O, gave 18 g. Et 2-amino-α-phenyl-4-thiazoleacetate, m. 157° (from 95% EtOH). This, boiled 90 min. with 6 g. NaOH in 120 cc. 95% EtOH, gave 14 g. of the corresponding Na salt, which, boiled 1 day with 15 cc. concentrated HCl and 60 cc. H2O, gave 9 g. 2-amino-4benzylthiazole, m. 96-7° (from C6H6-petr. ether). This (19 g.) with 11.5 q. SC(NH2)2 and 25 g. iodine in 170 cc. 50% EtOH gave 16 g. bis(2-amino-4-benzyl-5-thiazolyl) sulfide, m. 190° (di-Ac derivative, m. 253° (from Ac20)]. H2O2 oxidation of 11 g. Ac derivative in 2 steps as above gave 3 g. 5,5'-bithiazole, m. 261°.

=> log y COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	108.23	447.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.75	-15.75

STN INTERNATIONAL LOGOFF AT 12:22:23 ON 07 FEB 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

NEWS 14 JAN 31

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Web Page URLs for STN Seminar Schedule - N. America
NEWS 1
                "Ask CAS" for self-help around the clock
NEWS
     3 DEC 05
                CASREACT(R) - Over 10 million reactions available
NEWS
NEWS 4
        DEC 14
                2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5
        DEC 14
                2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
                CA/CAplus to be enhanced with updated IPC codes
NEWS 6 DEC 14
NEWS 7
        DEC 21
                IPC search and display fields enhanced in CA/CAplus with the
                IPC reform
                New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
NEWS 8 DEC 23
                USPAT2
NEWS 9 JAN 13
                IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
                New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
NEWS 10 JAN 13
                INPADOC
NEWS 11 JAN 17
                Pre-1988 INPI data added to MARPAT
                IPC 8 in the WPI family of databases including WPIFV
NEWS 12 JAN 17
NEWS 13 JAN 30
                Saved answer limit increased
```

Monthly current-awareness alert (SDI) frequency

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:27:46 ON 07 FEB 2006

added to TULSA

=> file reg COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:28:00 ON 07 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5 DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Program Files\Stnexp\Queries\107645293.str

chain nodes :

6 7 8 9 10 18 19 20 21

ring nodes :

1 2 3 4 5 12 13 14 15 16 17

chain bonds :

2-6 5-18 6-7 6-9 7-8 7-10 13-19 18-19 18-21 19-20

ring bonds :

1-2 1-5 2-3 3-4 4-5 12-13 12-17 13-14 14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 2-6 6-7 7-8 13-19 18-19 18-21

exact bonds :

2-3 3-4 4-5 5-18 6-9 7-10 19-20

normalized bonds :

12-13 12-17 13-14 14-15 15-16 16-17

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS

10:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS

20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 12:28:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

0 ANSWERS 100.0% PROCESSED 20 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

132 TO 668 PROJECTED ITERATIONS: PROJECTED ANSWERS:

0 SEA SSS SAM L1 L2

=> s 11 ful

FULL SEARCH INITIATED 12:28:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 335 TO ITERATE

7 ANSWERS 100.0% PROCESSED 335 ITERATIONS

SEARCH TIME: 00.00.01

7 SEA SSS FUL L1 L3

=> file caplus

SINCE FILE TOTAL ENTRY SESSION COST IN U.S. DOLLARS

166.94 167.15 FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:28:32 ON 07 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7 FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

4 L3 T.4

=> d 14 ibib hitstr abs 1-4

ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1042064 CAPLUS

DOCUMENT NUMBER: 143:332555

Aqueous composition comprising thiazole derivative TITLE:

Ueno, Ryuji; Hirata, Ryu; Harada, Yasuhiro INVENTOR(S):

PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan PCT Int. Appl., 46 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND DATE				APPLICATION NO.						DATE				
	WO 2005089755			A1 20050929			WO 2005-JP5607						20050318					
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
			co,															
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	KZ,	LC,	
		-	LR,															
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	
		SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	zw
	RW	BW,	GH,	GM,	KE,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
		AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙT,	LT,	LU,	MC,	NL,	PL,	PT,	
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	
		MR,	NE,	SN,	TD,	TG												
PRIOR	ITY AP	PLN.	INFO	.:					1	US 2	004-	5539	56P		P 2	040	318	
OTHER SOURCE(S): MARPAT 143:332555																		
TT	IT 727022 01 7																	

TT 737823-01-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation and stability of aqueous composition comprising thiazole derivative)

737823-01-7 CAPLUS

а

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-[4-[(aminoiminomethyl)amino]pheny 1]- (9CI) (CA INDEX NAME)

AB The present invention provides an aqueous composition comprising a thiazole derivative

or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alc., boric acid or its salt, and water. The aqueous composition is very stable and can be stored for

long time. For example, a 0.3% aqueous solution of N-[4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl]acetamide (I) (pH 6) was prepared using HCl acid and an additive selected from glycerin 2.5%, mannitol 4.7%, or boric acid 1.68%. The solution was stored at 40° in the low-d. polyethylene container. The concentration of the thiazole compound I after 1 mo, 3 mo, and 6 mo was

105.4, 110.6 and 112.3% of the original 100% concentration of I for glycerin, 103.7, 108.4 and 109.6% for mannitol, and 104.9, 106.2, and 108.2% for boric acid, resp.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857384 CAPLUS

DOCUMENT NUMBER: 141:350160

TITLE: treatment of vascular hyperpermeable disease using

acylaminothiazoles and related compounds as vascular

adhesion protein-1 (VAP-1) inhibitors.

INVENTOR(S): Ueno, Ryuji; Nagashima, Akira; Inoue, Takayuki;

Ohkubo, Mitsuru; Yoshihara, Kousei

PATENT ASSIGNEE(S): Sucampo Ag, Switz.; Fujisawa Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIN)	DATE			APPLICATION NO.					DATE				
WO 2004087138				A1 20041014			WO 2004-JP4596						20040331					
W: .	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KΡ,	KR,	ΚZ,	LC,		
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,		
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,		
	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,		
	BY,	KG,	ΚZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,		

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2004-JP4596

W 20040331

CA 2520957 AA 20041014 CA 2004-2520957 20040331 EP 1608365 A1 20051228 EP 2004-724735 20040331

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK PRIORITY APPLN. INFO.:

US 2003-458370P P 20030331

OTHER SOURCE(S): MARPAT 141:350160

IT 737823-01-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-[4-[(aminoiminomethyl)amino]pheny l]-(9CI) (CA INDEX NAME)

IT 737823-02-8P 737823-03-9P

RN

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors) 737823-02-8 CAPLUS

CN Carbamic acid, [4-[[[2-(acetylamino)-4-thiazolyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-03-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-(4-aminophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

GΙ

$$\bigcup_{N \text{ HN}} \bigvee_{N \text{ HN}} \bigvee_{N \text{ HN}} \bigvee_{N \text{ H2}} \bigvee_{1}$$

AB A method for treating a vascular hyperpermeable disease (except macular edema), comprises administration of a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. Thus, N-[4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide (preparation given) was refluxed with HCl and cyanamide in EtOH for 26 h to give title compound (I). I inhibited human plasma VAP-1 (SSAO) with IC50 = 0.15 µM. REFERENCE COUNT:

11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648516 CAPLUS

DOCUMENT NUMBER: 141:190785

TITLE: Preparation of thiazole derivatives as VAP-1

inhibitors for treatment of macular edema and other

VAP-1 associated diseases

INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka;

Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIN	D	DATE			APPLICATION NO.						DATE			
					-													
WO	2004	0675	21		A1 20040812			0812		WO 2	004-		20040127					
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI	

20040127 CA 2514573 AΑ 20040812 CA 2004-2514573 US 2004-764529 US 2004259923 Α1 20041223 20040127 20051026 EP 2004-705519 20040127 EP 1587800 A1 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK 20030127 PRIORITY APPLN. INFO.: US 2003-442509P P Р 20030331 US 2003-458369P Р US 2003-517377P 20031106 WO 2004-JP708 W 20040127

OTHER SOURCE(S): MARPAT 141:190785

IT 737823-01-7P, 2-(Acetylamino)-N-[4-[[amino(imino)methyl]amino]phen yl]thiazole-4-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VAP-1 inhibitor; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)

RN 737823-01-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-[4-[(aminoiminomethyl)amino]pheny 1]- (9CI) (CA INDEX NAME)

TT 737823-02-8P, tert-Butyl [4-[[[2-(acetylamino)thiazol-4-

yl]carbonyl]amino]phenyl]carbamate 737823-03-9P,

2-(Acetylamino)-N-(4-aminophenyl)thiazole-4-carboxamide hydrochloride RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)

RN 737823-02-8 CAPLUS

CN Carbamic acid, [4-[[[2-(acetylamino)-4-thiazolyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 737823-03-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-(4-aminophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

GI

$$\bigcap_{\mathsf{Me}} \bigcap_{\mathsf{H}} \bigcap_{\mathsf{N}} \bigcap_{\mathsf{S}} \bigcap_{\mathsf{N}} \bigcap_{\mathsf{N}}$$

AΒ Title compds. of formula R1NHXYZ [I; wherein R1 = acyl; X = a bivalent (un) substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, C6H4-R2; R2 = ABDE; A = a bond, alkylene, NH, SO2; B = a bond , alkylene, CO, O; D = a bond, alkylene, NH, CH2NH; E = (un)protected amino, N=CH2, dihydrothiazol-2-yl, dihydroimidazol-2-yl, C(=NH)R3; R3 = H, alkyl(thio), NHR4; R4 = H, NH2, alkyl; and pharmaceutically acceptable salts thereof] were prepared as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl) methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH2Cl2. Deprotection of [2-(acetylamino)thiazol-4-yl] methyl acetate using K2CO3 in MeOH, followed by reaction of the resulting alc. with MnO2 in MeOH/CHCl3 provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh3 and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)] ethenyl] thiazol-2-yl] acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC50 = 0.15 μ M and 0.012 μ M, resp.), but not the enzyme activities of other amine oxidases (IC50 >100 µM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). Treatment of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreous/plasma ratio of fluorescein concns. = $5.39 \pm$ 0.73 \times 10-3 and 8.93 \pm 1.14 \times 10-3, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or treating VAP-1 associated diseases, especially macular edema (no data).

II

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:506123 CAPLUS

DOCUMENT NUMBER: 127:205746

TITLE: Synthesis of methyl 2-acetylamino-5-(1,3-dithian-2-

yl)thiazole-4-carboxylate

AUTHOR(S): Feliu, Lidia; Ajana, Wadi; Joule, John A.;

Lopez-Calahorra, Francisco; Alavarez, Mercedes

CORPORATE SOURCE: Laboratori de Quimica Organica, Facultat de Farmacia,

Univ. de Barcelona, Barcelona, 08028, Spain

SOURCE: Heterocycles (1997), 45(7), 1299-1308

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:205746 IT 194663-84-8P 194663-88-2P 194663-89-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(synthesis of Me 2-acetylamino-5-(1,3-dithian-2-yl)thiazole-4-

carboxylate)

RN 194663-84-8 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-phenyl- (9CI) (CA INDEX NAME)

RN 194663-88-2 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-5-formyl-N-phenyl- (9CI) (CA INDEX NAME)

RN 194663-89-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-5-(1,3-dithian-2-yl)-N-phenyl-(9CI) (CA INDEX NAME)

AB The synthesis of Me 2-acetylamino-5-(1,3-dithian-2-yl)thiazole-4-carboxylate by formylation of a 4-substituted thiazole and then reaction with 1,3-propanedithiol is described as a model for synthesis of

thiazolopyridoacridine alkaloids. The utility of different ortho-directing groups (ODGs) for the lithiation of the thiazole 4-position has been studied.

REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y COST IN U.S. DOLLARS	SINCE FILE	TOTAL
COD1 11. C.D. 202211.0	ENTRY	SESSION
FULL ESTIMATED COST	20.90	188.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
DIDCOOK! AMOUNTS (LOK SOUTH)	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

STN INTERNATIONAL LOGOFF AT 12:28:55 ON 07 FEB 2006